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New approaches to overcome cancer cell resistance and 
survival 
1. Nature remains an endless source of medical drugs. (this thesis) 
2. Protein Phosphorylation controls a wide number of cellular 
events and arose as potential target of therapy. (this thesis) 
3. Although cancer cells were shown to display an excessive 
phosphorylation of certain signaling transduction proteins, the 
importance of phosphatases has so far been neglected. (this thesis) 
4. Hedgehog signaling might be interesting for overcoming MDR 
resistance in myeloid leukemia. ( this thesis) 
5. In Biology, it is delightful to understand a biological process, but 
it is equally interesting to understand how and why it runs out of 
control. 
6. "Only through curiosity can we discover opportunities, and only 
by gambling can we take advantage of them". Clarence Birdseye 
7. "Science has promised us truth. It has never promised us either 
peace or happiness". Gustave le Bon 
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Cancer is the most public health problem in developed countries and is 
a rapidly increasing problem in developing countries [1]. GLOBOCAN, based 
on the International Agency of Research on Cancer (IARC), estimated 12. 7 
million new cases of cancer in 2008 and 7 .6 million deaths. The estimative in 
the United States is 1,5 million new cases and more than 500 thousand deaths 
from cancer in 2010 [2]. This complex disease affects different tissues, displays 
uncontrolled cell growth, cell invasion to adjacent tissue and sometimes, 
metastasis. The very coordinated sequence of cellular events that keeps 
homeostasis in the body is broken in cancer cells and a new symphony 
regulates the proliferation and survival of cancer cells. In the last few years, 
considerable progress has been achieved concerning cancer biology. However, 
achieving an efficient treatment with low side effects, which targets specifically 
cancer cells and overcomes resistance, remains a challenge. 
Searching for molecular targets in cancer cells has been an excellent 
strategy. Protein phosphorylation arose as a potential target of therapy, once 
cancer cells were shown to display an excessive phosphorylation of certain 
signaling transduction proteins. Reversible phosphorylation, a post­
translational modification which controls every event in the cell physiology, is 
mediated by protein kinases and phosphatases. The protein kinases catalyze 
the transference of phosphate groups from ATP to hydroxyl groups of serine, 
threonine, or tyrosine amino acid residues. In contrast, the protein 
phosphatases catalyze the hydrolysis of phosphorylated amino acid residues. 
Some protein kinases are highly active in different cancer types, mainly due to 
fusion genes and gain of function mutations. For instance, 30% of acute 
myeloid leukemia (AML) display an activating mutation of the FLT3 receptor 
tyrosine kinase which is associated with a poor prognosis [3]. BCR-ABL 
fusion protein, an active kinase, is present in almost all patients with Chronic 
Myeloid Leukemia (CML) and enhances proliferative capability and resistance 
to apoptosis of hematopoietic stem or progenitor cells [4]. In fact, the first 
clinically successful tyrosine kinase inhibitor was imatinib mesylate (gleevec, 
approved in May 2001 ), a pioneer of a new approach to treat cancer patients 
[5]. Imatinib mainly inhibits ABL, and kills myeloid cells containing the BCR­
ABL mutation without affecting on normal cells. Imatinib therapy is generally 
well tolerated, and minimal side effects are observed compared with other 
chemotherapies [ 4]. Targeting BCR-ABL with specific kinase inhibitors such 
as imatinib has drastically improved survival of CML patients [6]. 
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In addition, imatinib also inhibits the c-Kit and PDGFR, and may 
therefore find a role in the treatment of gastrointestinal stromal tumor (GIST) 
formation, in which these tyrosine kinases are deregulated [7]. 
As kinases are upregulated in many types of cancer, it is logical that 
they are considered as targets of therapy. The first approach to counterbalance 
kinase activity is by increasing protein phosphatase activity. As such, 
phosphatases can be valuable targets for therapy and may help to understand 
the failure of kinase inhibitors therapies [8]. A notable example of phosphatase 
as target of therapy is the phosphatase and tensin homolog PTEN that is 
frequently mutated or deleted in a wide variety of solid tumors [9]. PTEN 
mutation has been associated with 5-27% of localized and S0-60% of 
metastatic prostate tumors [10]. This dual specificity phosphatase, acting as 
both lipid and protein phosphatase, classically converts phosphatidylinositol 
3,4,5- phosphate (Ptdins(3,4,5)Ps) at the plasma membrane to 
phosphatidylinositol 4,5- phosphate (Ptdins(4,5)P2). Thereby, PTEN directly 
antagonizes the activity of phosphatidylinositol 3-0H kinase (PisK) and 
inhibits AKT activation, a serine-threonine kinase which is involved in 
proliferation, migration, survival and antiapoptotic pathways [11]. Hence, 
delivery of PTEN via gene therapy has shown promise, in combination with 
other type of therapies [ 11 J. 
Despite the identification of specific kinase and phosphatase-related 
treatment options, many other types of cancer remain without a specific 
treatment. Moreover, most kinase inhibitors are not as specific as imatinib, 
thereby causing adverse effects. The pursuit of improved cytotoxic agents 
remains a considerable focus in the discovery of new anti cancer drugs. 
Nature is not only a great source of pharmaceutical agents, but also of 
chemopreventive compounds. Fruits, vegetables and teas have been shown to 
possess cancer preventing properties, at least in part due to their high content 
in polyphenols [12]. Flavonoids and phenolic acids represent the majority of 
polyphenols present in food [13]. In the last few years, numerous studies have 
shown the cancer-preventing properties of flavonoids, using both cancer cell 
lines and animal tumors as model systems [ 14-16]. For instance, the flavonoid 
fisetin (3,7,3',4'-tetrahydroxyflavone) exerts antiproliferative effect on the 
human prostate cancer cell lines PCs [17] and LNCap [17]. Fisetin also 
inhibits tumor growth and reduces serum prostate specific antigen (PSA) 
levels in athymyic nude mice implanted with Androgen Receptor-positive 
human prostate cancer cells [15]. Another flavonoid, apigenin, 4', 5, 7,­
trihydroxyflavone, has been effective against a wide variety of cancer cells such 
as breast [18], colon [19], ovarian [20] and prostate [21 J cancer. 
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Another class of natural compound widely investigated for their 
biological activities is the terpenoids. In particular the diterpenoid ferruginol 
has been described as a promising anticancer agents due to its effect on 
leukemia [22] and prostate cancer cell lines [23, 24]. Additionally, ferruginol 
displays different biological properties such as anti-ulcerogenic [25], 
cardioactive [26], and anti-oxidative [27] properties. 
Throughout human history, natural products have been used for many 
different applications in medicine. With regard to cancer, a wide number of 
important new clinical drugs have been obtained from natural sources. A new 
drug can be obtained by purification of active compounds from a specific plant, 
by structural modification of natural compounds or by synthesis of new 
compounds designed based on a natural compound [28]. For example, 
Paclitaxel (Taxol®) is a diterpene found in leaves of several species of Taxus 
and used in treatment of drug-refractory metastatic ovarian cancer. Paclitaxel 
was first isolated from the bark of the yew Taxus brevifolia, a tree native to 
western North America. As the amount of paclitaxel in Taxus is very low, the 
semisynthesis from another natural compound 10-deacetyl-baccatin III was 
required as an alternative. [28]. Docetaxel (Taxotere®) is an improved 
version of paclitaxel with better pharmacological properties and potent 
anticancer activity against several human cells. These clinical compounds 
exemplify the role of natural compounds as a viable source of new drugs. 
Despite the continuous discovery of anticancer agents, some patients 
do not respond to treatment due to acquisition of multidrug resistance (MDR) 
against chemotherapy. Several molecular and cellular mechanisms might be 
involved in MDR, such as alteration in DNA repair, defective regulation of 
apoptotic gene expression, enhanced intracellular drug detoxication and 
overexpression of membrane drug transport proteins ( eg. P-glycoprotein, P­
gp) [29]. Thus, the development of resistance is the second challenge, after 
find a chemotherapeutic drug, in the clinical management of cancer. 
Outlines of this thesis 
The general goal of this thesis 1s further our understanding into 
cancer biology regarding dysregulation of signaling pathways in pathogenesis 
and resistance, in addition to proposing alternatives for chemoprevention and 
development of new drug agents. 
This thesis will initially discuss the role of phosphatases in the major 
signaling pathways involved in hematological malignancies, i.e. the Ras-Raf­
ERK, Jak-Stat and PisK-PKB-mTOR pathways (Chapter 2). This is following 
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by a discussion on the involvement of Hedgehog signaling in the maintenance 
of chemoresistance in myeloid leukemic cells (Chapters). Next, we describe our 
studies into the effect of three natural compounds in cancer cell survival. The 
first natural compound studied was the flavonoid fisetin (Chapter 4) which 
causes death of myeloid leukemia HL60 cells through reduction of ERK 
phosphorylation and an increase of pS8 and JNK phosphorylation. The 
flavonoid apigenin (Chapter 5) induced apoptosis in HL60 and autophagy in 
TFI cells. The last natural compound described is ferruginol (Chapter 6), 
which promotes downregulation of Ras/Pl SK and ST AT s and 5, resulting in 
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ABSTRACT 
Most aspects of leukocyte physiology are under the control of 
reversible tyrosine phosphorylation. It is clear that excessive phosphorylation 
of signal transduction elements is a pivotal element of many different 
pathologies, including haematological malignancies and accordingly, strategies 
that target such phosphorylation have clinically been proven highly successful 
for treatment of multiple types of leukemias and lymphomas. Cellular 
phosphorylation status is dependent on the resultant activity of kinases and 
phosphatases. The cell biology of the former is now well understood; for most 
cellular phosphoproteins we now know the kinases responsible for their 
phosphorylation and we understand the principles of their aberrant activity in 
disease. With respect to phosphatases, however, our knowledge is much 
patchier. Although the sequences of whole genomes allows us to identify 
phosphatases using in silica methodology, whereas transcription profiling 
allows us to understand how phosphatase expression is regulated during 
disease, most functional questions as to substrate specificity, dynamic 
regulation of phosphatase activity and potential for therapeutic intervention 
are still to a large degree open. Nevertheless, recent studies have allowed us to 
make meaningful statements on the role of tyrosine phosphatase activity in the 
three major signaling pathways that are commonly affected in leukemias, i.e. 
the Ras-Raf- ERK 1/2, the Jak-STAT and the PlsK-PKB-mTOR pathway. 
Lessons learned from these pathways may well be applicable elsewhere in 
leukocyte biology as well. 
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1 .  INTRODUCTION 
Haematological malignancies account for approximately I O% of cancer 
in adults and 40% of pediatric cancers [ I ]. Annually, more than 100,000 new 
cases of leukemia, lymphoma or myeloma are diagnosed in the US alone, 
resulting in 60,000 deaths per year [2]. A host of genetic differences and 
molecular aberrations affecting blood cells at different stages of differentiation 
lead to a wide range of haematological tumors with different clinical 
manifestations. Many haematopoietic signaling pathways are regulated by 
protein and lipid phosphorylation, a process generally mediated by kinase 
activity. As proper regulation of phosphorylation events is critical for cellular 
homeostasis, dysregulation of activity of a single protein kinase can result in 
oncogenic transformation, characterized by increased cell division, growth, 
decreased differentiation and/ or cell death [SJ. Indeed, numerous protein 
kinases have well-defined, causative roles m human haematological 
malignancies. Several of these fall into the class of receptor tyrosine kinases 
(RTK). For instance, activating mutations of the FL Ts RTK are found in so% 
of Acute Myeloid Leukemia (AML) patients and contribute to myeloid 
pathogenesis [4]. Others include activating point mutations or the generation 
of activating fusion partners due to diverse translocations involving the 
platelet derived growth factor (PDGF) receptor, c-KIT or the fibroblast 
growth factor (FGF) receptor (reviewed in [5]). In addition, inappropriate 
activation or over-expression of non-receptor kinases have been reported in a 
wide range of haematological malignancies. 
Interestingly, most kinase deregulations observed in haematological 
cancers seem to affect one or more of three major signaling pathways: 
i) the Ras-Raf-MEK- extracellular signal regulated kinase (ERK 1 / 2) pathway; 
ii) the Jak-signal transducer and activator of transcription (STAT) pathways; 
iii) the phosphatidylinositol kinase (PlsK)- protein kinase B (PKB/ AKT)­
mammalian target of Raparnycin (mTOR) pathway [6]. 
Aberrant expression or activity of kinases within these pathways 
themselves has been described independent of disturbed RTK signaling. The 
balance between activation and de-activation of signaling pathways is a 
delicate one, ,ivhich is regulated not only through phosphorylation by kinases, 
but also through de-phosphorylation events induced by a diverse range of 
phosphatases. Intuitively, by counterbalancing the activity of kinases, 
phosphatases should primarily act as tumor suppressors. However, novel 
regulatory actions of phosphatases in cancer are emerging, not only as a 
2 1  
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negative modulator of kinase activity but also as causative agents m 
themselves [7] . 
Although the role of aberrant kinase activity and the potential for 
tyrosine and serine/threonine kinase inhibitors in the treatment of various 
leukemias have been investigated and reviewed extensively [8- 1 1] ,  the role of 
phosphatases in haematological malignancies has received less attention to 
<late. In this review, we address the mechanisms by which some phosphatases 
may affect haematological malignancies and discuss their potential in 
therapeutic treatment. We explore general characteristics of those 
phosphatases, their role in the signaling pathways in the homeostatic cell and 
the result of their dysregulation in the progression or suppression of 
haematological malignancies. 
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2. PROTEIN PHOSPHATASES 
Two major families of protein phosphatases can be distinguished based 
on their substrate specificity; the serine/threonine phosphatases (STP) and 
protein tyrosine-phosphatases (PTP) (Table 1 ) . Recently, a third class of 
protein histidine-phosphatases has emerged, but relatively little information is 
available on this group of phosphatases (reviewed in [ 1 2] ). Of the 1 48 human 
protein phosphatase genes recognized, only so encode for STP [ 1 2- 1  SJ . 
Despite there being only few STPs, more than 400 genes coding for 
serine/threonine kinases are identified, accounting for the majority of protein 
phosphorylation. This suggests a large degree of substrate-promiscuity of 
STPs. For this reason, although alterations in PPP family members have been 
described in (haematopoietic) cancer cells, and STPs appear to be viable cancer 
therapy targets [ 1 4- 1 5] this group will not be further discussed in this review. 
Of the 1 07 PTPs, only 8 1  are thought to be catalytically active and 
dephosphorylate phosphotyrosine residues, corresponding to 90 protein 
tyrosine kinases, of which around 80 are suggested to be catalytically active. 
This implies that there is a comparable substrate specificity of PTKs and 
PTPs, and an equal contribution in regulating tyrosine phosphorylation 
patterns. This is further suggested by the parallel tissue distribution of PTPs 
and PTKs, with hematopoietic tissues expressing the highest proportion of all 
PTPs [ 1 6] .  Within the PTPs, different classes are recognized based on amino 
acid sequence in the phosphatase catalytic domains. Class I is by far the largest 
and can be subdivided into classical PTPs and dual specificity PTPs (DUSP), 
which aside from dephosphorylating both tyrosine and serine/ threonine 
residues also recognize other substrates. The classical PTPs can be further 
separated into receptor PTPs (RPTP), and non-receptor PTPs (NRPTP), 
whereas the DUSPs are separated into 7 distinct categories (Table 1 ). Of these, 
the MKPs show specific activity towards mitogen-activated protein (MAP) 
kinase-ERK 1 /2 pathway, and are as such of particular interest in tumors 
where over-activation of this pathway is found [ 1 7] .  Of particular interest is 
phosphatase and tensin homolog (PTEN), which is ordered under the DUSPs 
as it contains the cysteincased motif that classifies PTPs, [ 1 8] but seems to 
have a higher specificity for the S position of the inositol ring of the lipid 
phosphatidylinositol S,4,5 phosphate (Ptdlns(S,4,5)Ps), and can therefore also 
be classified as a lipid phosphatase [ 1 9-20] . Lipid phosphatases generally 
counteract the role of the PlsK-PKB-mTOR pathway by dephosphorylating 
PIPS, and are classified by the position of the phosphate group they remove. 
23 
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There are 1 O mammalian 5-inositol phosphatases known to date, two of which 
are the SH-domain containing inositol phosphatases, SHIP 1 and SHIP2. 
In this review we will focus our attention on PTPs that counteract the 
three major signaling pathways commonly associated with haematological 
cancers, i.e. the Ras-Raf- ERK 1/2, the Jak-STAT and the PlsK-Pl{B-mTOR 
pathway (Figure 1 ). The biochemical properties of these phosphatases and 
their potential role in haematological malignancies will be discussed. 
Table 1 .  Classification of phosphatases. 
Family Class Sub-Class Discussed in this 
{members} review 
pp PTP Class I {Classic} RPTP {2 1} CD4·5 
NRPTP ( 1 7) PTP I B, TCPTP 
SHP I ,  SHP2 
HePTP 
Class I Dual specificity Ml{Ps ( I I )  DUSP-1 /MKP 1 ,  
phosphatase (DUSP) DUSP2/PAC- 1 ,  
DUSP 1 6/MKP-7 
Atypical DUSPs ( 1 9) 
Slingshots (s) 
PRLs (s) 
CDC Ms (4) 
M yotubularins ( 1 6) 
PTENs {5} PTEN 
Class I I  LMWPTP {I} LMWPTP 
Class I I I  CDC25 {s} 
Ase-based PTPs EiA {4� 









IP5P SHIP I ,  SHIP2 
PP: protein phosphatase; IP: inositol phosphatase; PTP: protein tyrosine phosphatase; STP: 
serine/threonine phosphatase. STPs are subdivided into monomeric Mg�+-dependent phosphatases (PPM) 
and a larger class of phosphatases (PPP) whose substrate specificity is determined by the formation 
multimeric holoenzyme complexes. PTPs are subdivided into Class I ,  I I ,  I I I  and Asp-based PTPs. Class I 
PTPs consists of RPTP: receptor PTP and NRPTP: nonreceptor PTPs. The I Ps are classified based on the 
position of the inositol ring which they dephosphorylate; I P4·P: inositol polyphosphate 4-phosphatase; IP SP: 
inositol polyphosphate 4-phosphatase. 
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RTK 
l \. Proliferation 
'» Drug Reslslance Differe
ntiation 
Apoptosis Inhibition 
Figure 1 .  The three major pathways dysregulated in haematological 
malignancies. The Janus kinase (JAK)- signal transducer and activator of transcription 
(STAT), Ras- Raf-MEK-extracellular signal regulated kinase (ERK) and 
phosphatidylinositol s-OH kinase (PlsK)-protein kinase B (PKB/ AKT)-mammalian 
target of Rapamycin (mTOR) pathways are often deregulated in blood disease. The 
nature of their deregulation is indicated in black boxes. Proteins that are constitutively 
active as a result of gene mutations are indicated in grey. RTK: Receptor Tyrosine 
kinase; MDS: Myelodysplastic syndrome; AKT; Protein kinase B (PKB/ AKT); PDK; 
phosphoinositide-dependent protein kinase- I .  
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3.  JAK-STAT SIGNALING 
There are 4 members of the janus family of tyrosine kinases (JAKs); 
Jak 1, Jak2, Jaks, and Tyk2. Cytokine stimulation of cells results in receptor 
dimerization, bringing their associated JAKs into close proximity to each other 
and allowing JAK cross- phosphorylation. The subsequent activation of JAKs 
enables their phosphorylation of target proteins, which include the receptor 
itself and their major substrates; ST A Ts. Cytoplasmatic ST A Ts, of which 7 
family members are known in mammals, are activated upon tyrosine 
phosphorylation, which lead to their dimerization, nuclear translocation and 
regulation of target genes expression [21]. Mutations and translocations in 
the JAK genes (e.g. JAK2V6 1 7F) leading to constitutively active JAK proteins 
are associated with a variety of haematopoietic malignancies, including acute 
myeloid and lymphoblastic leukemias (JAK 1, JAK2), acute megakaryoblastic 
leukemia (JAK2, JAK3), T-cell precursor acute lymphoblastic leukemia (JAK 1 ), 
MPD and polycythemia vera (JAK2) [22-24]. 
Aberrant STAT activation has been observed in several leukemias as 
well (reviewed in [25]). Interestingly, STAT activation is not always linked to 
increased JAK activity in these diseases; the oncogenes Bcr-Abl and TEL­
PDGFR, as well as c-src have been described to activate STAT 1, ST ATS or 
STAT5 independently of JAKs [26-27]. Careful modulation of the 
JAK/STAT pathway is essential for normal cell homeostasis, and can be 
regulated negatively or positively by protein phosphatases depending on the 
PTP involved, intensity levels of the pathways and cellular context. CD45, 
SHP-1, SHP-2, PTP 1 B, TC-PTP and LMWPTP [22, 28-29] have all been 
demonstrated to modulate JAK/STAT pathways, and will be discussed below. 
3. 1 CD45 
3. 1 . 1  Characteristics and signaling 
CD45 (otherwise known as Leukocyte Common Antigen) is a 
transmembrane tyrosine phosphatase expressed on most haematopoietic cells 
and their precursors except for mature erythrocytes and platelets' [30J . The 
intracellular tail of CD45 contains tandem repeats of two potential 
phosphatase domains, only one of which seems to be active (for review see 
[3 1]. CD45 is a critical positive regulator of T cell antigen receptor (TCR)­
and B cell antigen receptor (BCR)-mediated signaling required for the 
activation and development of lymphocytes. In  humans, loss of CD45 in 
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humans leads to severe combined immunodeficiency disease [32-34]. Cells 
isolated from CD45-deficient mice show decreased B-cell differentiation and 
accumulation of pro-B-cells, which correlates with hyperactivation of JAK I 
and JAK3 upon cytokine stimulation [35]. The negative regulatory role of 
CD45 on JAK/ST AT signaling originates either from direct association and 
dephosphorylation of JAK I or JAK2, or from an alternative mechanism that 
involves the recruitment of the adaptor protein DOK-I [36-37]. Loss of CD45 
was also shown to increase Interleukin (IL)-3-mediated JAK2 activation and 
proliferation in mast cell lines, and EPO-dependent formation of erythroid 
burst-forming units (BFU-E colonies) [36], suggesting that CD45 activity 
drives differentiation in favour of proliferation. 
Other proteins identified as molecular targets of CD45 are the Src 
Family Kinase (SFKs) members [38]. CD45 can dephosphorylate both the 
kinase domain and the COOH-terminal tyrosine SFKs (Figure 2). 
Dephosphorylation of the positive regulatory site on some SFKs leading to 
their inactivation was shown for Hck and Lyn during integrin mediated 
adhesion in macrophages [39], p56lck kinase activity in developing 
thymocytes [ 40] and Lyn in B cells [ 41 J. However, dephosphorylation of 
COOH-terminal tyrosine, opens up the Src kinase to ( auto )phosphorylation on 
activating residues. This appears to be the most commonly observed role for 
CD45 in haematopoietic cytokine signaling, providing a rationale for the 
positive regulatory function of CD45 in antigen receptor signaling [35], and 
might explain why activating CD45 mutations can result m 
lymphoproliferation and autoimmune disease [ 42]. Our group has shown that 
exclusion of CD45 from lipid raft signaling complexes prevents negative 
regulation of SFKs by CD45, providing a possible explanation for the dual 
positive and negative regulation of SFK activity by this phosphatase [ 43]. 
3. 1 .2 Role in malignancy 
Different splice variants of CD45 are expressed in haematological cells 
during different stages of their differentiation. The low molecular weight 
isoform CD45RO seems to be associated with maturing blood cells, and is 
expressed on memory T-cells, maturing myelocytes and activated B-cells en 
route to becoming plasma cells [ 44-45]. High molecular weight isoforms, 
CD45RAB, CD45RBC, CD45RABC and CD45RB, are variably expressed on 
naive T-cells and pre-B-cells [ 46]. Relatively little is known about the 
different roles of these isotypes, although differences in cellular functioning 
have been shown in T-cells recombinantly expressing different CD45 isoforms 
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[ 47] . In haematological malignancy, isotype expression is often de-regulated, 
as was shown for AML [44, 48] and Myeloma (MM) [49-50] . However, 
whether this reflects differences in signaling or variation in differentiation 
status of cells corresponding to F AB classification remains to be determined. 
CD45 deficiency in malignant T-cells was shown to result in resistance 
to apoptosis [5 1 -52] , whereas overexpression of CD45 in growth factor­
dependent cell Lines frequently causes growth arrest and/ or cell death [so] . 
It would therefore stand to reason that tumor cells might down-regulate CD45 
expression in order to escape apoptotic processes. However, although loss of 
CD45 expression has been reported in patients with Hodgkin's lymphoma and 
in > IO% of patients with paediatric Acute Lymphoblastic Leukemia (ALL), 
CD45 is still widely expressed in various types of hematological malignancies, 
and high expression levels of CD45 correlate with poor prognosis in AML and 
childhood ALL [53-56] . Interestingly, recent studies suggest that targeting 
CD45 with specific antibodies might improve survival of AML bearing mice by 
increasing chemotherapy uptake [57] . 
CD45 has been shown to play an important and complicated role in 
Multiple Myeloma. During normal B-cell lineage differentiation CD45 
expression gradually declines, but is not lost, resulting in CD45+/ dim plasma 
cells. In both normal and MM bone marrow CD45bright and CD45+/dim 
plasma cell fractions can be identified, although the CD45+/dim fraction is 
significantly bigger in MM patients [58], and seems to increase during 
progression of the disease to more malignant stages [ 59] .  In so% of patients, 
CD45 expression is completely annihilated on blood or bone marrow plasma 
cells, representing end stage disease and correlating with poor prognosis [60-
6 1 ] . As CD45 is a negative regulator of the JAK-ST AT pathway, loss of CD45 
expression might partly explain the constitutive activation of this pathway 
observed in MM patients [62] . 
Several studies have investigated the proliferative capacity of the 
different B-and plasma cell fractions in normal and MM bone marrow and 
blood, and have shown that the small CD45bright compartment has a 
significantly higher cell proliferation index than the CD45-/dim fractions [50, 
63] . CD45 expression plays a crucial role in determining signaling and 
proliferation of human myeloma cell responses to IL-6, insulin growth factor 
(IGF)- 1 and other growth factors. It has repeatedly been shown that CD45+ 
MM cells are more responsive to IL-6 stimulation, leading to increased 
proliferation in this plasma cell fraction [64-65] . This effect is most likely due 
to an increased IL-6-induced Src kinase activation in CD45+ cells [66-67] . 
Interestingly, depending on cellular context, expression of CD45 can also 
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make cells more susceptible to apoptosis signals, which might be due to the 
dual role of CD45 in SFK activity or the decreased expression of the anti­
apoptotic factor Bcl2 observed in CD45+ cells [58, 68]. Another explanation 
for this phenomenon was presented by Descamps et al, who show that IGF- 1 -
induced activation of the PisK/PKB survival pathway is decreased in CD45+ 
cells, possibly as a direct result of IGF-R dephosphorylation by CD45 [69]. 
CD45 expressing MM cells appear to be of a more immature subtype 
compared to their CD45-negative counterparts as determined by co-expression 
of other cell surface markers [50, 70]. In agreement with this, Matsui and co­
workers showed that clonogenic capacity was contained within a CD45+ 
fraction of MM plasma cells, thus displaying potential progenitor cell 
characteristics [7 1]. In contrast, others showed that clonogenic potential was 
limited to CD45- MM cells [72]. This apparent discrepancy might be 
explained by differences in experimental model potentially leading to the 
exposure of cells to different cytokines, as it has recently been demonstrated 
that IL-6 induced colony growth is mostly apparent in CD45+ MM cell lines, 
whereas IGF- 1 -induced colony formation was restricted to CD45- cells [73]. 
In summary, the role of CD45 in haematological malignancies is a 
complicated one; expression of CD45 is associated with poor prognosis in 
AML, possibly as a result of increased SFK activity, and CD45 might 
potentially be used as a target for treatment in AML. In contrast, loss of CD45 
expression is a poor prognostic factor in MM. The increased activity of the 
PisK/PKB pathway in CD45- cells, in combination with the increased JAK­
STAT activity observed in these patients, presents an opportunity for the use 
of kinase inhibitors of these pathways in MM treatment, whereas proliferation 
of CD45+ cells might be targeted by SFK or CD45 phosphatase inhibitors. 
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Figure 2. CD45 signaling in haematopoietic cells. Upper panel : cytokine or growth 
factor (e.g. Interleukin-6 [IL-6] or insulin like growth factor- I [IGF- 1 ] )  stimulation 
results in dimerization of the corresponding receptor, bringing their associated JAKs 
into close proximity to eachother and enabling STAT activation. In addition, PISK 
activety leads to formation of Ptdins(S,4,5)Ps, which subsequently activates PDK 1 and 
PKB/ AKT. Lower panel: one the targets for CD45 is the Src family of kinases, 
represented here as Src. CD45 can dephosphorylate Src at its COOH terminal 
tyrosine, allowing subsequent phosphorylation and activation by cytokine stimulation, 
providing a positive regulation of Src kinase activity. Alternatively, CD45 can 
dephosphorylate Ser at its positive regulatory sequence, leaving it inactive. I n  addition, 
CD45 can negatively regulate JAK/STAT and PisK/PKB signaling, by 
dephosphorylating JAK and growth factor receptors, respectively. 
3 .2 PTP IB 
3.2. 1 Characteristics and signaling 
The ubiquitously expressed Protein Tyrosine Phosphatase lB  
(PTP 1 B) i s  located on the cytosolic face of the endoplasmic reticulum (ER) due 
to a hydrophobic sequence at its C-terminal end. PTP 1 B is involved in 
multiple normal and malignant signaling pathways [SJ by regulating RTKs, 
including epidermal growth factor receptor (EGFR) [74], PDGFR [75], 
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insulin receptor [76] and IGF-1 [77]. Dephosphorylation of RTKs by PTP1B 
occurs after endocytosis and translocation of the RTK to the ER, where after 
they are recycled to the cell membrane or directed to lysosomes [78]. PTP l B  
is thus able to dephosphorylate RTKs from different cell compartments, 
despite its localization to the ER. In addition to RTKs, PTP 1 B has other 
membrane-associated substrates: it can negatively regulate cytokine signaling 
through JAK2 and TYK2, either through dephosphorylation of STAT5a/b, or 
by direct association with the RTKs [79-81]. In addition, PTP1B has been 
shown to regulate integrin signaling through Src kinases [82]. 
Due to its negative regulation of multiple RTKs, PTP1B deficiency 
could lead to increased oncogenic signaling. Indeed, PTP 1 B deficient 
fibroblasts display increased IGF-1 receptor, EGFR, and PDGFR tyrosine 
phosphorylation [83]. However, Dube and co-authors reported that PTP l B  
can also act as a positive regulator of Ras signaling downstream of RTKs 
through increased p 120RasGAP (Ras GTPase-activating protein) expression 
and p62Dok (downstream of tyrosine kinase) phosphorylation [75], which 
partly explains why PTP1B knockout mice do not display an increased 
incidence of tumors. In fact, overexpression of PTP 1 B has been shown in a 
variety of (solid) tumors, including colon cancer cells in which it activates Src 
kinase signaling by decreasing its negative regulatory phosphorylation [84]. 
In addition, overexpression of PTP1B is enough to induce breast cancer in 
mammary gland cells, demonstrating a role for PTP 1 B as oncogene in its own 
right [85]. As a dual role of PTP1B is arising, absence of its activity may 
either suppress or promote oncogenic transformation [7 5]. 
3.2.2 Role in malignancy 
In humans, PTP 1 B is one of the negative regulators of cytokine­
induced JAK2- STAT3/5 pathways [79], and mice deficient for PTP1B 
showed hyperphosphorylation of JAK2 [86]. Genetic ablation of PTP1B in 
p53 null mice decreased survival rate and increased susceptibility towards the 
development of B lymphomas [87], although no correlation with 
JAK2/STAT5 activation was observed in this study. In addition, PTP1B can 
negatively modulate Bcr-Abl [88], a constitutively active fusion kinase 
expressed as a consequence of t(9;22), the so-called Philadelphia chromosome. 
This oncoprotein is found in 15-30% of adults with AML, and in nearly all 
CML patients, where it plays a major role in the development and progression 
of CML through chronic, accelerated, and blast phases [89-90]. Expression of 
Bcr-Abl results in constitutive activation of STAT5 and alterations in signal 
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transduction and gene expression profiles that are associated with cytokine 
independence [9 1 ]. In addition to recognizing Bcr-Abl as a substrate, PTP 1 B 
disrupts the formation of a Bcr-Abl/Grb2 complex, thereby inhibiting 
signaling events and oncogenic transformation initiated by this oncoprotein 
[88]. Overexpression of PTP I B  or inhibition of Bcr-Abl induced erythroid 
differentiation of CML cell line K562 and inhibition of PTP I B  attenuates the 
induction of differentiation and apoptosis by STI57 1 ,  a selective Bcr-Abl 
inhibitor, in CML cells [92]. This latter study also showed that STI57 1 -
resistant ALL cells have a significantly reduced PTPI B activity, providing 
strong evidence that reduction of PTP I B  expression and activity leads to 
resistance of Bcr-Abl-positive leukemia cells to STI5 7 1 .  
However, increased PTP IB  expression levels have been observed in 
activated B cell-like diffuse large B-cell lymphomas. This was associated with a 
decreased IL4- mediated ST A T6 dephosphorylation, which is independent of 
Jak l ,  but not JAK2 [93]. Thus, whereas decreased PTPI B may increase 
tumorigemc1ty by enhancing proliferative JAK2/STAT5 signals, 
overexpression of PTP 1 B renders cancer cells unsusceptible to the anti-tumor 
effect of IL-4-ST A T6 activation. The potential use of PTP 1 B in treatment of 
haematological malignancy may therefore completely depend on its expression 
level, and the signaling pathways activated in these illnesses. 
3.3 TC-PTP 
3.3. 1 Characteristics and signaling 
TC-PTP (T Cell Protein Tyrosine Phosphatase) is an intracellular 
enzyme encoded by Ptpn2. TC-PTP is mainly haematopoietic and alternative 
splicing of its gene allows expression of two distinct proteins, a p45 nuclear 
form called TC45 or TC-PTPa, and a p48 cytoplasmic form called TC48 or 
TC-PTP 1 b. TC-PTP-/- mice display defective haematopoiesis and immune 
function, characterized by anaemia and splenomegaly secondary to 
sequestration of erythrocytes and accumulation of myeloid cells [86]. In 
addition, TC-PTP-null mice develop severe systemic inflammation, a 
phenotype with potential implications in oncogenesis. 
TC-PTP and PTPI B share over 70% amino acid sequence identity 
within their catalytic domains. However, while PTP I B  is predominantly ER­
localized, TC-PTP is largely nuclear. TC-PTP has been shown to control 
cytokine signaling events by its negative action on the JAK/STATs pathways 
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[94] . Both TC-PTP and PTP IB selectively recognize a motif centered on the 
characteristic double tyrosine residues present in the JAK activation loop, but 
TC-PTP exhibits specificity for JAK I and JAKs, while PTP I B interacts with 
JAK2 and TYK2. TC45/TC-PTP I B is responsible for selective JAK 
dephosphorylation and deactivation of nuclear STAT I ,  STATS, and STATS 
[95-96]. TCPTP was also shown to interact with TRAF2 downstream of the 
proinflammatory cytokine TNF. This interaction inactivates Src and 
suppresses MAPK signaling [97]. These results identify TC-PTP as a key 
modulator of inflammatory signals as well as lymphocyte functions. 
3.3.2 Role in malignancy 
Despite its clear function in normal haematopoiesis, the role of TC­
PTP in oncogenic transformation remains circumspect. Similar to PTP I B, a 
role for reduced TC-PTP in STl57 I resistance of CML cells has been 
established [98] . However, as for PTP IB, increased nuclear TC-PTP 
expression, correlating with decreased ST A T6 signaling was observed in 
activated B-cell like lymphomas compared to other types of B-cell lymphomas 
and may facilitate tumor survival [99] . Bourdeau and co-authors observed 
that TC-PTP-deficient bone marrow stromal cells fail to support normal B 
lymphopoiesis due to abnormally high secretion of interferon-0, which 
reduced 2-fold the mitotic index of IL-7-stimulated TC-PTP-/- pre B-cells. 
They noted a 40% increase in apoptosis of murine early pre-B leukemic cells 
cultured within a TC-PTP-deficient bone marrow stroma environment [94] . 
Moreover, they describe constitutive phosphorylation of ST AT I in TC-PTP­
/- pre-B cells, which may find practical application in the treatment of cancer. 
Unlike other STATs, STAT I acts as a tumor suppressor (reviewed by [100] . 
Thus, reducing TC-PTP activity, thereby increasing STAT6 and STAT ! 
activity, may help reduce tumor burden and metastasis. TC-PTP-specific 
blocking agents might provide a useful pharmacologic approach toward this 
goal. 
3 .4 SHP-1 
3.4. 1 Characteristics and signaling, role in malignancy 
Src homology 2 domain-containing phosphotyrosine phosphatases 
(SHP)-1 are a subfamily of cytoplasmatic non-receptor PTPs. SHP-1 (also 
known as PTPI C or HCP - Haematopoietic Cell Phosphatase) and SHP-2 
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(discussed below) are characterized by the presence of two N-terminal SH2 
domains, a classic PTP domain and a C-terminal tail [ 10 1]. Their SH2 
domains permit association with phosphotyrosine from proteins such as 
activated receptors or signaling molecules, triggering activation of the 
phosphatase domain and, subsequently, dephosphorylation of the substrate. 
SHP- 1 is mainly expressed in haematopoietic cells although it is also 
present in epithelial and smooth muscle cells. Via its SH2 domains, SHP- 1 is 
recruited to c-Kit, BCR, TCR and the receptors for FCyIII, IL-s and 
erythropoietin (EPO), thereby playing a role in the control of signaling 
cascades that couple growth factor receptors to haematopoietic cell 
differentiation [ 102- 103]. Binding of SHP- 1 to the EPO receptor results in 
dephosphorylation of the receptor-associated kinase JAK2 at position Tyr 1008, 
thereby reducing its activity [28, 10 1]. Mice deficient for SHP- 1 display 
hyperphosphorylation of JAKl and JAK2 following Interferon-a (INF-a), 
Growth Hormone (GH) or EPO treatment, resulting in important 
immunological and haematopoietic dysfunctions [ 104]. In humans, the Shp-1 
gene is frequently altered in cancer cells, and various haematological 
malignancies, such as lymphomas, Myeloma and AML show silencing of Shp-1 
by methylation [ 105-107]. In addition, decreased SHP- 1 mRNA and protein 
expression levels have been observed in diverse leukemic cell lines and 
paediatric AML [ 108- 109]. 
SHP- 1 may also affect leukemia development through its negative 
modulation of the Bcr-Abl pathway. Amim and co-authors (2007) observed 
that SHP- 1 levels are markedly decreased in advanced stage CML patients 
compared with those in chronic phase. However, neither mutation nor DNA 
methylation was detected in the Shp-1 gene in CML cell lines or patient 
samples, suggesting that the decrease in SHP- 1 in advanced stage CML 
patients is due to posttranscriptional modifications [ 1 10], and implying that a 
decrease in SHP- 1 expression levels plays a role in the progression of CML. 
Together, these results suggest a potential role for SHP- 1-inducing 
agents in cancer treatment. Interestingly, proof of concept of this hypothesis 
comes from experiments showing that restoration of SHP- 1 expression in 
anaplastic large cell lymphoma using 5-aza-2'-deoxycitidine results in 
abrogation of constitutive JAKs- STATS signaling and increased drug 
sensitivity [ 1 1 1]. 
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3.5 LMWPTP 
3.5. J Characteristics and signaling 
Low molecular weight protein tyrosine phosphatases (LMWPTPs ); 
also known as acid phosphatase locus 1 (ACP 1 ) ,  are a family of 1 8-kDa 
enzymes involved in cell growth regulation, cytoskeleton rearrangement and 
modulation of the immune response. This small molecule, which interacts with 
growth factor receptors and proliferation signaling pathways, possesses some 
interesting biochemical and structural characteristics. LMWPTP activity is 
regulated by phosphorylation/ dephosphorylation or oxidation of the protein. 
It possesses two phosphorylation sites, which seem to work as switches for 
different functions of the phosphatase. Bucciantini et al .  have shown that SFK 
are able to phosphorylate both sites, triggering two different effects [ 1 1 2] .  
Phosphorylation of tyrosine residue 1 3 1  increases the activity of LMWPTP 
25-fold, whereas phosphorylation of tyrosine 1 32 leads to Grb2 recruitment. 
The second regulatory mechanism able to modify LMWPTP activity is the 
oxidation of the 1 2  and 1 7  cysteine residues, which renders the phosphatase 
inactive. However, the presence of an additional cysteine in the catalytic s ite 
(Cys 1 7) makes LMWPTP able to undergo formation of an intramolecular S-S 
bridge. This event prevents the complete and irreversible oxidation of the 
catalytic cysteine (Cys 1 2), enabling LMWPTP to rapidly recover its activity 
[ 1 1 3] .  
LMWPTP has been shown to be  associated with molecules involved in 
cell growth and proliferation, such as PDGFR [ 1 1 4] ,  JAK2 [ 1 1 5] ,  STAT5 
[29, 1 1 6] ,  Focal adhesion kinase (FAK) [ 1 1 7] ,  Ephrin A2, receptors (Eph A2) 
[ 1 1 8] and �-Catenin [ 1 1 9] .  Although mostly regarded as negative regulator 
of kinase activity, a positive action of 
LMWPTP in cell growth and proliferation signaling has been also 
described [ 1 1 5, 1 20] . LMWPTP is an important regulator of STAT5 activity 
during megakaryocyte differentiation. Rigacci and co-workers suggested that 
the association of LMWPTP with STAT5 prevents phosphorylation of this 
transcription factor in the absence of a growth factor stimulus [29] . In 
contrast, LMWPTP oxidation mediates the sustained phase of JAK2 
phosphorylation, which is required for the antiapoptotic effects of IGF-1 and 
serum on pancreatic cells [ 1 1 5] .  This suggests that inhibition of LMWPTP 
leads to enhanced and sustained phosphorylation of the JAK/STAT pathway 
and suppression of apoptosis, and as such makes this PTP an interesting 
candidate in IGF- 1-mediated MM cell survival. However, the oxidative switch 
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of LMWPTP and its function is not completely understood, and it has also 
been observed that oxidation of this phosphatase is involved in Grb2 binding 
and increased ERK activation, implying that LMWPTP oxidation can directly 
trigger a prosurvival signal against the oxidant environment [ 120]. 
3.5.2 Role in malignancy 
Increased expression levels of LMWPTP have been reported in 
several human tumors, such as neuroblastoma, breast and colon cancer. 
Analysis of patient survival indicates that higher LMWPTP levels are 
predictive of an unfavourable outcome, meaning that LMWPTP could confer 
tumor aggressiveness and its expression might be used as a marker in some 
types of cancer [ 121  J. 
Interestingly, LMWPTP has been pointed out together with ZAP70 
as predictors for treatment requirement in a case reported by Chen et al 2005. 
These authors have shown that a patient with chronic lymphocytic leukemia 
presented a gradual loss of LMWPTP and ZAP70 as well as the active form of 
ZAP70 (phospho-ZAP70 tyr492) during continued chemotherapy. In addition, 
the return of these proteins to normal levels correlated with requirement for 
treatment [ 122]. Therefore, although LMWPTP has a negative regulatory 
function in JAK/ST AT activation and hence would appear to be tumor 
suppressive, its overexpression in many cancers suggests that this does not 
hold true for transformed cells, and may make this phosphatase a target for 
therapy in haematological malignancies. However, the regulation of its 
switches (phosphorylation and oxidation) and state (activated and inhibited) 
and their importance for the normal and cancer cell biology require further 
study. 
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4. RAS-RAF-MEK-ERK SIGNALING. 
The Ras signaling pathway has been extensively studied and reviewed. 
Upon cytokine signaling, the adaptor protein Grb2, which is complexed to the 
guanine nucleotide exchange factor (GEF) Son of Sevenless (Sos), is recruited 
to activated receptors through its SH2 domain. The subsequent membrane 
localisation of this GEF allows activation of the membrane-bound small 
GTPase Ras by facilitating its ADP release and subsequent ATP binding. Ras 
activation results in a cascade of mitogen-activated protein kinase (MAPK) 
activation, where MAPK kinase kinase ( e.g., Raf) activates MAPK kinase ( e.g., 
MEK I /2), which subsequently phosphorylates MAPK (e.g., extracellular 
signal regulated kinase; ERK I /2) [ 1 23] .  MAPKs are subdivided into three 
subfamilies based on sequence similarity, differential regulation and substrate 
specificity: ERK 1 /2,  c-Jun N-Terminal l{inase (JNK) (JNK 1 ,2 and 3) and p38 
(a,j3,8 and y) [ 1 24] .  
Activating Ras mutations, predominantly investigated i n  leukemias 
and MDS, have been observed in a large cohort of studies (Reviewed in [ 1 25] . 
Ras activity and function depends on its membrane localisation, a process 
facilitated by farnesylation of the protein, and farnesyl transferase inhibitors 
have therefore been extensively tested in tumor cell biology. However, clinical 
phase I I  trials with these inhibitors were only marginally successful, and 
despite achieving clinically relevant positive results in some studies, this did 
not seem to be correlated to RAS mutation status of patients [ 1 26- 1 28] .  
Downstream of Ras, mutations i n  Raf and ERK I /2 have been observed i n  a 
number of haematological malignancies (reviewed in [ 1 29] ) . Increased 
phosphorylation of ERK 1 I 2 is frequent in leukemia, and appears to play an 
important role in drug resistance [ I SO] . In contrast, in low risk MDS patients, 
a decreased ERK I /  2 activity was observed in neutrophils and CDs4+ 
progenitor cells, which correlated with decreased cell functionality [ 1 3 1 - I SSJ . 
As such, phosphatases interfering in MAPK signaling may be of functional 
consequence in haematological disease and may provide a target for treatment. 
Some such phosphatases include SHP-2, HePTP, and the MAPK phosphatases 
(MKPs), and these will be further discussed below. 
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4. 1 SHP-2 
4. 1 . 1  Characteristics and signaling 
The protein tyrosine phosphatase SHP-2 is encoded by the PTPN 11 
gene (protein tyrosine phosphatase non-receptor-type 11) and localized on 
12q24 [134]. SHP-2 is expressed ubiquitously, but particularly strongly in 
blood cells. In its basal state, SHP-2 activity is suppressed by intramolecular 
interactions between residues in the "backsideloop" of the N-SH2 domain (the 
side opposite the phosphotyrosyl peptide binding pocket) and the catalytic 
surface of the PTP domain [135]. Upon growth factor or cytokine 
stimulation, SHP-2 is recruited via its SH2 domains to phosphorylated 
tyrosine residues on RTKs (e.g. Kit-ligand, IL-3, EPO and granulocyte­
monocyte colonystimulating factor (GMCSF)) an<l/ or scaffolding adaptors, 
such as insulin receptor substrate, fibroblast growth factor receptor substrate, 
or Grb2-associated binder (GAB) proteins [1.36]. Phosphotyrosyl peptide 
binding to the N-SH2 domain disrupts the autoinhibitory interface; leading to 
exposure of the PTP domain and catalytic activation [7, 1.35]. Activation of 
SHP-2 generally leads to activation of the Ras/Ras/ERK pathway, but its 
precise target(s) remains controversial. SHP-2 activates SFKs evoked by RTK 
and integrin signaling in fibroblasts, and SFKs in turn are required for 
sustained Ras activation on endomembranes [137]. 
Other authors suggest that SHP-2 ensures Ras signaling by 
dephosphorylating potential recruitment sites for p120RasGAP, a GTPase 
activating protein that promotes Ras inactivation [1.38]. SHP-2 is essential for 
myeloid differentiation [83], and can negatively modulate c-I{it signaling by 
interacting with specific phosphotyrosine residues on this receptor [103]. Kit 
signaling is important in erythropoiesis, lymphopoiesis, megakaryopoiesis and 
mast cell development and function, and its expression and constitutive 
activation is found in for instance mast cell leukemia and AML [ 139]. 
4. 1 .2 Role in malignancy 
SHP-2 was the first PTP implicated in leukemogenesis. Somatic gain 
of function mutations in the PTPN 11 gene are the most common cause of 
sporadic juvenile myelomonocytic leukemia (JMML), implicated in about 35% 
of cases [140]. In addition, PTPN l 1 mutations occur at lower incidence in 
other myeloid neoplasms such AML (-5% ), chronic myelomonocytic leukemia 
(CMML), and myelodysplastic syndrome (MDS) [140-141], as well as in the 
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most common form of childhood leukemia, B-acute lymphoblastic leukemia (B­
ALL) (�10%) [7, 96]. Germline mutations in the SHP-2 gene occur in 50% of 
individuals with Nooman syndrome (NS), a developmental disorder with short 
stature, facial dysrnorphia, skeletal anomalies and heart defects [ 14< l] .  
Children with this syndrome have a growth disorder as well as  a 
predisposition to develop JMML [ 142] . Activating PTPN 1 1 mutations 
negatively regulate the cellular response to Growth Hormone (GH) and 
explain the growth disorder observed in these patients. In vitro experiments 
demonstrated that SHP-2 associates directly with the GH receptor (GHR) in 
response to G H [ 143] and acts as a cytosolic phosphatase of ST AT 5, 
downregulating its activity [144]. In addition, a decreased STATS activation 
has been observed in NS/JMML cells with PTPNl mutation [145]. As 
discussed above, SHP-2 is required for full activation of the Ras/Raf/Erk 
pathway and for multiple receptor-evoked functions, including cell 
proliferation, differentiation, and migration [101]. Indeed, gain of function 
mutations in PTPN 11 have been shown to result in hyperactivation of ERK 
and protein kinase B activation [146-147]. Thus, the predisposition of the 
Noonan Syndrome patients to JMML is related to the activation of 
Ras/MAPK pathway by SHP-2 activation. It is important to emphasize that 
mutations in the RAS family members KRAS or NRAS genes, PTPN 11 gene, 
or the RAS-GAP NF 1 are observed in 65%-85% of JMML patients [ 148]. 
Konieczna and co-authors (2008) found that constitutive activation of 
SHP-2 in mice cooperates with progression of myeloproliferative disorders. 
They showed that Interferon Consensus Sequence Binding Protein (ICSBP, 
also known as IRF8), an interferon-regulatory transcription factor, functions 
as a leukemia tumor suppressor only when phosphorylated. Coexpression of a 
constitutively active form of SHP-2 synergized with ICSBP haploinsufficiency 
to accelerate progression to AML, induce cytokine hypersensitivity and 
apoptosis resistance in vivo [ 134 J. 
SHP-2 can also function as a positive factor in IL-6 signaling by 
stabilizing JAK2 or inducing Src kinase activation [149] . IL-6-induced 
JAK 1 ,2-STATs signaling is one of the major growth signals in Myeloma cells 
[62] . It has recently been shown that c-MET enhances IL-6-induced 
proliferation of MM cells through increased activation of SHP2, suggesting a 
possible role ofSHP-2 in MM pathology [150]. 
In conclusion, the evidence to date suggests that the role of SHP-2 in 
leukemogenesis is more prominent than its role in tumor suppression, 
implying a potential role for SHP-2 inhibitors as a molecular target of therapy. 
Interestingly, this seems to be corroborated by the finding that increased 
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expression of SHP-2, which was correlated with enhanced FLTS signaling in 
AML patients, was reduced by treatment of AML cells with a c-KIT /FL Ts 
kinase inhibitor [ 15 1 ]. 
4.2 HePTP 
4.2. 1 Characteristics and signaling, role in malignancy 
Haematopoietic PTP (HePTP), also named leukocyte PTP (LC-PTP), 
1s a NRPTP that contains a kinase interacting motif, allowing it to bind to 
ERK and the MAPK pS8 [ 152]. This results in conformational changes in 
both the PTP and its substrate, leading to dephosphorylation of the substrate, 
and subsequent phosphorylation of HePTP by the bound kinase [ 15SJ. In T­
cells, HePTP functions as an early response gene, regulating phosphorylation 
state during IL-2-induced proliferation [ 154]. HePTP overexpression results 
in decreased ERK phosphorylation upon TCR signaling [ 155], whereas its 
reduction increased PMA-induced ERK 1 I 2 activity in spleen cells from 
HePTP knock out mice [ 156]. In its capacity as a modulator of ERK 1 /2 
activity and nuclear translocation, HePTP is also involved in megakaryocyte 
differentiation [ 157]. In addition, HePTP can be phosphorylated by protein 
kinase A in B-cells, where it inhibits pS8 induction by betaadrenergic receptor 
agonist signaling [ 15 8]. 
Expression of HePTP is limited to tissues of haematological origin 
such as thymus, spleen and all myeloid and lymphoid cells. As such, it is 
interesting to note that the HePTP gene is mapped next to another 
haematopoietic specific PTP, CD45, on chromosome l qS2 [ 159] and might 
therefore be generated by gene duplication of a common ancestral gene [ 160]. 
Deletions of this chromosomal region have been frequently found in B-cell 
lymphomas, which corresponds with a significantly decreased protein 
expression of HePTP observed in paediatric B-cell lymphoma cases [ 1 6 1 -
1 62]. In contrast, triplication of the HePTP gene and protein overexpression 
was observed in MDS and AML patients, suggesting a cell-type specific role 
for aberrant HePTP expression in haematological malignancies [ 1 6SJ . 
However, further studies will have to correlate changes in HePTP expression 
to downstream signaling strength in haematological malignancies, and 
determine whether this promising candidate phosphatase may be a potential 
target for treatment in haematological tumors. 
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4.3 MKPs 
4.3. 1  Characteristics and signaling 
MAPKs transduce extracellular signals from environmental stress 
hormones, growth factors and cytokines which results in control of diverse 
physiological processes such as proliferation, differentiation, migration and 
apoptosis (reviewed in [ 1 7, 1 64]). MAPK phosphatases (MKPs), a family of 
DUSPs, are able to inactivate MAPKs through dephosphorylation of tyrosine 
and/ or threonine residues in the activation loop of MAPKs. Based on sequence 
similarity, substrate specificity, gene structure and subcellular localization the 
ten MKPs can be classified into three subfamilies. The first group is composed 
of nuclear MKPs which include DUSP1 /MKP- 1 ,  DUSP2/PAC- 1 ,  
DUSP4/MKP-2 and DUSP5/hVH-s. The second group of cytoplasmic MKPs 
comprises DUSP6/MKP-3, DUSP7 /MKPX and DUSP9/MKP-4, and the 
final group consists of DUSPs/h VH-5, DUSP 1 0/MKP-5 and DUSP 1 6/MKP-
7, which are found both in the cytoplasm and the nucleus. Abnormalities in 
MAPK pathways have been associated with a wide variety of human diseases, 
including cancer (reviewed in [ I  7]). The role of ERK 1 / 2 in haematological 
malignancies is well documented, whereas the involvement of the JNK and p.38 
MAPKs is more circumspect [ 1 29] . Activation of ERi{ is usually associated 
with cell proliferation and survival, whereas JNK and p38 contribute to cell 
apoptosis in response to stress [ 1 65]. The balance between MAPK and MKP 
activity directs cell fate to either survival or apoptosis. Negative regulators of 
ERi{, such as MKP DUSP2/PAC 1 ,  are excellent candidate tumor suppressors. 
However, other MKPs, like MKP- 1 ,  have been associated with survival and 
tumorigenesis and are overexpressed in many types of cancer [ 1 65] . It is 
interesting that different DUSPs can have either a positive or negative 
regulatory role in ERK activation, as increased ERK pathway activation is 
observed in 30 to 50% of AML cases, whereas some low-risk MDS patients 
show decreased ERi{ phosphorylation [ 1 32, 166]. 
4.3.2 Role in malignancy 
Recently, the DUSP 1 6/MKP-7 was shown to be associated ,-vith 
leukemia. Altered subnuclear localization of the transcription factor Runx 1 ,  
responsible for normal haematopoiesis, was linked to the etiology of AML by 
upregulating microRNA-24 (miR-24). miR-24 expression leads to inhibition of 
Ml{P-7 expression, consequently enhancing myeloid cell proliferation and 
4 1  
Chapter 2 
blocking granulocyte differentiation by increasing p38 phosphorylation [ I  67]. 
Although this may seem somewhat counterintuitive, as p38 activity has been 
associated with cell death and reduced tumorigenesi8 [168], p38 has also been 
shown to be detrimental for granulocyte development and others have 
demonstrated that decreasing constitutive p38 activation may restore normal 
hematopoiesis in malignant cells [ I  69-170]. 
The MKP DUSP2/PAC-1 is predominantly expressed in 
haematopoietic tissue, and acts as a negative regulator of MAPK signaling 
[I 71-173]. Loss of DUSP2/PAC-1 expression has been associated with 
elevated levels of ERK activation in acute leukemia, as Kim and co-authors 
showed that increased expression and activity of ERK and MEK in 1 7 of 26 
cases (65.4%) indeed corresponded to downregulation of DUSP2/PAC-1 
[I 74] .  Thus, downregulation of MKPs can be responsible for the increased 
MAPK activation that is often described to contribute to haematological 
malignancy. Increasing these MKPs' activity for treatment of these diseases 
remains a challenge. 
However, enhanced MKP act1v1ty has also been linked to 
haematological illness. Constitutive overexpression of two transcripts related 
to DUSP2/PAC-1 was observed in large granular lymphocyte (LGL) leukemia 
[I 7 5]. LGL leukemia is a lymphoproliferative disorder originating either from 
mature T cells or natural killer (NK) cells, and often associated with 
autoimmune disease (reviewed m [I 76]. The physiological role of 
DUSP2/PAC-1 in the immune system was described by Jeffrey et al (2006) 
who showed that PAC- I -null mice display a decreased expression of 
proinflammatory mediators and cytokines such as IL-6, IL12-a, 
cyclooxygenase-2 and 11..-I B in response to LPS stimulation [I 73]. As the 
etiology of LGL leukemia is not completely elucidated, the discovery of 
DUSP2/PAC-1 overexpression in this disease has provided a focus in the 
search for a therapeutic target. 
Another MAPK phosphatase with a possible role in haematological 
cancer is the DUSP I /MKP-1, expression of which is induced by growth 
factors and stress signals in human cells [I 7 7] .  Initially, MKP-1 was shown to 
dephosphorylate ERK and negatively modulate cell proliferation [I 78]. 
However, recent studies have described an antiapoptotic effect of MKP-1 by 
negatively modulating JNK and p38 [179]. In addition, enhanced activity of 
the RAF /MEK/ERK pathway can be associated with increased mRNA levels 
of DUSP I /MKP-1 as shown in a study from Staber and co-workers, who 
demonstrated overexpression of MKP-1 accompanied by RAF /MEl{/ERK 
pathway upregulation in bone marrow of relapsed AML patients compared to 
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AML samples before high-dose chemotherapy [I SO]. This positive regulatory 
role for Ml{P-1 in cell survival was later confirmed by others, showing that 
MKP- 1 depletion in breast cancer induces apoptosis [ I 65]. 
Together, these data indicate that MPKs can exert both positive and 
negative actions on leukemogenesis, and suggest that that they might be 
viable targets for interference. Especially downregulation of MKP-1 would 
seem a promising avenue of investigation in cancer treatment. However, more 
research into the exact mechanisms of the different MKPs is clearly needed. 
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5.  PI3K-PKB SIGNALING 
PisK signaling is initiated upon growth factor or chemokine receptor 
activation, either through direct recruitment of the SH2 domain containing 
p85 subunit of PisK to the receptors or through binding of the kinase to active 
Ras GTPase. Once translocated from cytosol to plasma membrane, this lipid 
kinase phosphorylates membrane anchored phosphoinositides on the S­
position of the inositol ring. The main products formed are Ptdlns(S,4)P2 and 
Ptdlns(S,4,5)Ps, which act as second messengers by recruiting molecules with 
a phospholipid binding (PH) domain to the membrane, where they are 
subsequently activated. One of these is protein kinase B (PKB, also known as 
Akt), which plays a major role in cell survival and phosphorylates, amongst 
others, mTOR, GSKs and the forkhead transcription factors. Many tumors, 
including blood cancers, present with constitutive activation of the PisK-PKB­
mTOR pathway (reviewed in [ 1 8 1 - 1 82]). Although activating mutations in 
the PlsK gene (PIKsCA) and PKB gene (AKT E 17K) have been described, 
their occurrence seems to be rare in haematological malignancies [ 1 83- 1 84 J. 
More often, constitutive PisK signaling is thought to be a secondary effect: 
the presence of activating mutations in receptor tyrosine kinases or Ras, 
oncogenic translocation products Bcr-Abl and Tel-Abl, as well as autocrine 
cytokine signaling loops have all been cited as contributing factors [ 1 85]. 
Regardless of the activating mechanism, targeting this pathway with 
inhibitors of either PisK/PKB or mTOR appears to be a promising approach 
in the treatment of leukemias (reviewed in [ 1 86]). Phosphatases counteracting 
the PlsK-initiated signaling cascade include PTEN, SHIP and SHIP-2. Their 
role in normal cell physiology and leukemic transformation will be discussed 
below. 
5 . I  PTEN 
5. 1 .  I Characteristics and signaling 
Phosphatase and tensin homolog (PTEN), located on 1 0q2S.S, is a 
dual-specificity phosphatase that has both lipid and protein phosphatase 
activity. PTEN classically converts Ptdlns(S,4,5)Ps at the plasma membrane 
to Ptdlns( 4,5)P2, thereby directly antagonizing the activity of PisK [ 1 87]. 
Therefore, PTEN inactivation results in constitutive activation of the 
PisK/PKB pathway and subsequent increases in protein synthesis, cell cycle 
progression, migration and survival [ 1 88]. 
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Although several studies where PTEN was overexpressed or analysed 
m tumorigenic cell lines and tissues have shown that PTEN was mostly 
localized in the cytoplasm, studies in healthy tissues have suggested that 
PTEN is originally localized in the nucleus [ 1 89- 1 9 1 ] .  Loss of nuclear PTEN 
has now been observed in a variety of tumors, suggesting an association 
between a lack of nuclear PTEN and mitotic index [ 1 92- 1 94] . This seems to 
be corroborated by the fact that nuclear presence of PTEN is apparent in 
quiescent cells, but in actively dividing cells PTEN localizes mostly in the 
cytosol [ 1 95] . 
5.1 .2 Role in malignancy 
Deletion of Pten m mouse haematopoietic stem cells leads to a 
myeloproliferative disorder which is followed by acute T-ALL [ 1 96] . In 
humans, many somatic mutations have been described for the PTEN gene, 
although these occur in the minority of the tumors. Until recently, PTEN 
mutations had only been described sporadically in leukemia and lymphomas. 
However, Gutierrez and collaborators have now identified abnormalities in the 
PTEN gene with a frequency of 8.7% in T-cell acute lymphoblastic leukemia 
(T-ALL) patients, including homozygous and heterozygous deletions [ 1 97] .  
These inactivating mutations carry a negative prognostic risk, related 
to a high risk of treatment failure [ 1 98] . This statement is in agreement with 
Palomero and co-workers who have reported the association of PTEN 
mutations and non-responsiveness to y- secretase inhibitors (GSI). GSI target 
the NOTCH I signaling pathway, which is present in the majority of T-ALL 
cases, and was shown to reduce PTEN expression via HES ! .  This in turn 
leads to a constitutive PKB activation which renders the cells resistant to GSI 
[ 1 99] . 
Loss of functional PTEN has been attributed to PTEN promotor 
hypermethylation in a number of cancers. Recently, Pten epigenetic mutations 
have been also described in JMML. Liu et al suggested that DNA 
hypermethylation in the 5' upstream region of the PTEN gene was responsible 
for deficient PTEN gene expression in 77% of the patients analysed [200] . In 
addition, reduced PTEN expression in ALL due to promoter methylation 
resulted in imatinib resistance in ALL cell lines [20 1 ] .  However, these data 
were disputed by Batz et al 2009, who showed that hypermethylation of the 
PTEN upstream CpG island in JMML is infrequent and probably not a 
relevant epigenetic mechanism of disordered PTEN expression in leukemia 
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[202]. Many reasons could account for this difference such as geographic 
variation or other heterogeneity between the two patient cohorts. 
Other regulatory mechanisms for PTEN expression have been 
described. For instance, down modulation of PTEN expression, resulting in 
constitutive PKB activation in leukemia, has been attributed to the increased 
expression of oncogenic microRNA miR-21 and miR-155 in these tumor cells 
[203]. Antisense oligonucleotides targeting these miRNAs restored PTEN 
expression and enhanced apoptotic activity. Aberrant microRNA expression 
has been described in a number of malignancies, and strategies to target these 
miRNAs for the treatment of cancer are under investigation [204]. 
Low PTEN protein expression has been observed in AML, ALL, and 
paediatric B-ALL by flow cytometry, but surprisingly, increased expression 
was observed in monocytic leukemia [205]. In addition, using 
immunohistochemistry, Gauffiun et al. found protein overexpression of PTEN 
in paediatric ALL samples [ 109]. These conflicting data might be explained 
by Sylva and co-workers who reported increased PTEN protein levels in T­
ALL cells, but found that this was correlated with decreased PTEN activity as 
a result of increased casein kinase 2 (CK2) activity and reactive oxygen species 
(ROS) production in these cells [206]. Inhibiting CK2 activity and ROS 
production restored PTEN activity, and reduced PisK/PKB signaling in this 
study. PTEN is also inactivated through phosphorylation on serine/threonine 
residues at its C-terminus, and phosphorylated PTEN levels are associated 
with poor prognosis in AML [207-208]. 
It has been suggested that resistance to the apoptosis inducing agent 
TRAIL was due to constitutive PTEN phosphorylation in ALL cell lines 
[209]. As CK2 is the main kinase responsible for PTEN phosphorylation, 
there might be a potential role for CK2 inhibitors in the treatment of 
haematological malignancies presenting with PTEN phosphorylation. In fact, 
the use of CK2 as therapeutic target in AML was suggested after its 
expression was found to be an unfavourable prognostic factor in these 
leukemias, although unfortunately PTEN phosphorylation status was not 
investigated in this study [210]. 
46 
Reversible phosphorylation in haematological molignances 
5.2 SHIP 1 /2 
5.2. 1 Characteristics and signaling 
Although PTEN is classified as PTP, most of its actions in cancer are 
derived from its major role as a lipid phosphatase. Other lipid phosphatases 
have been described that are important in health and disease [20] . One of 
these is the SH2 domain containing 5- inositol phosphatase, SHIP, which 
dephosphorylates inositol lipids at the 5D position of the inositol ring, 
hydrolysing Ptdins(3,4,5)P3 to Ptdins(S,4)P2. As such, SHIP has mostly been 
seen as negative regulator of PisK activity. However, the SHIP- I protein 
contains an N-terminal SH2 domain, a central conserved 5-phosphatase 
domain, two potential phosphotyrosine binding domains, and a C-terminal 
praline rich SHs binding region [19]. These different regions ensure that 
besides being a lipid phosphatase, SHIP also acts as an adaptor protein by 
binding to other molecules, such as Src kinase and the Ras activating protein 
Grb2 (reviewed by [211-212]). Therefore, studies into increased and 
eliminated SHIP expression on cellular effects need to be interpreted with 
care, as they might not only reflect the effect on the Ptdins(S,4)2 levels, but 
also take into account other SHIP functions. For instance, expression of an 
IGF-R mutant resulting in improper membrane localisation of SHIP 1 did not 
affect PKB activity, although IGF-induced ERK phosphorylation was 
down regulated, suggesting a Ptdins( S,4 )P2-independent effect [213] . In 
addition, more and more evidence suggests that although PTEN is the major 
regulator of PisK signaling by decreasing Ptdins( S,4,5)P3 levels, fine tuning 
of PisK signaling is performed by SHIPs and not necessarily inhibitory. 
Although Ptdins(3,4,5)Ps is required, exogenous Ptdins(3,4)P2 enhances PKB 
phosphorylation, and is necessary for full PKB activation [214] . These results 
were further explained by Ma and colleagues, who showed that whereas 
Ptdins(3,4,5)P3 was responsible for Thr308 phosphorylation of PKB, 
Ptdind(3,4)P2 was required for Ser473 and hence membrane activity of PKB 
[215] . Nevertheless, the level of phosphorylation of PKB on Thr308, but not 
Ser473, was associated with poor prognosis in AML patients, suggesting that 
Ptdins(3,4,5)P3 is the major determinant of clinical outcome [216] . 
5.2.2 Role in malignancy 
Multiple isoforms of SHIP- I have been described, including a full 
length 145 kDa SHIP- I ,  a -135 kDa SHIPbeta containing a deletion between 
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the tyrosine binding motifs [217-218], a -108 kDa SHIPdelta which lacks 167 
nucleotides in the C-terminal region [219] and a stem cell specific 104 kDa 
isoform s-SHIP (also termed SIP-110 in humans) which lacks the SH2 domain 
[220-224]. SHIP- I and SHIP-2 share 38% amino acid homology [225-227], 
but whereas SHIP-2 is ubiquitously expressed, SHIP- I is predominantly found 
in cells of the hematopoietic lineage and bone marrow microenvironment, 
with a higher expression in CD34+ progenitor cells and T-cells and a lower 
expression in B-cells and granulocytes [228-229]. In addition, SHIP- I rather 
then SHIP2 is responsible for controlling Ptdlns(3,4,5)P3 levels in 
hematopoietic cells [230]. SHIP-/- mice show increased haematopoietic stem 
cell numbers and proliferation, splenomegalomy and pulmonary macrophage 
infiltration [231]. Importantly, SHIP-/- mice display disturbed 
haematopoiesis as evidenced by decreased lymphopoiesis and increased 
myelopoiesis resulting in Myeloproliferative disease, suggesting that cell 
lineages are differentially affected by SHIP deletion [232]. Luo and co­
workers demonstrated the presence of a SHIP inactivating mutation in a 
patient with AML. Transduction of T-cell lines with SHIP harbouring this 
mutation resulted in increased cytokine induced PKB phosphorylation and 
drug resistance [233]. This same group later reported the presence of multiple 
mutations in the coding region of the SHIP gene INPPSD in a cohort of 
Chinese leukemia patients [234], although a similar study in a Caucasian 
population showed that coding-region SHIP mutations were rare, and no 
differences in gene expression between AML and healthy controls were 
observed [235]. Very recently, an American group reported decreased SHIP 
RNA and protein levels in almost all primary ALL samples studied, in 
conjunction with inactivating mutations and alternative splicing in the SHIP 
gene sequence [236]. Primary CLL samples do not contain SHIP2, and 
variable expression of SHIP I ;  decreased expression and tyrosine 
phosphorylation of SHIP 1 was observed in CLL patients that are positive for 
the tyrosine kinase ZAP70, a poor prognostic indicator [237]. In addition to 
mutations in the SHIP gene itself, SHIP might also play a role in Bcr-Abl 
mediated malignancies, as SHIP expression is inhibited by this oncogenic 
fusion kinase, and SHIP-2 binds specifically to the SH3 domain of Abl. [238-
239]. As activity of SHIPs is regulated by their protein levels, these studies 
imply a role for decreased SHIP activity in haematological malignancies 
[240]. Indeed, a SHIP agonist was identified, which increased SHIP activity, 
decreased PKB/ AKT phosphorylation and was able to induce cytotoxicity in 
Myeloma cells [241-242]. 
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However, there is some controversy concerning the exact role of SHIP 
in tumor cell survival. A recently published report shows that loss of SHIP 
expression may increase leukemia incidence [243], whereas others have shown 
that SHIP deletion did not result in increased leukemogenesis but rather 
inhibited cell growth [244]. In addition, whereas overexpression of SHIP 1 
leads to apoptosis in murine myeloid cells, reexpression of SHIP in Jurkat T­
cells, normally devoid of both SHIP and PTEN, leads to increased cell cycle 
time, but not apoptosis [245-246]. As Ptdind(3,4)P2 is capable of PKB/ AKT 
activation, SHIP activity may actually contribute to PKB activation and hence 
lead to growth and survival of neoplastic cells. Indeed, beside Ptdins(3,4,5)Ps, 
Ptdins(3,4)P2 levels are increased in leukemia cells and increased levels of 
Ptdins(3,4)P2 promote the transformation and tumorigenicity of mouse 
embryonic fibroblasts [247-248]. Furthermore, a recently identified specific 
SHIP- I inhibitor was able to reduce leukemic and MM cell growth in vitro, 
which could be rescued by the addition of endogenous Ptdind(3,4)P2 to 
cultures [249]. It is therefore very likely that PKB activity and subsequent 
cellular effects, such as survival, are very delicately regulated by the levels of 
Ptdins(3,4,5)P3 and Ptdins(3,4)P2, where disruption in either direction could 
lead to cell death. Its clear involvement in diverse haematological malignancies 
and the availability of both agonists and antagonists make SHIP an interesting 
target candidate for treatment of blood disease. 
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Figure 3. The role of phosphatases on the three major kinase pathways dysregulated 
in haematological malignancies. The JAK-STAT pathway can be upregulated by SHP2 
which stabilizes JAK2. On the other hand, LMWPTP, SHP- 1 ,  PTP I B  and CD45 can 
negatively modulate JAKs. Inhibition of Bcr-Abl by PTP 1 B can also negatively 
modulate STAT signaling. In addition, CD45 is able to directly inactivate Receptor 
Tyrosine Kinases (RTK) and inactivate Src, thus affecting JAK-STAT signaling. 
ST A Ts can be dephosphorylated by LMWPTP in the cytosol and by TCPTP in the 
nucleus. RTKs can be dephosphorylated and inactivated by TCPTP in the cytosol face 
of Endoplasmic Reticulum (ER). In MAPK pathways, the main phosphatases involved 
are MAPK phosphatases (MKP). MKP can dephosphorylate ERK in the cytosol 
(DUSP 1 6) or in the nucleus (DUSP2/PAC- 1 and DUSP 1 /MKP- 1 ) . Another 
phosphatase able to negatively modulate ERK is HePTP. The major negative 
modulator of PisK-PKB signaling is the lipid phosphatase PTEN. PTEN can 
dephosphorylate Ptdins(S,4,5)Ps to Ptdlns(4,5)P2, thereby preventing PKB activation. 
Ptdins(S,4,5)Ps can also be dephosphorylation by SHIP at the position 5, although the 
ensuing product Ptdins(S,4)P2 has also been shown to be able to activate PKB. 
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6. CONCLUDING REMARKS 
Most research to date has focussed on the role of kinases in cancer cell 
biology, and as a consequence, kinase inhibitors play a major role in novel 
therapeutic development. However, it is becoming increasingly clear that 
phosphatases are involved in numerous diseases, including haematological 
cancers, thus providing an additional focus of interest in drug development 
(Figure 3, Table 2). In fact, several specific serine/threonine and tyrosine 
phosphatase inhibitors are under development, some of which have already 
been shown to be orally tolerable [ 1 4, 250-25 1]. Phosphatases are generally 
regarded as inhibitors of oncogenic signaling and hence tumor suppressors, 
which might account for the lack of attention they have received in 
haematological cancer treatment to date. Reduction of phosphatase activity is 
observed in a number of malignancies and seems difficult to overcome using 
targeted medicine. The challenge here would be to develop compounds that 
activate rather than inhibit phosphatases. For SHP- 1 this has already been 
achieved; in a search for SH2-domain inhibitors, Park et all discovered that 
SHP- 1 is specifically activated by peptidyl aldehydes [252]. However, this 
approach would not work in patients where reduced phosphatase activity is a 
result of an inactivating mutation or deletion. Gene therapy or protein delivery 
systems such as TAT fusion proteins would be required to help these patients 
[253]. Unfortunately, such technologies are still in infancy and safety issues 
make them unlikely to contribute substantially towards cancer treatment in 
the upcoming years. In some instances, i.e. PTEN and SHIP, it has been 
reported that reduced phosphatase expression in leukemic cells was a result of 
aberrant miRNA expression [254]. As mentioned before, these miRNA are 
now being considered as targets for therapy [255]. 
Although downregulation of phosphatase activity often is apparent in 
hematological malignancy, there is also a growing body of evidence suggesting 
that overexpression of phosphatases might contribute to the tumor pathology, 
as is the case with for instance SHP-2, LMWPTP, PTP 1 B  and CD45. In these 
cases, specific inhibitors might find clinical applications. However, as not all 
patients exhibit increased phosphatase activity, the use of these inhibitors calls 
for personalised medicine. In addition, as some phosphatases might have both 
positive and negative regulatory functions, extensive research is needed to 
discover the long-term effects of the use of these inhibitors. Due to their major 
role in cell growth, proliferation and survival, protein and lipid phosphatases 
are of great potential interest in cancer treatment, and deserve a lot more 
attention than they currently receive. Further research into their precise role 
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m normal and tumor cell biology might, m time, make them a more 
appreciated clinical target. 
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Table 2. Involvement of phosphatases in normal and malignant signaling. 
PTP N I fi Sub N f Ch C 
CD45 Reduced .JAK/STAT Src, JAK [38] 1. Deletion I. Severe Combined Immunodeficiency Syndrome [ss, 34] 
Reduced/increased Src 2 .  Increased expression 2. Poor prognosis in AML and ALL [53-56] 
3. Reduced expression S. Increased IGF- 1 ,  decreased IL-6 signalling in MM [68,697 
PTP 1 B  Reduced RTK RTKs (such as EGFR [74], I. Increased expression I .  Decreased anti-tumorigenic STAT6 in DLBCL [93] 
Reduced .JAK/STAT PDGFR [75], Insulin Receptor 2. Reduced expression 2. Role in CML resistance [92] 
[76] , IGFR [77], BCR-Abl 
[88], .JAK2, TYK2, STATS 
[244--2467. 
TC-PTP Reduced .JAK/STAT .JAK l ,  JAK3 [247], STAT ! ,  1 .  Increased expression 1. Decreased anti-tumorigenic ST A T6 in DLBCL [93] 
STATS, STATS [248,249] 2. Reduced expression 2. Role in CML resistance [98] 
SHP- 1  Reduced .JAK/STAT JAK, Kit [250, 25 1]  1 .  Silencing by  methylation I. Observed in leukemia, lymphoma, MM [ 1 05- 1 07] 
2. Decreased protein expression 2. Observed in CML [1 1 0] 
LMWPTP Reduced JAK/ST AT JAK, STATS [252] Increased expression Unfavourable prognosis in solid tumours and leukemia [ 1 2 1- 1 22] 
SHP-2 Reduced GH signalling .JAK2, Src [ 1 49], ICSBP [ 1 34], 1. Constitutive active I. Myeloproliferative disease in mice [ 1 34] 
Enhanced Ras/MAPK Kit [255], STATS [256] 2. Gain-of-function mutation 2. Predisposition to JMML, growth disorder. Observed in AML, CMML, MDS, 
Reduced .JAK/STAT GH receptor [1 43] B-ALL [7 ,96, 1 40- 1 427 
HePTP Proliferation pathway pS8, ERK 1 /2 [ 1 55] I .  Triplication of gene and I. Observed in MDS and AML [ 1 63] 
ERK 1 /2 overexpression of protein 2. Observed in paediatric B-cell lymphoma [ 1 6 1 , 1 62] 
2 .  Decreased expression 
DUSP 1 Reduced MAPK ERK 1 /2, .INK and p38 [ 1 64]. Overexpression Increased Ras-MAPK signalling in bone marrow from relapsed AML patients 
pathways [ 1 80] 
DUSP2 Reduced MAPK ERK 1 /2, .JNK and p38 [ 1 64] . I. Loss of protein I. Increased ERK 1 /2 signalling in acture leukemia [ 1 74] 
pathways 2. Overexpression transcript 2. Observed in LGL leukemia, possible role in autoimmune disease [1 75] 
DUSP 1 6  Reduced MAPK ERK 1 /2, .JNK and p38 [ 1 64]. Silencing by microRNA-24 Alters myeloid cell proliferation and d ifferentiation [ 1 67] 
pathways 
PTEN Reduced PI3K/PKB Ptdins(3,4,5)Ps at position 3 1 .  Homozygos and heterozygos deletion 1 .  Associated with poor prognosis in T-ALL [ 1 96, 1 97] 
pathway [ 1 87] 2. Hypermethylation 2. Deficient PTEN expression in JMML, increased imatinyb resistance in AML 
s. Decreased expression [200,20 1]  
4 .  Increased Expression S. Observed in AML and B-ALL [ 1 09] 
5. Silencing by miRNA-2 1 or miRNA- 4. Observed in monocytic leukemia and paediatric B-ALL [205] 
1 55 5.Constitutive PKB activity in leukemia [203] 
6. Inactivating phosphorylation 6. Correlates with poor prognosis in AML [207,2087 
SHIP Reduced PI3K/PKB Ptdins(3,4,5) P3 at position 5 I .  Inactivating mutation 1. Observed in AML, leads to drug resistance [22 1 J 
pathway [20, 1 87] 2. Decreased expression 2 .  Observed in ALL and CLL [224,225] 
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Chapter 3 
ABSTRACT 
The development of resistance against chemotherapy remains one of 
the major challenges in the clinical management of leukemia. There is still 
limited insight into the molecular mechanisms that maintain the 
chemotherapy- resistant phenotype, despite the obvious clinical relevance that 
such knowledge would have. In this study, we show that the chemotherapy­
resistant phenotype of myeloid leukemia cells correlates with activation of the 
Hedgehog (Hh) pathway, whereas in chemosensitive cells, such activation is 
less pronounced. Importantly, the overexpression of Hh pathway components 
induces chemoprotection and inhibition of the pathway reverts 
chemoresistance of Lucena- I cells, apparently by interfering with P­
glycoprotein-dependent drug resistance. Our data thus identify the Hh 
pathway as an essential component of multidrug resistance (MDR) myeloid 
leukemia and suggest that targeting the Hh pathway might be an interesting 
therapeutic avenue for overcoming MDR resistance in myeloid leukemia. 
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INTRODUCTION 
Intrinsic and acquired multidrug resistance (MDR) against 
chemotherapy remains a major challenge in the management of cancer in 
general and of leukemia in particular. Several potential molecular or cellular 
mechanisms responsible for MDR have been elucidated. Alterations in DNA 
repair, defective regulation of apoptotic gene expression, enhanced 
intracellular drug detoxification and overexpression of membrane drug 
transport proteins (for example, P-glycoprotein; P-gp) are all contributing 
mechanisms leading to MDR [ I] .  However, despite our increased 
understanding of MDR, current treatment options are still limited. This is at 
least to a certain extent because of the fact that the fundamental molecular 
events driving the MDR phenotype of leukemic cells remain obscure. The 
characterization of signaling pathways sustaining the MDR phenotype is 
therefore of utmost importance and such knowledge would be useful for 
designing rational novel therapies for MDR cancers. 
The Hedgehog (Hh) signaling pathway is complex and entails two 
cellular receptors, that is, patched- I (Ptch- 1 )  and smoothened (Smo ). Under 
unligated conditions, Ptch I represses Smo, thereby silencing the Hh signaling 
pathway. Binding of the ligand (Sonic Hedgehog, Indian Hedgehog or Desert 
Hedgehog) to Ptch- 1 alleviates Ptch- 1 -mediated inhibition of Smo, thereby 
initiating an intracellular signaling cascade leading to the activation and 
nuclear translocation of Gli transcription factors [2-5] . 
Hh signaling, originally characterized as part of the morphogenetic 
code, is critical for growth and differentiation during embryogenesis [2-5] . 
However, Hh more recently emerged as a signaling system that remains active 
in adulthood, in which it mediates tissue regeneration and remodeling, 
hematopoietic homeostasis and T-cell maturation; however, as a downside, Hh 
has emerged as a critical mediator in various forms of oncogenesis. 
Interestingly, Hh signaling seems important in normal stem cell self-renewal, 
as abnormal Hh expression or deficient Ptch- 1 activity leads to a pre­
malignant stem cell displaying unrestrained local proliferation [6, 7]. 
Moreover, the Hh pathway seems to be essential in the survival and expansion 
of Ber- Abl+ leukemic stem cells [7] . In line with these findings, Zhao and 
colleagues [8] recently showed that Hh signaling has an important role in 
hematopoietic stem cell self-renewal and in maintenance of cancer stem cells in 
leukemia, although the loss of Hh signaling through conditional deletion of 
Smo in the adult hematopoietic compartment had no apparent effect on adult 
hematopoiesis in mice [9] , warranting further studies as to its actual role in 
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the hematopoietic compartment. Together, these considerations prompt 
further investigation into the potential role of the Hh pathway in the 
pathophysiology of leukemic disease. 
Various lines of evidence suggest that Hh might function in leukemia 
to promote hemoresistance. It has previously been shown that Hh signaling 
induces resistance to radiotherapy and an MDR phenotype in esophageal 
adenocarcinomas [10]. In apparent greement, a significant upregulation of Hh 
and Gli-1 expression was observed in the majority of residual solid tumors 
after chemoradiotherapy, suggesting that Hh signaling contributes to 
chemotherapy resistance in such tumors. Whether the Hh pathway has a 
similar role in leukemia remains lusive, and this study therefore aimed at 
deciphering the potential role of Hh in chemotherapy resistance in leukemia. 
To this end, we compared Hh pathway activity in chemotherapy-sensitive 
parental K562 cells and in MDR-resistant Lucena- I daughter cells [1 I ]. We 
established that Hh signaling maintains the chemoresistant phenotype in an 
apparently P-gpdependent manner and propose that Hh inhibition might be an 
attractive treatment strategy to revert ( or prevent) chemoresistance in 
myeloid leukemia. 
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MATERIALS AND METHODS 
Compounds, antibodies, constructs and cell lines 
Vitamin Ds, cyclopamine, mitoxantrone, daunorrubicin and vincristine 
were obtained from Sigma (St Louis, MO, USA). Gant6 1 was obtained from 
Alexis (Laufelfingen, Switzerland). Polyclonal antibodies against Gli I and 
Ptch- 1 were purchased from Cell Signaling (Beverly, MA, USA). Antibodies 
against Smo, a-tubulin and f3-actin were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA), whereas the monoclonal anti-P­
glycoprotein antibody was obtained from Sigma. 5E I Shh-blocking antibody 
was obtained from the Developmental Hybridoma Bank (Iowa City, Iowa, 
USA). K562, U- 937, Jurkat, KG I a, ACHN and PCs cells were purchased from 
the American Type Culture Collection (A TCC, Rockville, MD, USA), Lucena­
I cells were kindly donated by Professor Vivan Rumjaneck, GLC4-doxo cells 
were obtained from the oncology laboratory of the University of Groningen 
(The Netherlands). SmoM2-GFP in pMES was a generous gift from Dr 
Eberhart. 
Cell culture and transfections 
Cells were cultured in RPMI supplemented with non-essential amino 
acids and IO% fetal calf serum according to routine cell culture procedures. 
Transfections were performed using Amaxa Cell Line Nucleofector Kit V 
(VCA- 1 003) from Lonza Cologne AG (Cologne, Germany) according to the 
manufacturer's directions. Briefly, cells were transfected with SmoM2- GFP (5 
µg DNA/I x 1 06 cells) or GFP (2.5 µg DNA/I x 1 06cells) expression vectors. 
Next, transfected cells were placed in RPMI 0.5% fetal calf serum for 1 6  h, and 
subsequently treated with vincristine for 48 h and analyzed by fluorescence­
activated cell sorting or MTT assays. For reversion assays, cells were treated 
with mitoxantrone, doxorubicin, vincristine or imatinib, in combination with 
cyclopamine ( 1 0  µM), vitamin Ds (10 µM) or Gant6 1 (5 µM). 
Cell viability assay 
Cells (Sx 1 01') were seeded in flat-bottom 96-well plates treated with 
the indicated concentrations of drugs. During the last 2 h, 0.5 mg/ml thiazolyl 
blue tetrazolium bromide (MTT) was added [2 1 ]. After incubation, the 
supernatant was discarded; cells were lysed in 1 00 µL of 0. IN  HCl in 
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isopropanol and absorbance was measured at 570 nm in a Benchmark Plus 
Microplate Spectrophotometer (Bio-Rad, Hercules, CA, USA). 
Quantitative reverse transcription-PCR 
After RNA isolation according to routine procedures, quantitative 
PCRs detecting the expression level of different proteins and GAPDH were 
performed. hP-gp-F 5'-GGCAAAGAAATAAAGCGACTGAA-3', hP-gp-R 5'­
GGCTGTTGTCTCCATAGGCAAT-3', hMRP1-F 5'-CTTCTGGAGGAAT 
TGGTTGT AT AGAAG-3', hMRP 1-R 5'-GGT AGACCCAGACAAGGA T 
GTTAGA-3', SuFu-F 5'-CCTCCAGATCGTTGTGTCT-3', SuFu-R 5'-TCC 
GCATGTCAGTATCAGC-3', hGli l -F 5'-CAACTTGCCAGCTGAAGTCT-
3', hGli1-R 5'-GATCCTGTATGCCTGTGGAGT-3', hGAPDH-F 5'-AAGG 
TGAAGGTCGGAGTCAAC-3', hGAPDH-R 5'-TGGAAGATGGTGATG 
GGA TT-3'. Standards consisted of dilutions of RNA from K562and Lucena- I .  
Nuclear extract preparation 
Nuclear extracts were prepared according to routine procedures. 
Briefly, 2 x 107 cells were harvested and washed twice with ice-cold phosphate­
buffered saline and resuspended in 0.2 ml of ice-cold cell extract buffer ( 1 O mM 
HEPES-KOH, pH 7.9, 1 .5 mM MgCl2, 1omM KC1, o.5 mM dithiothreitol and 
0.2 mM phenylmethysulfonyl fluoride). Cells were kept on ice for 10 min to 
allow them to swell, mixed by vortex for 1 o s and centrifuged at 4°C at 14 000 
g for 30 s. The supernatant was discarded, and the pellet was resuspended in 
30 ml of nuclear extraction buffer (20 mM HEPES-KOH (pH 7.9), 25% 
glycerol, 420 mM NaCl, 1 .5 mM MgCl2, 0.2 mM EDTA, o.5 mM 
dithiothreitol and 0.2 mM phenylmethysulfonyl fluoride), placed on ice for 20 
min and centrifuged at 4°C at 14 000 g for 2 min. The remaining supernatant 
was used as nuclear extract in western blotting assays. 
Western blotting analysis 
Cells (2.5x107) were lysed in 200 µl of lysis buffer (50 mM Tris-HCl 
(pH 7.4), 1 % Tween-20, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM 
EGTA, 1 mM O-Vanadate, 1 mM NaF and protease inhibitors (1 mg/ml 
aprotinin, 10 mg/ml leupeptin and lmM 4-(2-amino-ethyl)-benzolsulfonyl­
fluoride- hydrochloride) on ice for 2 h. Protein extracts were cleared by 
centrifugation and the protein concentration was determined using the Lowry 
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method [22]. An equal volume of 2xSDS gel loading buffer ( l O0mM Tris-HCl 
(pH 6.8), 200mM dithiothreitol, 4% SDS, 0.1 % bromophenol blue and 20% 
glycerol) was added and samples were boiled for 10 min. Cell extracts were 
resolved by SDS-PAGE (12%) and transferred to polyvinylidene difluoride 
membranes. Membranes were blocked in I% fat-free dried milk or bovine 
serum albumin (2%) in TBS/0.05% Tween-20 and incubated overnight at 4°C 
with appropriate primary antibody at I :  1000 dilutions. After washing in 
TBS!0.05% Tween-20, membranes were incubated with antirabbit, antigoat 
and antimouse horseradish peroxidase-conjugated secondary antibodies at 
I :2000 dilutions in blocking buffer for I h. Blots were imaged using LumiLight 
Plus ECL (Roche, Basel, Switzerland) on a LAS-sooo imaging system. 
Statistical analysis 
Unless otherwise indicated, all experiments were conducted in 
triplicate and the results shown in the graphs represent the mean and s.e. Data 





Sensitivity to chemotherapeutic drugs of K562 and Lucena-I cells 
Studying therapy-induced drug resistance in vitro remains a challenge, 
but Lucena- I cells have previously been described as vincristine-resistant 
leukemia cells derived from vincristine- sensitive K562 parental cells [ 11 J 
(Figure 1 ); indeed, in our hands, the microtubule polymerization inhibitor 
vincristine, as well as other therapeutically important drugs such as the DNA 
intercalating mitoxantrone and doxorubicin, efficiently kills K562 cells, 
whereas these drugs only minimally affect Lucena-I survival (Figure l a). 
Chemoresistance of Lucena-I was accompanied by upregulation of drug 
transporters P-gp and MRP-1, (Figure 1 b) whereas the P-gp inhibitor 
verapamil partially reverted drug resistance. We concluded that the 
comparison of K562 and Lucena-I constitutes a valid model to study induced 
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Figure I .  Cell viability of K562 and its multidrug-resistant counterpart Lucena- I cells 
in the absence and presence of hemotherapeutic drugs. (a) K562 and Lucena- I cells 
were treated with vincristine (0-500 nM), mitoxantrone (0-5 µM) and doxorubicin 0-
5 µM) for 48 h, and cell viability was assessed by MTT reduction assays. (b) 
Expression level of effiux pumps (P-gp and MRP- I )  in 562 and Lucena- I cells as 
determined by quantitative PCR. (c) Lucena- I cells were treated with vincristine in the 
absence or presence f the pump inhibitor verapamil ( 5 µM) and cell viability was 
assessed by MTT reduction assays. Shown are mean ± s.e.m. (n:2:3) . 
Different sensitivity to chemotherapeutic drugs is determined by the Hh 
pathway 
We decided to study whether activation of Hh signaling is a 
characteristic of chemoresistance under our experimental conditions. 
Importantly, as shown in Figure 2a, the bona fide Hh target gene Gli 1 displays 
sevenfold increased mRNA levels in Lucena- I cells, compared with the 
chemosensitive parental line, whereas Sufu expression levels (which are 
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suggested to be inversely associated with Hh signaling [12], although this is 
not generally established) were reduced by twofold. At the protein level, we 
observed that Sonic Hedgehog was induced, together with the classical Hh 
target genes Gli and Ptch-1, in chemoresistant cells (Figure 2b ). Finally, 
nuclear extracts showed the hallmark appearance of full-length Gli 1 in the 
nuclei of chemoresistant cells, but not in those of chemosensitive cells (Figure 
2c ). Overall, these data show that the chemotherapy-resistant phenotype 1s 
accompanied by a constitutively activated Hh signaling; pathway. 
a 
7.5 
C o ­- N  













. Ptch-1 ::::=:::;:::::::===:, 
I - � f Sonic Hedgehog F-, ...-. 1 1}-actin 
1 .00 
·i fl 0.75 e ::ii:: a. ... 
:J � 0.50 QJ 0 
� "Cl  i; o  





Ji-actin nuclear extract 
p-actln cytoplasmic extract 
Figure 2. Hedhehog (Hh) signaling in K562 and its multidrug-resistant counterpart, 
Lucena- I .  (a) K562 and Lucena- I present differences in Hh pathway components. 
Shown are Gli I and SuFu mRNA expression levels as determined by quantitative 
PCR. (b) Expression levels of the Hh pathway components Gli I ,  Ptch- 1 ,  Smo and Shh 
on the protein level as determined by western blot analyses. (c) Gli I protein levels in 
nuclear extracts of K562 and Lucena-I as determined by western blotting. 
The Hh pathway maintains the multidrug-resistant phenotype 
To investigate the importance of Hh signaling in chemoresistance, 
K562 cells were transfected with SmoM2-GFP (a constitutively active Smo 
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variant) or GFP-overexpressing constructs. The transfections were effective 
(efficiency of approximately 40% (data not shown)) and resulted in increased 
Gli 1 and Ptch-1 expression levels (Figure Sa) .  As shown in Figure Sb, 
induction of Hh signaling by SmoM2 overexpression protected K562 leukemia 
cells from vincristine treatment. Furthermore, vincristine treatment increased 
the percentage of SmoM2-GFP-positive cells, but not that of GFP-only 
transfected cells (Figure Sc), suggesting that Hh pathway activity might be an 
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Figure 3. Overexpression of Hh pathway components is sufficient for chemoprotection 
of K562 cells. (a) K562 cells were transfected with SmoM2-GFP or GFP expression 
constructs, after which Gli 1 and Ptch- 1 levels were determined by western blotting. 
(b) K562 cells transfected with SmoM2 are protected against vincristine-induced cell 
death. (c) Vincristine treatment increased the percentage of SmoM2-GFP-positive 
cells but not that of GFP-only transfected cells. Shown are mean±s.e.m. (n=S) .  
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Pharmacological inhibition of Hh signaling reverts resistance in Ber-Ahl+ 
cells 
We observed that chemoresistance was accompanied by induction of 
Hh signaling and that activation of Hh signaling is sufficient for acquiring 
chemoresistance; however, therapeutically, it is more interesting to investigate 
to which extent the chemoresistant phenotype actually depends on activation 
of this pathway. Thus, we pharmacologically inhibited the Hh pathway in 
Lucena-I cells and analyzed the effect on chemoresistance. As shown in Figure 
4a, Hh pathway inhibitors cyclopamine [13] and vitamin Ds [3] indeed 
inhibited Hh pathway activity in Lucena- I cells (using Ptch-1 levels as read 
out). Importantly, both Hh inhibitors did not affect cell survival per se in 
concentrations up to 10 µM (Figure 4b). The presence of Hh inhibitors, 
however, substantially enhanced the sensitivity of Lucena- I cells to vincristine 
to levels not markedly different from those of the parental line (IC5o 
approximately 10 nM in both cases; compare Figures I and 4c). This effect was 
not restricted to microtubules system-targeted chemotherapy, as doxorubicin­
or mitoxantrone sensitivity was also restored to the levels of the parental cell 
line following inhibition of the Hh pathway. 
To provide further proof for the notion that inhibition of the Hh 
pathway may revert chemoresistance, Lucena-I cells were treated with 
vincristine in combination with Gant61 (inhibitor of Gli 1 transcriptional 
activity) [14]. As shown in Figure 4d, Gant61 efficiently inhibited Hh 
pathway activity and the inhibition of Gli I transcriptional activity by Gant61 
indeed reverses chemoresistance, suggesting that the increased level of Gli l 
(Figure 2a) is important to maintain the resistant phenotype in Lucena-I cells. 
To determine whether the effect of Hh inhibition is specific for MDR leukemia 
cells, the combinations mentioned above (Hh pathway inhibitors plus 
vincristine) were also tested in K562 cells. As shown in Figure 4e, Hh 
inhibitors hardly effected vincristine-induced cell death (at least in comparison 
with the effect observed in Lucena-I cells (Figure 4c ), suggesting that the 
chemosensitization induced by Hh pathway inhibitors is specific for MDR 
cells. Overall, it seems that pharmacological inhibition of the Hh pathway 
might constitute an interesting opportunity for chemosensitization in the 
management of MDR myeloid leukemic disease. 
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Figure 4. Hh signaling inhibitors counteract chemoresistance of Lucena- I cells. (a) 
Ptch- I expression with and without cyclopamine or vitamin Ds treatment. (b) 
Cyclopamine and/or vitamin Ds treatment (0- 1 0  µM for 48 h) does not affect the 
viability of K562 and Lucena- I cells as assessed by MTT reduction assays. (c) Both 
cyclopamine and vitamin Ds sensitize Lucena- I cells for chemotherapeutic drugs. 
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Lucena-I cells were treated with increasing concentrations of vincristine, 
mitoxantrone or Doxorubicin in the presence of 1 0  µM cyclopamine or vitamin Ds for 
48 h. (d) Treatment of Lucena- I cells with the Gli- 1 inhibitor Gant6 1 inhibits Ptch-1 
levels and reverts chemoresistance to vincristine. (e) Hh pathway inhibitors do not 
sensitize K562 cells for vincristine. K562 cells were treated with increasing 
concentrations of vincristine, in the presence of cyclopamine, vitamin Ds or Gant6 1 
for 4·8 h. Shown are mean ± s.e.m. (n�S). 
Myeloid specificity of chemosensitization by inhibition of Hh signaling 
To address the specificity of the effects observed, a more or less 
random panel of leukemia cells and solid cancers was exposed to 
pharmacological Hh inhibition, and effects of this treatment on 
chemosensitivity were assessed. As evident from Figure 5, neither solid 
cancers nor T-cell leukemia showed much evidence for such 
chemosensitization. Although these results show that alleviation of therapy 
resistance using Hh inhibitors is restricted to the myeloid compartment, they 
also provide good evidence that effects observed are specific and cannot be 
explained from an off-action of the pharmacological inhibitors involved. 
Pharmacological inhibition of Hh signaling interferes with P-gp expression 
Subsequently, we were interested as to whether we could dissect the point of 
interaction of Hh signaling with the classical cellular physiology of leukemic 
cell. As Hh appears to affect the resistance of MDR leukemia cells, we 
hypothesized that targeting the Hh pathway might reduce P-gp levels. As 
shown in Figure 6, all Hh inhibitors indeed reduced expression levels of P-gp, 
although to different extents. 
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Figure 6. Hh pathway inhibitors sensitize Lucena- I cells dependent on P-glycoprotein 
expression. P-glycoprotein expression in Lucena- I cells was analyzed after 24• h of 
treatment with cyclopamine, vitamin Ds and Gant6 I .  Shown on the left is a 
representative experiment, whereas the quantification of three independent 
experiments is shown on the right (mean ± s.e.m.). 
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DISCUSSION 
Intrinsic and acquired MDR against chemotherapy remains one of the 
major problems in the management of leukemic disease [ I o, 1 5- 1 8] .  The 
majority of leukemia patients (7 5%) of <60 years do present an initial complete 
remission after chemotherapy. However, 60% of these responders will 
ultimately present disease relapse, usually occurring within the first 2 years 
after the start of treatment [ I SJ . Despite our increased understanding of 
MDR and the elucidation of several underlying mechanisms [ I ,  6, 1 9] ,  
treatment options are still limited. The characterization of signaling pathways 
sustaining MDR is thus essential for designing rational novel therapies for 
MDR leukemia. In this study, we show that the chemotherapy-resistant 
phenotype of myeloid leukemia cells correlates with the activation of Hh 
signaling, that overexpression of Hh pathway components induces 
chemoprotection and that inhibition of the pathway reverts chemoresistance of 
Lucena- I cells. Our data thus identify the Hh pathway as an essential 
component of MDR leukemia, and suggest that targeting the Hh pathway 
might be an interesting therapeutic avenue for overcoming MDR resistance in 
myeloid leukemia. These data provide a mechanistic explanation as to the 
previous observation that inhibition of the Hh pathway in Kasumi l ,  -3 and 
TF I myeloid cell lines increased sensitivity to suboptimal doses of the 
antimetabolite cytarabine [20] . We propose that activation of the Hh pathway 
is both sufficient and essential for resistance to classical chemotherapy in 
myeloid leukemia. 
The mechanism of action of Hh inhibitors is probably dependent on its 
effect on P-gp expression levels (as shown in Figure 6). This immediately 
explains that the chemosensitization induced by Hh inhibitors in combination 
with vincristine is only observed in Lucena- I cells and is not (very) effective 
in K562 or GLC4-doxo cells .  These latter cells express MRP- 1 ,  but not P-gp, 
and sensitization can consequently not be induced in these cells by Hh 
inhibitors that target P-gp. Overall, these data indicate an important role of 
the Hh pathway in the maintenance of the MDR phenotype in myeloid 
leukemias. Our findings might be relevant for the treatment of MDR leukemia, 
but in addition, our data may be relevant for the early detection of resistance. 
Indeed, the expression of sentinel markers (for example, Ptch- 1 )  of activation 
of the Hh pathway in peripheral blood myeloid leukemia cells may be an 
indication that a patient is developing chemoresistance and is possibly a useful 
predictor of treatment failure, necessitating the switch to alternative therapy. 
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Further studies are obviously essential to address the validity of these latter 
points. 
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ABSTRACT 
Flavonoids, polyphenolic phytochemicals, are ubiquitous in plants and 
are commonly present in the human diet. They may exert diverse beneficial 
effects, including antioxidant and anticarcinogenic activities. The present 
study was designed to evaluate three biomolecules that play important roles in 
the apoptotic process: mitogen-activated protein kinases, protein phosphatases 
and NFKB, using HL60 cells treated with fisetin as an experimental model. 
Our results demonstrated that cells treated with fisetin presented high 
expression of NFKB, activation of MAPK pSS and an increase of 
phosphoprotein levels; inhibition of enzymes involved in redox status 
maintenance were also observed. Our findings reinforce the hypothesis that 
fisetin is likely to exert beneficial and/ or toxic actions on cells not through its 
potential as antioxidant but rather through its modulation of protein kinase 
and phosphatase signaling cascades. Additionally, our results also indicate that 
the cellular effects of fisetin will ultimately depend on the cell type and on the 
extent to which they associate with the cells, either by interactions at the 
membrane or by uptake into the cytosol. 
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INTRODUCTION 
Flavonoids are polyphenolic compounds widely found in plants [ I ] .  
Components of fruits, vegetables and beverages, such as wine and tea, many 
flavonoids are present in a regular diet [2] . Flavonoids exhibit a variety of 
effects such as inhibition of malignant cell growth [ I ] , regulation of 
lymphocyte activation, cell proliferation and differentiation [2-4] . These 
biological effects of flavonoids on cells can be due to the inhibition of different 
key enzymes. For these reasons, the flavonoids can be considered potential 
compounds in the selective blocking of signal transduction pathways and in 
the design of more potent analogues for use in proliferative disease therapies. 
Several studies have demonstrated that, depending on their structures, 
flavonoids can be potent inhibitors of several kinases involved in s ignal 
transduction, mainly protein kinase C (PKC) [5] and tyrosine kinases [6] . On 
the other hand, some flavonoids can activate cell differentiation through 
activation of the Ras-ERK cascade [7] . 
Fisetin is a common dietary component found in several fruits and 
vegetables [8] . Some authors have demonstrated different biological activities 
for this flavonoid: inhibition of topoisomerase II, an essential nuclear enzyme 
for DNA replication [9, 1 0] ,  neuroprotective, cardioprotective and anti­
carcinogenic activities, which have been attributed to its antioxidant properties 
[7, 1 1 - I S] ,  inhibition of cellular proliferation and in vitro angiogenesis [ 1 4] ,  
induction of apoptosis i n  leukemic cells [ I S] .  Recently, Haddad et al. [ 1 5] 
have demonstrated that fisetin caused cell cycle arrest (G2/M) in a prostate 
cancer human cell line (PCs). In addition, fisetin inhibited glucose uptake in a 
competitive manner in a myeloid cell (U9S7), which indicated that this 
flavonoid could be used as an alternative blocker of glucose uptake in vitro 
[ I  6] . The present study was designed to evaluate three biomolecules that play 
important roles in the apoptotic process: mitogen-activated protein kinases 
(MAP Ks), protein phosphatases and NFKB, using HL60 cells treated with 
fisetin as an experimental model. Our results demonstrated that cells treated 
with fisetin presented high expression of NFKB, activation of MAPK pS8 and 
an increase of phosphoprotein levels; inhibition of enzymes involved in redox 
status maintenance was also observed. 
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MATERIALS AND METHODS 
Materials 
HL60 cells were from A TCC (Rockville, MD) and fisetin (Figure 1) 
was from Sigma Chemical Co. (St Louis, MO). The polyclonal antibodies 
against antiphosphop.38 mitogen-activated protein kinase (p.38), antiphospho­
p42/ 44 (ERK 1/2), antiphospho-c-jun NH2- terminal protein kinase (JNK), 
antiphospho-MAPK/ ERK kinase 1 (MEK 1 ), antirabbit and antimouse 
peroxidase conjugated antibodies were obtained from Cell Signaling 
Technology (Beverly, MA). 
Cell culture 
HL60 cells were routinely grown in suspension in RPMI 1640 medium 
supplemented with IO% fetal bovine serum, 1 % penicillin-streptomycin 
(10,000 U/mL penicillin and I0mg/mL streptomycin) and I %  glutamine, 
grown at 37°C under a humidified 5% CO2 atmosphere. In all experiments 3 x 
105 cell/mL were seeded, and after 72 h the cells were treated with fisetin for 
24 h. Fisetin dissolved in dimethyl sulfoxide (DMSO) was added to the culture 
medium and adjusted to a final DMSO concentration of 0.1 %. 
Cell viability 
Cell viability was assessed by the trypan blue dye exclusion and the 
MTT reduction assays as previously described [17]. 
Western blotting 
Cells (3 x 107) were lysed in 200 µL cell lysis buffer (50mM Tris-HCl 
pH 7.4, 1% Tween 20, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM 
EGTA, l mM o-vanadate, l mM sodiumfluoride, and protease inhibitors 
( l mg/mL aprotinin, IOmg/mL leupeptin, and l mM phenylmethylsulfonyl 
fluoride (PMSF)) for 2 h on ice. Protein extracts were cleared by 
centrifugation, and the protein concentration was determined using the Lowry 
method [1 SJ. Twice the volume of sodium dodecyl sulfate (SDS) gel loading 
buffer (100 mM Tris-HCl, pH 6.8, 200 mM dithiothreitol, 4% SDS, 0.1% 
bromophenol blue, and 20% glycerol) was added to the samples and the 
mixture boiled for 1 O min. Cell extracts, corresponding to 3 x 105 cells, were 
resolved by SDS-polyacrylamide gel (12%) electrophoresis (PAGE) and 
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transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were 
blocked for 1 h in 1% fat-free dried milk or bovine serum albumin (2%) in Tris­
buffered saline (TBS) -Tween 20 (0.05%) and incubated overnight at 4°C with 
appropriate primary antibody at 1: 1000 dilution. After washing in TBS-Tween 
20 (0.05%), membranes were incubated with antirabbit or antimouse 
horseradish peroxidase-conjugated secondary antibodies, at 1:2000 dilutions 
(in all Western blotting assays), in blocking buffer for 1 h. Detection was 
performed by using enhanced chemiluminescence (ECL). 
Antioxidant enzyme activities 
Total superoxide dismutase (SOD) activity was determined from the 
rate of inhibition of ferrocytochrome c oxidation, at 550 nm, in a standard 
reaction medium [19]. The manganese superoxide dismutase (MnSOD) 
activity was measured after inhibition of the Cu/Zn isoenzyme by addition of 
l mM KCN [20]. Catalase activity was determined by measuring the decrease 
in absorption of H202 at 240 nm [21]. Glutathione peroxidase (GPX) activity 
was determined by measuring the NADPH oxidation rate in the presence of 
GSH and GSH reductase [22]. Marker enzyme activties for oxidative stress 
Aconitase activity was measured at 25°C by following the change in the 
absorption at 340 nm, due to NADP+ reduction [23]. Fumarase activity was 
measured at 25°C by following the increase in absorbance at 240 nm at 25°C in 
a standard reaction mixture [24]. All the measurements were carried out in a 
UV-VIS spectrophotometer (Hitachi, model U-2001 ). 
OH 
OH 




The Western blots represent three independent experiments. Cell 
viability was expressed as the mean ± standard error of three independent 
experiments run in triplicate. Data for each assay were statistically evaluated 
by analysis of variance (ANOVA). 
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RESULTS AND DISCUSSION 
Differential effect of fisetin on HL60 cells and normal human lymphocyte 
viabilities 
We have previously described cytotoxic effects and mechanism of 
action of different compounds on cancer cells [25-27]. Other natural products 
have also been reported as important sources of potential chemotherapeutic 
agents [28-S0J. Flavonoids, widely distributed in vegetables, fruits, and wine, 
have been shown to exert anticarcinogenic effects [ 10, I S, I 5, S I ]. However, 
the molecular mechanisms by which flavonoids can act against cancer cells 
need to be elucidated. To establish the specificity of fisetin action on HL60 
cells we checked, in parallel, the effect of this compound on normal human 
lymphocytes viability using the MTT assay. It was observed that after 24 
hours of fisetin-treated HL60 cells, the mitochondrial activity was decreased, 
displaying an IC50 value around SO µM (Figure 2). In agreement with other 
authors [ I S], it was also observed that fisetin induced HL60 cells death by 
apoptosis. Interestingly, human lymphocyte viability remained unchanged, 
even in the presence of fisetin at concentrations up to 200 µM. These results 
suggest that fisetin can be an interesting candidate for cancer treatment with a 
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Figure 2. Cytotoxicity of fisetin in leukemic cells and normal human lymphocytes. 
HL60 cells ( • )  and normal human lymphocytes ( • )  were treated with different 
concentrations of fisetin for 24 h. In the absence of fisetin, the MTT reduction was 
considered as 100%. The experiment was performed in a 24-well plate. Results 






Figure 3. Effect of fisetin on MAPKs phosphorylation in HL60 cells. Cells were 
treated with different concentrations of fisetin ( 1 0, 20, 30 and 50 µM). Soluble lysates 
were matched for protein content and analyzed by Western blot. One representative 
immunoblot of three independent experiments is presented. 
Effect of fisetin on MAPKs phosphorylation and NFKB expression in 
HL60 cells 
To obtain more insight into the molecular mechanisms mediated by 
fisetin on HL60 cells, we examined the phosphorylation state of total proteins 
and MAPKs, in response to fisetin at concentrations up to 50 µM. Fisetin 
caused activation of p.38 and JNK MAPKs, while ERK was inhibited (Figure 
3). Williams et al. [32] have demonstrated that flavonoids and their 
metabolites differentially acted on Pis-kinase, Akt/ protein kinase B 
(Akt/PKB), tyrosine kinases, PKC, and MAPK signalling cascades. Inhibitory 
or stimulatory actions at these pathways are likely to profoundly affect cellular 
function by altering the phosphorylation state of target molecules and/ or by 
modulating gene expression. 
In addition, we also observed that cells treated with fisetin presented 
high expression of NFKB (Figure 4 ). Decrease in MAPKs phosphorylation 
(Figure 3) and in the expression of NFKB p65 (Figure 4) in HL60 cells at 
fisetin concentrations higher than 20 µM could be ascribed to different steps of 
apoptosis. Our results indicate that depending on the fisetin concentration two 
steps of apoptosis can be reached: early and late apoptosis. Apparently, fisetin 
concentrations up to 20 µM caused early apoptosis, that was reinforced by the 
overexpression of NFKB. Recently, Kanno et al. [33] demonstrated that the 
overexpression of NFKB is a pivotal event for apoptosis in HL60 cells induced 
by the flavonoid naringenin. It has been shown that the transcription factor 
NFKB participated in cell growth, differentiation and inflammatory responses 
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induced by different signals related to the regulation of apoptosis and 
neoplastic transformation [34, 35]. The pro- and antiapoptotic regulatory 
functions of NFKB have been shown to depend on the cell type, the 
differentiation state of the cell, and the nature of the apoptotic stimulus [35]. 
Our data provided evidence that the overexpression of the subunit NFKB p65 
in cell death was associated with ROS generation. Some authors observed that 
ROS per se were potent inducers of apoptosis [36] and that the hydrogen 
peroxideinduced apoptosis required the release of mitochondria- derived ROS 
and the activation of NFKB [37]. Our results demonstrating the ability of 
NFKB p65 overexpression to induce apoptosis are in agreement with published 
data implicating NFKB to the induction of cell death in certain cells such as 
neurons, Schwann cells, prostate carcinoma, and embryonic kidney cells [38-
42]. 
NFKB p65 
Figure 4. Fisetin changes the expression of NFKB p65. After treatment of HL60 cells 
with different concentrations of fisetin for 24 h, equal amounts of protein ( soµg) of 
total lysates were subjected to immunoblot analysis with NFKB (p65) antibodies. 
Effects of fisetin on protein phosphorylation in HL60 cells 
In order to analyze the phosphorylation state in HL60 cells treated 
with fisetin, we examined the tyrosine and threonine phosphorylation on the 
cellular proteins. Phosphorylation of both residues increased in the cells 
treated with fisetin, except for a decrease in tyrosine phosphorylation at 50 
mM fisetin (Figure 5). Our results indicated that the fisetin action in HL60 
cells was accompanied by an increase m tyrosine and threonine 
phosphorylations. We have observed that fisetin inhibited cytosolic 




Figure 5. Effect of fisetin on protein phosphorylation levels. Cells were treated with 
fisetin ( 10, 20, 30 and 50 µM), and the tyrosine (A) and threonine (B) phosphorylations 
were evaluated by immunoblotting. One representative immunoblot of three 
independent e xperiments is presented. 
Fisetin induces oxidative stress and decrease in antioxidant enzymes 
activities in HL60 cells 
In order to analyze the cellular redox status after treatment of HL60 
cells with fisetin we quantified the activities of aconitase, fumarase, catalase, 
glutathione peroxidase and two isoforms of superoxide dismutase (SOD), i .e. 
the MnSOD (mitochondrial isoform), and the CuZnSOD (cytosolic isoform). 
Treatment of HL60 cells with fisetin resulted in inactivation of mitochondrial 
aconitase, an enzyme sensitive to oxidative stress, but not fumarase, a 
mitochondrial enzyme sensitive to oxidative stress (Table I). Fisetin caused 
also an expressive decrease in the antioxidant enzymes catalase, MnSOD, 
CuZnSOD and GPX. 
Our results suggest that fisetin can induce oxidative stress through 
ROS production. ROS can lead to cell death through inactivation of 
mitochondrial aconitase, an iron-sulfur (Fe-S) protein [ 43]. Recent studies 
showed that ROS are emerging as obligatory mediators of cell death signaling 
in response to stimulation of TNF receptors and induction of JNK and p38 
signaling [ 44•-4•7]. A MAPK phosphatase (MKP) was identified as a critical 
molecular target of ROS during TNFa-induced apoptosis, due to oxidation of 
an essential cysteine residue to sulfenic acid [ 46]. MKP plays a critical role in 
the regulation of the activity of MAPKs [ 48, 49]. Thus, ROS-dependent 
inhibition of MKPs caused persistent activation of JNK by TNFa, and, 
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ultimately, programmed cell death via either a necrotic or an apoptotic 
pathway [ 47]. These findings are in agreement with our results since, besides 
activating JNK and p.38, fisetin also caused an increase of phosphoprotein 
levels which can be due to either inactivation of protein phosphatases or 
activation of protein kinases, activities which are highly sensitive to oxidant 
agents. 
Table I. Effects of fisetin on antioxidant enzymes activities of HL60 cells. Cells were 
treated with fisetin ( 1 00 µM) and enzyme activities were determined as described in 










Control + Fisetin 
2.32 mU/mg 0.11 mU/mg 
0.029 mU/mg 0.029 mU/mg 
0.23 mU/mg 0.11 mU/mg 
0.66 mU/mg 0.22 mU/mg 
6.22 mU/mg 2.46 mU/mg 
11.74 mU/mg 3.33 mU/mg 
In summary, our results have reinforced the hypothesis that fisetin was 
likely to exert beneficial and/ or toxic actions on cells not through its potential 
to act as antioxidant but rather through its modulation of protein kinase and 
phosphatase signaling cascades. Additionally, our results also indicated that 
the cellular effects of fisetin ultimately depended on the cell type, and on the 
extent to which it associated with the cells, either by interactions with the 
membrane or by uptake into the cytosol. 
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ABSTRACT 
Natural food-based compounds show substantial prmmse for 
prevention and biotherapy of cancers including leukemia. In general their 
mechanism of action remains unclear, hampering rational use of these 
compounds. Herein we show that the common dietary flavonoid apigenin has 
anticancer activity, but also may decrease chemotherapy sensitivity, depending 
on the cell type. We analyzed the molecular consequences of apigenin 
treatment in two different types of leukemia, the myeloid and erythroid 
subtypes. Apigenin blocked proliferation in both lineages through cell cycle 
arrest in G2-M phase for myeloid HL60 and Go/GI phase for erythroid TF I 
cells. In both cell lines the JAK/STA T pathway was one of major targets of 
apigenin. Apigenin inhibited PisK/PKB pathway in HL60 and induced 
caspase-dependent apoptosis. In contrast, no apoptosis was detected in TF I 
cells, but initiation of autophagy was observed. The block in cell cycle and 
induction of autophagy observed in this erythroleukemia cell line resulted in a 
reduced susceptibility towards the commonly used therapeutic agent 
vincristine. Thus, the present study shows that although apigenin is a 
potential chemopreventive agent due to the induction of leukemia cell cycle 
arrest, caution in dietary intake of apigenin should be taken during disease as it 
potentially interferes with cancer treatment. 
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INTRODUCTION 
Apigenin (4',5,7-trihydroxyflavone), a common dietary flavonoid 
abundantly present in fruits and vegetables, displays promising biological 
effects such as prevention and therapy of prostate cancer, suppression of 
tumorigenesis and angiogenesis in melanoma [I] and breast, skin and colon 
carcinomas [2]. It has been shown to exhibit anti tu moral effects in leukemia 
cells via induction of apoptosis through activation of caspases, inhibition of 
fatty acid synthase and topoisomerase and modulation of Bax and Bcl-2 
expression [SJ and indeed a variety of studies have documented anti-leukemic 
effects of apigenin [4-7]. Despite apigenin seems to be promise as a 
chemopreventive in leukemia, a rational design of trails investigating its 
potential in this respect awaits further elucidation of its molecular mode of 
action. 
Studies in breast cancer cells have identified some of the potential key 
protein kinases potentially responsible for apigenin effects, in particular PlsK, 
PKB and ERK I/2 and other upstream kinases involved in cancer development 
and progression [8]. However, the effects of apigenin on these kinases in 
leukemia have not been investigated. 
The promise of apigenin now urgently calls for investigations as to its 
molecular mode of action in leukemia cellular physiology. This consideration 
prompted us to analyze the molecular pathways activated by apigenin 
treatment on the leukemic cell. To this end we established the induction of cell 
cycle arrest and cell death in two models of leukemic disease, myeloid (HL60 
cells) and erythroid (TF I cells). 
Abbreviations: AIF, apoptosis-inducing factor; Atg, autophagy-related (Atg) genes Bax, Bcl-2 
associated x protein; Bcl-2, B-cell lymphoma protein 2; c-myc, transcriptional regulator protein; 
Cdc2, cell division control protein 2; CD Ks, cyclin-dependent kinases; ERK I /2, extracellular 
signal-regulated protein kinase I /2; GSK-sl3, glycogen synthase kinase-s !3; JAK2, janus family 
of tyrosine kinase 2; LCsB, Light Chain s isoform B; LMWPTP, low molecular weight protein 
tyrosine phosphatase; LY294002, PlsK inhibitor; MAPKpS8, mitogen-activated protein kinase 
pS8; mTOR, mammalian target of rapamycin, a Ser/Thr protein kinase; p2 I ,  tumor suppressor 
protein; p70S6K, 70-kDa ribosomal protein S6 kinase; PARP, poly (ADP-ribose) polymerase; 
PDl{- 1 ,  phosphoinositide- dependent protein kinase I ;  PlsK, Phosphoinositide s-kinase; PKB, 
protein kinase B; PTEN, phosphatase and tensin homolog; S6, S6 ribosomal protein; SHP-2, Src 
homology 2 domain-containing phosphotyrosine phosphatase 2; Src, Src family of protein 
tyrosine kinases; STAT, signal transducer and activator of transcription; TNF-a, tumor 
necrosis factor alpha; TNFR, tumor necrosis factor receptor; ZV ADfo1k, pan caspase inhibitor. 
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MATERIAL AND METHODS 
Cell lines and reagents 
HL60, K562 and TF I cells were purchased from A TCC (Rockville, 
MD, USA). Apigenin was from Sigma-Aldrich (St. Louis, MO, USA). 
Polyclonal antibodies against AIF, p-PKB(Ser-473), p-cdc2(Thr15), CDK4, 
CDK6, cleaved caspase s, cleaved PARP, caspase 8, caspase 7,c-myc, p-GSK­
s�(Ser-9), p-PlsK p85, p-PDK(ser241), p-JAK2(Tyr1007 /1008), p­
Src(Tyr416), p-STATs(Tyr705), p-STAT5(Tyr-694) p-p38(TyrI08/I82), p­
SHP2(Tyr542), p-PTEN(SerS80), p-mTOR(Ser2448), p-p70S6K(Thr389), p­
S6(Ser235/236), Beclin-1, LC3BI/II, Atg5, Atg7, Atg12, antirabbit and 
antimouse peroxidase-conjugated antibodies were from Cell Signaling 
Technology (Beverly, MA, USA). p21, TNFR l antibodies were from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). Antibody against LMWPTP was 
purchased from Abeam (Cambridge, MA, USA). Apigenin and vincristine were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Caspase inhibitor Z­
VADfmk and apoptosis kit detection (annexin V-FITC and Propidium iodide) 
were from BD Biosciences (San Diego, CA, USA). The Pl3K inhibitor 
LY294002 was from Alexis (Laufelingen, Switzerland) and TNFa was from 
Biovision Inc. (Mountain View, CA, USA). 
Cell culture 
Leukemia cells were cultured in RPMI 1640 contammg IO0U/mL 
penicillin, 100 µg/mL streptomycin and I O% fetal bovine serum, at 37°C in a 
5% CO2 humidified atmosphere. For TF l cells, 5 ng/mL GMCSF was added 
to medium. 
Human lymphocytes were obtained from healthy volunteers and 
isolated by density through Ficoll Paque® gradient. Mononuclear cells were 
harvested and cultured in RPMl1640 containing 100 U/mL penicillin, 100 
µg/mL streptomycin, 10% fetal bovine serum and concanavalin A (5 µg/mL) 
for 48 h when the treatment was done. 
MTT assay 
Cell viability was assessed by MTT reduction assay as described by 
Mosmann (1983) [34]. Non-treated cells were taken as 100% of viability and 
IC50 values were determined from three independent experiments. 
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Western blotting 
Cells were lysed in cell lysis buffer [50mM Tris-HCl pH 7.4 
containing 1% Tween 20, 0.25% sodium deoxycholate, I 50mM NaCl, I mM 
EGTA, I mM o-vanadate, I mM sodium fluoride, I µg/mL aprotinin, IO  
µg/mL leupeptin and I mM PMSFJ. After I 5 min centrifugation the cleared 
lysates were immunoprecipitated and resolved by reduced SDS­
polyacrylamide gel electrophoresis, the blots were incubated with the indicated 
antibodies and the bands were visualized with ECL 
PTP Activity 
Cells were lysed in cell lysis buffer (20mM HEPES pH 7.7, 2.5 mM 
MgCL2, 0.I mM EDTA, 1% NP40, mM 4-(2-amino-ethyl)­
benzenesulfonylfluoride hydrochloride, 1 mM DTT, IO mg/mL aprotinin, and 
IO  mg/mL leupeptin). After 1 5  min of centrifugation, the cleared lysates were 
immunoprecipitated with GammaBind G Sepharose (GE Healthcare, Diegem, 
Belgie) and the phosphatase activity was determined using the PTP no 
radioactive assay kit from Sigma. 
Flow Cytometry for apoptosis analysis 
To perform the Annexin and PI assay, the FITC Annexin V Apoptosis 
Detection Kit II from BD Biosciences (San Diego, CA, USA) was used. Briefly, 
control and apigenin-treated cells were collected, washed twice in cold PBS, 
ressuspended in binding buffer (provided in the kit) and stained with Annexin 
V FITC and Pl. 
Flow Cytometry for Cell Cycle Analysis 
After treatment with apigenin, cells were spun down, washed with 
PBS and ressuspended in work solution (0.96 g/mL sodium citrate, 1 mg/mL 
Ribonuclease A, 0.02 mg/mL propidium iodide, 0.01 % Triton X-I OO). After 
incubation in the dark for 60 min at room temperature, the samples were 
analyzed using FACSCalibur flow cytometer (BD Bioscience). 
Electron Microscopy (EM) 
HL60 and TF 1 treated or non-treated with apigenin for different 
periods were washed in RPMI, pelleted, and subsequently fixed in 2 % 
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glutaraldehyde in 0. 1 M phosphate buffer for 24 h at 4°C. Cells were 
dehydrated, osmicated, and embedded in Epon8 I 2 according to routine 
procedures [35]. Semithin sections ( I to 0.5 µm) were examined by electron 
microscope (Philips 20 I ;  Philips, Eindhoven, The Nether lands). 
Statistical analysis 
All experiments were performed in triplicate and the results shown in 
the graphs represent the means and standard errors. Cell viability data were 
expressed as the means ± standard errors of 3 independent experiments 
carried out in triplicates. Data from each assay were statistically analyzed by 
ANOV A. Differences were considered significant when the p value was less 
than 0 .05. Western blottings represent 3 independent experiments. 
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RESULTS 
Apigenin as a food-based anti-leukemia compound 
Leukemia cells and human peripheral blood lymphocytes were treated 
with apigenin (Figure I A) in concentrations up to 200 µM, for 24h. As shown 
in Figure 1 B, apigenin caused a dose-dependent reduction in viable leukemia 
cells. IC50 of apigenin on HL60 was SO µM, with complete loss of viability at 
100 µM. In contrast, erythroleukemic cells were more resistant, 60% ± 6 
reduction of viability at 100 µM was observed for both K562 and TF 1 cell 
lines. Importantly, no strong effect of apigenin treatment was observed on 
normal human peripheral blood lymphocytes, only 20% of cells were sensitive 
to apigenin at the highest concentrations. These results indicate that apigenin 
shows promise as a food-based anti-leukemia compound. 
Apigenin reduces survival due to cell cycle arrest 
As HL60 and TFl cells showed more sensitivity toward apigenin, we 
continued our studies with these two cell lines. We further investigated 
whether the reduced cell numbers were a result of reduced cell cycling or 
increased cell death, by following the number of viable cells over the hours 
using vital stain Trypan Blue. Apigenin 20, SO and 40 µM reduced to 
60.4%±11.7, 79.4%±15.5 and 55.8%±7, respectively, the number of viable 
HL60 cells (figure 1 C) while the non treated cells showed 170% of viability, 
indicating that apigenin both stops cell proliferation and drives HL60 cells 
into cell death. TF 1 cells showed I 7 5%, I 25% and I 20% of viable cells at 24h 
treatment with 25, 50 and 100 µM of apigenin respectively, while non-treated 
cells showed 225% viability (figure I D). Even after S6 h of 50 and 100 µM 
apigenin, the cell viability remained the same as control at oh, and the base line 
on 100% was not passed (figure I D) indicating that apigenin did not induce 
cell death in TF 1 cells, but blocks cell proliferation. 
Through analysis of DNA content by flow cytometry, we observed cell 
cycle arrest of HL60 cells in G2/M phase by apigenin (Figure 2A), as the 
number of cells in G2/M phase increased dose dependently whereas the 
number of cells in S-phase decreased. At 100 µM apigenin there were 58%±8 
cells in G2/M phases compared to 11.2%±0.6 in non-treated cells (p<0.05).  
The percentage of cells in S phase dropped from 42.S%± I .S in non-treated 
cells to 21.4%±2 in treated cells (p<O.O 1 ). This was in agreement with an 
increase in apigenin-induced phosphorylation of Cdc2 at Tyr l 5 which results 
l 1 1  
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in inhibition of this kinase (Figure 2 C). Moreover, the expression of c-myc and 
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Figure I .  Apigenin reduces cell viability ofleukemia cells. (A) Molecular structure 
of apigenin. (B) Leukemia cells and human peripheral blood lymphocytes were treated 
with apigenin for 24 h. Cell viability was measured by MTT assay and cell viability of 
non-treated cells was considered as 1 00%. (C) Number of HL60 viable cells during 
different times of treatment with apigenin. After HL60 cells treatment with apigenin 
for 5, 1 2  and 24· h, the number of viable cells were quantified using Trypan Blue vital 
dye. (D) Number of TF l viable cells during different times of treatment with apigenin. 
TF 1 cells were treated with apigenin for 1 8, 24 and 36 h and using the Trypan Blue 
vital dye the cell viable was quantified. 
TFI cells were arrested in the Go/GI phase as shown in Figure 2 B. 
The number of cells in Go/GI phase increased from 40.7%±0.34 cells in 
untreated cells to 65.12%±1.11 upon treatment with 50 µM apigenin (p<0.01). 
The number of cells in S-phase was 44.6%±3.6 in non-treated cells and 
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decreased to 1 8 .6%±0.9 m cells, which received 50 µM apigenin. 
Corroborating these data, results shown in Figure 2D revealed that apigenin 
led to a complete degradation or inhibition of expression of CDK6, a protein 
essential for passage through the G I  /S phase restriction point. However, no 
changes were observed in CDK4 protein levels. Hence apigenin is a potent 
inhibitor of cell cycle progression in a variety of model systems of leukemia 
growth. 
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Figure 2. Apigenin induces cell cycle arrest. (A) Number of HL60 cells in 
different phases of cell cycle (Go/G I phase, S-phase and G2/M) as determined by 
propidium iodide staining followed by flow cytometry. (B) Number of TF I cells in 
different phases of cell cycle. Cell cycle analysis was performed by measuring DNA 
content by propidium iodide staining after treatment with specified concentrations of 
apigenin for 24 h. (C) Expression of p2 l and c-myc (middle and lower panel) and 
phosphorylation of CDC2 (upper panel), key-proteins in cell cycle control in HL60 
cells was determined by western blotting. (D) Expression CDK 4 and 6 in TF I cells 
by western blotting. Equal loading was confirmed by reprobing blots for �-actin 
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Downregulation of JAK/ST AT pathway in both cells and PlsK/PKB 
only in HL60 cells by apigenin 
We decided to establish the molecular details by which apigenin 
induces cell cycle arrest through the analysis of phosphorylation status of 
some kinases and phosphatases involved in leukemia cell proliferation and 
survival. Figure SA shows that treatment of HL60 cells with apigenin resulted 
in downregulation of PisK/PKB pathway, possibly due to a decrease in 
PisKp85 subunit expression. We also observed diminished phosphorylation of 
PKB Ser47S and of PDK-1 Ser241. In agreement with diminished PKB 
activity, we observed diminished GSKs-� Ser9 phosphorylation. Inhibition of 
the PisK/PKB pathway can be a direct consequence of activation of PTEN. As 
shown in figure SC, apigenin treatment decreases phosphorylation of PTEN at 
SerS80, leading to its activation, providing a mechanistic explanation for this 
action of apigenin. 
In contrast, no effect was observed on PisK/PKB pathway in TF 1 
cells treated with apigenin for 24 h (figure SB). Phosphorylation levels of PKB 
at Ser473 and phosphorylation levels of GSKs-� remained unchanged. Unlike 
HL60 cells, apigenin did not induce activation of PTEN in TF l cells, which 
remained strongly phosphorylated at SerS80 (Figure SC). Thus, apigenin has 
differential effects depending on the cell type involved. 
To obtain more information about the action of apigenin in cell 
survival, we analyzed MAPKpS8, JAK2 and STATS and 5. In HL60 cells 
treated with apigenin an increase in phosphorylation of MAPKpS8 was 
observed at Thr180/182, essential for pS8 catalytic action. However, in TF I 
cells, the pS8 activity remained unchanged after apigenin treatment (Figure 
SA). JAK/STAT pathway was downregulated in both cell lines, thus emerging 
as a general effect of apigenin in leukemia. Apigenin led to decreased 
phosphorylation of JAK2 and ST A Ts in both cell lines and ST AT 5 in TF I 
cells (figure SA and B). The strong negative effect of apigenin on STATS 
phosphorylation in TF 1 cells can be explained by increase of expression (figure 
SC) and activity of LMWPTP (figure SD), one of negative modulators of 
STA Ts, as well as the strong inhibition of SHP-2; LMWPTP activity was 
about 4-fold (385%±94), 2-fold (198%± 28) and I O-fold higher ( 1083%±47) in 
the presence of 25, 50 or 100 µM apigenin, respectively. In HL60 cells, the 
LMWPTP activity was inhibited about 44, 37 and 36% at 20, 30 and 40 µM 
apigenin, respectively. Another activator of ST A Ts, the Src protein kinase, 
was also inhibited by apigenin treatment, displaying decrease of 
phosphorylation at Tyr4 l 6, an activation site, in both cell lines, HL60 (figure 
1 14 
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SA) and TFI (figure sB). Hence, this general response towards apigenin across 
multiple types of leukemia may be important for explaining its broad anti­
leukemia effects. 
Both cell lines treated with apigenin displayed a decrease of 
phosphorylation of SHP2 at activator residue Tyr542 (Figure SC), which thus 
may also contribute to the growth inhibition of leukemic cells observed. 
TF I cells display a constitutive activation of mTOR and, 
consequently, activation of protein synthesis/ cell growth pathways (figure 
SE). In the presence of apigenin we observed downregulation of p70S6K 
phosphorylation and consequently, of S6 protein in TF I cell. HL60 cells, 
however, do not show constitutive activation of mTOR and p70S6K, although 
apigenin decreased S6 protein phosphorylation. Therefore, the functional 
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Figure 3. Analysis of cell proliferation pathways. Effect of apigenin treatment on 
key kinases involved in cell proliferation from HL60 (A) and TF l (B) cells. (C) Effect 
of apigenin treatment on phosphatases involved in proliferation of HL60 and TF l 
cells. Cells were treated with specified concentrations of apigenin for 24 h and the 
expression or phosphorylation of the proteins was determined by western blot. Equal 
loading was confirmed by reprobing blots for f.3-actin. (D) The activity of 
immunoprecipitated LMWPTP was measured after apigenin treatment of HL60 and 
TF l cells by Malachite green assay. (E) Effect of apigenin treatment on proteins 
involved in cell survival control. HL60 cells were treated with 50 µM apigenin for 5, 
1 2  and 24 h and TF 1 cells were treated with 1 00 µM apigenin for 1 8, 24 and 36 h and 
the phosphorylation of the proteins was determined by western blotting. Equal 
loading was confirmed by reprobing them for J3-actin. 
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Apigenin induces caspase-dependent apoptosis in HL60, but not in TFl 
cells 
In HL60, we observed a s ignificant increase in annexm V pos1t1ve 
cells, 3 1 .9%±4. l and 48. 1 3%±2.6 for 50 and 1 00 µM apigenin, respectively 
(figure 4A). Consistent with being more resistant to apigenin, only moderate 
induction of apoptosis was observed at high concentrations of apigenin in TFl 
cells; at 1 00 µM, 1 4.5%±0. l of cells stained annexin V positive (p<0.002). 
To obtain more information about apigenin-induced apoptosis in HL60 
and TF l cells, we pre-treated both lineages for l h with 50 µM of Z-VADfmk, 
a pan-caspase inhibitor, prior to the 24 h apigenin treatment. Figure 3 B shows 
that pre-treatment of HL60 cells with Z-VADfmk reduced the number of 
apoptotic cells 1 .3 fold when compared to cells which received apigenin only. 
No significant difference in apoptosis induction was observed in TF I cells pre­
treated with Z-VADfmk (figure 4B), suggesting that apigenin induces caspase­
independent apoptosis in TF I cells and caspase-dependent apoptosis in HL60 
cells. 
To understand the role of the PI3K/PKB pathway in apigenin-induced 
apoptosis, we treated cells for 2 h with 5 µM of LY294002, a PisK inhibitor, 
prior to the 24h apigenin treatment. As shown in figure 4C, inhibition of PI3K 
with LY294002 prior to apigenin treatment increased the number of apoptotic 
HL60 cells 1 .9 fold when compared to cells which received apigenin only, 
showing the importance of PisK/PKB pathways in apoptosis resistance in this 
lineage. No statistic difference in apoptosis induction was observed in TF I 
which received LY 294002 prior to apigenin treatment comparing to cells 
which received apigenin only (figure 4D), demonstrating that TFI cells are 
not dependent on PI3K/PKB pathway activation for their resistance to 
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Figure 4. Analysis of apigenin-induced apoptosis in HL60 and TFl cells. (A) 
Percentage of apoptotic cells after 24 h treatment with apigenin (25, 50 and 1 00 µM) 
was determined by flow cytometric analysis of Annexin V staining. (B) The effect of 
pan-caspase inhibitor Z-V ADfmk on apigenin-induced cell death. Cells were pre­
treated with 50 µM Z-V ADfmk for I hour prior to apigenin treatment. HL60 cells 
were treated with 50 µM apigenin and TF I cells were treated with I 00µM apigenin 
for 24 h. (C and D) Effect of PisK inhibitor Ly294002 on apoptosis induction in HL60 
(C) and TF I (D) cells. Cells were pre-treated with 5 µM Ly294•002 for I hour prior to 
24 h apigenin treatment. Afterwards, cells were stained with Pi and Annexin V. The 
combined Annexin V positive fractions were considered apoptotic. (*** p<0.00 I ,  
**<0.0 1 )  
Molecular mechanism of apoptosis induction by apigenin 
To further elucidate the apigenin induced cell death mechanisms in 
HL60 and TF l cells, we analyzed the levels of cleaved caspase .3, 7, 8 and 
PARP. We observed an increased dose (figure 5A) and time dependent effect 
(figure 5C) on cleaved caspase .3 levels in HL60 cells. This response was not 
observed in TF l cells; only after treatment with 100 µM apigenin a small 
amount of cleaved caspase .3 ( 1 7kDa fragment) became apparent (figure 5C). In 
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HL60 cell, caspase 8 cleavage in apigenin treated cells was observed, indicating 
that the apoptosis extrinsic pathway was also involved in apigenin cell death 
induction in this cell line (figure 5B). In HL60 the levels of full length caspase 
7 decreased when cells were treated with 50 µM apigenin, coinciding with 
increased presence of the 2okDa cleaved caspase 7 fragment (figure 5C). 
In TF 1 cells, neither cleavage of caspase 8 nor caspase 7 was observed 
(figure 5A and B). Furthermore, the levels of cleaved P ARP remained 
unchanged in apigenin treated cells. We observed an increased of AIF levels at 
25 and 50 µM of apigenin treatment in TF l cells (figure 5A), a strong 
indication of caspase-independent apoptosis. These results emphasize that 
despite the generalized leukemia growth inhibition observed, the molecular 
consequences of apigenin treatment show substantial context dependency. 
Apigenin and autophagy 
To obtain more insight into the apigenin response in TF 1 cells, we 
analyzed the apoptosis and autophagy pathway activation in the time domain. 
For apoptosis induction we used TNFa (10 ng/mL) as a control. TF l cells 
were slightly induced to undergo apoptosis by TNFa, as was deduced from 
cytokine induced cleavage of caspase 7 to its sokDa, but not 20kDa fragment 
and PARP cleavage. Interestingly, TNFa also induced cleavage of LCsBI into 
LCsBII after 24 and S6 h of treatment and also induced high expression of the 
autophagic proteins Atg5 and 12 (figure 6B). In addition, through EM we 
could observe the signature double membrane vacuoles, generally accepted as 
strongly indicative for autophagy (figure 6 D, F). In addition, TNFa activated 
P70S6K which led to high phosphorylation of S6 protein, indicative for protein 
synthesis (figure 6C), and apparently confirmed by EM, as TNFa-treated TF l 
cells showed high numbers of ribosomes on endoplasmic reticulum (ER) 
surface, indicative of high ER activity (Figure 6E). Apigenin also induced 
autophagy in TF l cells, but through inhibition of mTOR and P70S6K. We 
observed a strong reduction on phosphorylation of S6 protein. No changes in 
beclin -1 levels were observed, however there was a strong reduction of Atg5, 
7 and 12 on TF 1 cells treated with apigenin. These data led us to conclude 
that autophagy is a dominant response to apigenin treatment in at least some 
types of leukemia 
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Figure 5. Analysis of apoptosis pathway mechanism. (A) HL60 and TF l 
cells were treated with apigenin for 24 h. The expression of cleaved caspase S, cleaved 
PARP and AIF was evaluated by immunoblotting. (B) Levels of full length and 
cleaved caspase 8 (4 1 ,  4,3 and 1 8kDa.) were determined. (C) Levels of cleaved and 
uncleaved caspase 7 and cleaved caspase at different periods of apigenin treatment was 
investigated. HL60 cells were treated with 5oµM apigenin for 5, 1 2  and 24 h and TF 1 
cells were treated with 100 µM apigenin for 1 8 ,  24 and 36 h. Soluble lysates were 
matched for protein content and analyzed by Western blot analysis. Equal loading was 
confirmed by reprobing the blots with anti-j3-actin antibodies. 
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Figure 6. Effect of apigenin treatment on key kinase molecules involved in the 
autophagy and apoptosis from TFI cells. TFl cells were treated with 1 0  ng/mL 
TNFa or 1 00 µM apigenin for 24 and 36 h. (A) Levels of full length and cleaved 
caspase 7 (so and 2okDa), full length and cleaved PARP. (B) Levels autophagy 
proteins beclin- 1 ,  LCsB, Atg5, 7 and 1 2. (C) Analysis of P70S6K/S6 pathway by 
western blotting. The expression or phosphorylation of the proteins was determined 
by western blot analysis. Equal loading was confirmed by reprobing them for f3-actin. 
(D) Electron microscopy of TF 1 cells treated with TNFa for 24 h, detail of double­
membrane vacuole in formation (magnification 4•,500x). (E) Detail of endoplasmic 
reticulum, showing intense protein synthesis (magnification 1 0,000x). (F) Detail of 
double-membrane vacuole (magnification 1 0,000x). 
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Apigenin leads to apoptosis-like cell death in HL60 and involves 
autophagy in TFI as revealed by EM 
Further analysis of apigenin effects on HL60 and TFI cells was 
performed using EM, emphasizing the differential nature of apigenin responses 
in leukemia (figure 7, 8). In HL60 cells treated with apigenin for 8 hours, we 
observed classical apoptosis structures, chromatin condensation and reduction 
of cell volume (figure 7B). At 24 h of treatment most of cells showed electron 
dense cytoplasm with very condensed nucleus and many of non electron dense 
vacuoles (figure 7C), and some necrotic cells were detected (figure 7C). In the 
electron-dense-cytosol-cell we identified double-membrane vacuoles, as shown 
in detail in figure 7 D. TFI cells showed morphological changes only after 36 
h of treatment, where we could find speckles in the nucleus (arrows on the 
figure SC) and electron dense mitochondria in the cytoplasm (figure SC). In 
addition, a number of cells displayed non electron dense vacuoles and double 
membrane vacuoles, strong evidence of autophagy (figure SD). Thus there is 
not a common pathway leading to leukemia cell death, despite the general anti­
leukemia activity of apigenin and experiments were initiated to explore the 
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Figure 7. Electron microscopy of HL60 cells treated with apigenin for different 
time points. (A) Control cells, without treatment (magnification s,ooox). (B) Cells 
treated with apigenin for 8 h, displaying classical apoptotic cells ( condensed 
chromatin, reduction of cell size and no vacuoles); cells with dense mitochondria and 
no condensed chromatin and cells with size reduction, many vacuoles and no 
condensed chromatin (magnification s,ooox). (C) HL60 cell treated for 24 h (s,ooox), 
showing necrotic cells and cells with many vacuoles. (D) Cells treated for 24 h with 
apigenin, displaying cells with dense chromatin, many vacuoles and double membrane, 
detail in high magnification (20,000x) of vacuoles with cytosol content. 
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Apigenin diminishes the cytotoxic effect of the chemotherapeutic 
vincristine in TF I cells 
The role of autophagy in cells can be of dual consequence either it can 
prolong cell survival in the absence of nutrients or can result in cell death. 
Induction of autophagy is often associated with chemotherapy resistance. 
Indeed, TF 1 cells pretreated with apigenin 24h prior of vincristine showed 
diminishment of chemotherapic cytotoxic effect (figure 8E, F). TF l cells were 
treated with 1 00 µM apigenin for 24 h, after the number of cells of treated and 
non-treated cells was equalized, and cells were cultured with or without 
vincristine treatment for an additional 24 h. After the treatment, the viable 
cells were counting using the vital dye trypan blue (figure SE). In the absence 
of apigenin pre-treatment, vincristine reduced the number of viable to 
39.2%±6. 1 ,  compared to cells which did not receive vincristine ( 1 00% ). 
However, cells treated with apigenin prior to vincristine treatment showed 
l 4•7%±7 .3 of viability, compared to the cells which did not received vincristine 
( 1 00%). 
To obtain more data about the protective effect of apigenin against 
vincristine, we further analyzed apoptosis induction. TF 1 cells were treated 
with apigenin for 24 h, after which the number of cells of treated and non­
treated cultures was equalized followed by the presence or absence of 
vincristine treatment for an additional 24 h. After the treatment, we analyzed 
apoptosis induction using flow cytometric analysis of annexin V binding 
(figure 8F). Cells which received neither apigenin nor vincristine showed 
1 0. 7%±0.007 annexin V positive cells. Vincristine treatment alone induced 
annexin V staining in 33 .6%± 1 .4 of cells. Treatment of cells with apigenin 
alone (for a total of 48h) displayed 22.34%±0.4 annexin V positive cells. 
Strikingly, cells that were pretreated with apigenin followed by vincristine 
treatment showed a reduction in annexin V positive cells when compared to 
vincristine treatment alone ( 1 9.8%±0.2 of cells) (figure 8F). Thus we showed 
that apigenin protects TF 1 against cell death induced by vincristine. We 
conclude that although the effects of apigenin are generally chemopreventive 
with regard to leukemia disease, differential response may include resistance to 
chemotherapy. Thus, the use of such food-based compound as an adjuvant 
setting when disease is established might not be advisable. 
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Figure 8. Electron microscopy of TFl cells treated with apigenin for different 
time points. (A) Control cells, without treatment (magnification s,ooox). (B) Cells 
treated with apigenin for 24 h, display little morphological difference from non-treated 
cells (magnification s,ooox). (C) TF 1 cells treated for S6 h (magnification s ,ooox) 
present dense mitochondria, partly condensed chromatin and speckles (arrows) 
(magnification s,ooox). (D) Detail of vacuoles with double membrane in an 
authophagic cell (magnification 20,ooox) (E) Number of viable TF I cells after 
vincristine treatment with ou without apigenin pre-treatment. TF 1 cells were treated 
or not treated with 1 00 µM apigenin for 24h, after which cell numbers were 
normalized and cultured for another 24 hours with or without 2 µM vincristine. The 
number of viable cell was determined using Trypan Blue vital dye. (F) Determination 
of percentage of apoptotic TF I cells by flow cytometric analysis of Annexin V 
staining. Cells were treated or not treated with apigenin for 24 h, after which cell 
numbers were normalized and cells were cultured for another 24 hours with or 




Our research group has a long-standing interest in the possible 
beneficial biological effects of natural compounds and their derivatives on 
malignant disease [ 1 0- 1 4] .  In this work, we explored the effects of apigenin in 
leukemia, flavonoid common present in human diet, which is emerging not 
only as potent cancer preventing agents, but also useful for adjuvant therapy 
[ I  I ] .  Although the induction of apoptosis and cell cycle arrest, and inhibition 
of cancer-driving signaling pathways certainly supports the chemopreventive 
action, especially as untransformed lymphocytes do not seem to be really 
affected by the compound, the observed interaction with therapeutically 
relevant drugs seems to rule this compound out for adj uvant therapy as it may 
actually hamper treatment of established disease. 
In HL60 cells, apigenin induced cell cycle arrest in G2/M, whereas 
TF I cells were arrested in the Go/G I  phase. The control of cell cycle is 
mediated by many protein complexes such as CDK and cyclins. Cdc2,  normally 
driving cells into mitosis, is the ultimate target of pathways that mediate rapid 
arrest in G2, in response to DNA damage [ 1 5] .  CDK6 forms a complex with 
cyclin-D and targets the retinoblastoma protein, allowing passage through the 
G 1 /S phase restriction point [ 1 6] .  Many studies have shown that apigenin 
blocks cell cycle in cancer cells (Choi & Kim, 2009; Lepley, 1 997), however, 
depending on the cell type, apigenin can arrest the cell cycle in different 
phases, for example, it can lead G2/M arrest in colon carcinoma [2] , breast 
cancer and pancreatic cancer cells [ 1 9] .  Nevertheless, in human prostate 
cancer, LNCap and PCs cells ,  apigenin induced cell cycle arrest in Go/G I 
[20] . Our current study extends these observations that, depending on the 
cyclins affected, even in the leukemic compartment responses may be 
substantially different. The outcome of cell cycle arrest may depend on the 
phase in which the cell is arrested. Numerous studies, including those using 
dietary compounds, have linked G2/M arrest with subsequent apoptosis 
[2 1 ,22] , as was observed for HL60 cells in our study. In contrast, Go/G I 
arrest is seen upon reduction of mTOR activity [23] , and has been associated 
with induction of autophagy [24] , reminiscent of apigenin effects in TF I cells 
in the current study. p70S6K/S6 signaling has been implicated in inhibition of 
autophagy [25] and inactivation of the mTOR signaling pathway is a 
prominent consequence of PTEN activation [26] . In the present study, 
although apigenin was not able to activate PTEN in TF I cells, mTOR was 
strongly downregulated by apigenin. Thus this flavonoid may be an attractive 
therapeutic agent for treating tumors carrying inactivated PTEN. Studies with 
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cancer stem cells have shown that inhibition of mTOR pathways by rapamycin 
can block the generation or maintenance of leukemia-initiating cells in the 
PTEN-deficient mice [27]. 
The role of autophagy in cell survival is a dual one; it can either help 
cells to survive during stress or end in apoptosis in the absence of cell rescue 
[28]. The autophagic characteristics observed in HL60 cells suggest that the 
latter predominates in this cell type following exposure to apigenin, whereas in 
TF I cells autophagy is not followed by apoptosis, in apparent agreement with 
the therapy resistant phenotype of these cells. Only after S6 hours of stringent 
a pi gen in treatment did a small fraction of TF I cells show signs of ( a caspase­
independent form of) apoptosis. Interestingly, while showing hallmarks of 
apoptosis upon TNFa treatment, e.g. cleavage of PARP and caspase 
activation, EM analysis of TNFa-treated cells demonstrated characteristics of 
autophagy, confirmed by high levels of sentinel autophagic proteins beclin-1, 
LCsBII, Atg5, 7 and 12. In addition, TNFa induced activation of the 
p70S6K/S6 pathway, indicating that the induction of autophagy in TNFa 
treated cells is induced by high expression of autophagic genes related to 
vacuoles, rather as of inhibition of P70S6K/S6 pathway. 
Flavonoids have the potential to bind to the ATP-binding sites of a 
large number of proteins due to their similarity to ATP structure, which make 
flavonoids competitive inhibitors of protein kinases [29]. Apigenin had 
already been reported to be a competitive inhibitor of protein tyrosine kinases 
[so]. In this work we clearly observed that apigenin inhibited PKB/PisK 
pathway in HL60 cells, through activation of PTEN and downregulation of 
PDK I and PisK. Unlike HL60, TF I showed no changes in PisK/PKB 
pathway under apigenin treatment. Furthermore, MAPKpS8 was activated in 
HL60 cells treated with apigenin, but not in TF I cells. Recently it has been 
suggested that pS8 and JNK may be involved in the apoptotic process by 
repression of ERK pathways [s I]. Thus, the differential effects of apigenin 
observed on leukemia cell cycle are reflected by differential effects on kinase 
activities. 
Interestingly, the only common target of apigenin in both types of 
leukemia was the c-Src/ JAK/ST AT pathway, which constitutes a major 
mediator of cytokine activity. Constitutively active JAK2 proteins are 
associated with myeloproliferative disorders, acute lymphoblastic leukemia, 
acute myeloid leukemia and acute megakaryoblastic leukemia, and inhibition of 
STATS leads to increased apoptosis, decreased proliferation, and decreased 
tumor size [32]. JAK/STAT pathway is regulated by SHP2, which can 
stabilize JAK2 protein or inducing Src kinase activation. Constitutive 
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activation of SHP2 in mice cooperates with progression of myeloproliferative 
disorders [ss]. In the present work we observed that apigenin downregulated 
SHP2 and thereby JAK2, which led to a decreased phosphorylation and 
activation of STATS and 5. This effect was more apparent in TFI cells, which 
can be explained by the increased level and activity of LMWPTP, another 
JAK/STAT downregulator, in this cell line. Further experimentation should 
reveal whether the JAK/STAT signaling cassette really is the principal target 
for apigenin effect in cancer in general. 
Because apigenin induced cell cycle arrest and autophagy in TF I cells, 
we hypothesized that apigenin could inhibit the action of chemotherapeutic 
agents against leukemic cells. One of the most common chemotherapeutics is 
vincristine, and indeed upon apigenin treatment, cells became more resistant to 
vincristine-induced cell death. Vincristine binds to tubulin dimers, inhibiting 
the formation of microtubules. Disruption of the microtubules arrests mitosis 
in metaphase, therefore, apigenin-induced blockage of TFI cells in Go/GI 
phase might enable these cells to escape the action of vincristine. This action of 
apigenin clearly disqualifies this compound for adjuvant strategies once disease 
is established, at least in relation to vincristine. However, it is important to 
mention that when we combined apigenin with imatinib or mitoxantrone no 
difference was observed (unpublished data). Therefore, this observation 
reinforces our hypothesis that the undesirable action of apigenin in presence of 
vincristine might be related to the action mechanism of chemotherapic. 
In conclusion, apigenin is a potential chemopreventive and 
chemotherapeutic agent in leukemia due to the stimulation on signaling 
pathways that provoke inhibition of cell proliferation and cell cycle arrest of 
fast-cycling cells. This work emphasizes the importance of a deep analysis of 
molecular mechanism and biochemical details modified by a natural compound 
with clinically useful properties. Extreme care with respect to consumption of 
such apigenin-like compounds during chemotherapy must be exercised to 
prevent compromising clinical success, and trails using such compound should 
not be frivolously initiated. However, the possibility of using apigenin as a 
model for drug design should not be discarded. 
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ABSTRACT 
Ferruginol, a bioactive compound isolated from a Chilean tree 
(Podocarpaceae), attracts attention as a consequence of its pharmacological 
properties, which include anti-fungal, anti-bacterial, cardioprotective, anti­
oxidative, anti-plasmodial and anti-ulcerogenic actions. Nevertheless, the 
molecular basis for these actions remains only partly understood and hence we 
investigated the effects of ferruginol on androgen-independent human prostate 
cancer cells (PCs), a known model for solid tumor cells with an exceptional 
resistance to therapy. The results show that ferruginol induces PCs cell death 
via activation of caspases as well as apoptosis-inducing factor (AIF) as 
confirmed by its translocation into the nucleus. In  order to clarify the 
biochemical mechanism responsible for the anti-tumor activity of ferruginol, 
we analyzed a set of molecular mediators involved in tumor cell survival, 
progression and aggressiveness. Ferruginol was able to trigger 
inhibition/ downregulation of Ras/PisK, STAT s/ 5, protein tyrosine 
phosphatase and protein kinases related to cell cycle regulation. Importantly, 
the toxic effect of ferruginol was dramatically impeded in a more reducing 
environment, which indicates that at least in part, the anti-tumoral activity of 
ferruginol might be related to redox status modulation. This study supports 
further examination of ferruginol as a potential agent for both the prevention 
and treatment of prostate cancer. 
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I .  INTRODUCTION 
Prostate cancer is a major cause of cancer-related death among males 
and the second leading cause of cancer death in Western countries. Although 
recent years have seen an improvement in prostate cancer diagnosis, only a 
few novel therapeutic strategies have emerged and there has been little 
progress in improving survival [ 1 ,2]. Therefore, novel strategies for dealing 
with this disease are called for. Our research group has a long-standing 
interest in the possible beneficial biological effects of natural compounds 
and/ or their derivatives, such as antioxidants [SJ and anti-tumor agents 
[ 4e 10], and hence we were interested whether we could define novel 
compounds with therapeutic potential for prostate cancer. Among the different 
classes of natural compounds, the diterpenoids have been shown to present a 
potent anti-proliferative action [ 4, 1 1 ]. Ferruginol, an active compound 
isolated from the Chilean tree Persea nubigena and from the stem bark of 
Podocarpus andina (Podocarpaceae), is an abietane diterpene occurring in plants 
belonging to the Podocarpaceae, Cupressaceae, Lamiaceae and Verbenaceae 
families. This diterpene presents promising biological activities, such as anti­
fungal and anti-bacterial [ 1 2], miticidal [ 13], cardioactive [14], anti­
oxidative [15], anti-plasmodial [ 1 6] and anti-ulcerogenic [ 1 7] properties. 
We decided to investigate the potential effects of ferruginol in prostate 
cancer. In this work we show for the first time the molecular mechanism by 
which ferruginol, induces resistant prostate cancer cell death. Ferruginol was 
able to trigger inhibition/ downregulation of Ras/PisK, STAT s/ 5, protein 
tyrosine phosphatase and protein kinases related to cell cycle regulation. 
Importantly, the toxic effect of ferruginol was dramatically impeded under the 
condition of more reducing environment, which indicates that at least in part, 
the anti-tumoral activity of ferruginol might be related to redox status 
modulation. 
This study supports further examination of ferruginol as a potential 
agent for both the prevention and treatment of prostate cancer. 
Abbreviations: AIF, apoptosis-inducing factor; Bax, Bcl-2 associated x protein; CDKis, cyclin-dependent 
kinase inhibitors; CDI{s, cyclin-dependent kinases;DISC, death-inducing signaling complex; ERi{, 
extracellular signal-regulated kinase; ERK I /2, extracellular signal-regulated protein kinase I /2; GSl{-Sb, 
glycogen synthase kinase-Sb; Hsp27, heat shock protein 27;  MAPK, mitogen-activated protein kinase; MEK, 
MAPK/ERI{ kinase; p2 l, tumor suppressor protein; PCs, androgen-independent prostate cancer cell l ine; 
PIS!{, phosphoinositide S-kinase; Rb, retinoblastoma; ST AT, signal transducer and activator of 
transcription; TNFR, tumor necrosis factor receptor; F ADD, Fas-associated death domain protein; 
AKT /PKB, protein kinase B; PCNA, proliferating cellular nuclear antigen; NFkB, nuclear factor kappa B; 




2. MATERIAL AND METHODS 
2. 1 .  Cell line and reagents 
PCs cells were purchased from the American Type Culture Collection 
(ATCC, Rockville, MD). Ferruginol (Fig. IA) was extracted from the wood of 
P. nubigena Lind. and from the stem bark of P. andina (Poepp. ex Endl.) de 
Laub. (Podocarpaceae) as previously described [18] . Polyclonal antibodies 
against phospho pS8MAPK, phospho- p42/p44 MAPK (ERK1/2) 
Thr202/ 204, ERK 1 / 2, phospho- MEK 1 / 2 Ser2 I 7 / 221, pan-AKT, phospho­
AKT Ser47S, phospho-Hsp27 Ser82, phospho-c-Raf SerSS8, phospho- GSK-sb 
Ser9, AIF, phospho-cdc2 Thr l 5, phospho-Rb Ser795, phospho-STAT5 
Tyr694, phospho-PlsK p85 subunit, CDK6, CDK4, cyclin D l ,  cyclin Ds, 
PCNA, tubulin, anti-rabbit, anti-goat and anti-mouse peroxidase-conjugated 
antibodies were purchased from Cell Signaling Technology (Beverly, MA). 
Antibodies against p21, NFKB p65 subunit, phospho-STATS Tyr705, 
phospho-STATs Ser727, Bcl2, Bax, TNF receptor 1, FADD, IKKa and �-actin 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). LMWPTP 
antibody was from Abeam. Caspases S, 8 and 9 Colorimetric Assay Kits were 
obtained from R&D Systems (Minneapolis, MN). 
2.2. Cell culture 
PCs cells were cultured in RPMI containing 100 U/ml penicillin, 100 
mg/ml streptomycin and 10% fetal bovine serum, at S7°C in a 5% CO2 
humidified atmosphere. In all experiments, cells at semi-confluence were 
treated for 24 h with different concentrations of ferruginol. 
2.3. MTT assay for cellular viability 
Cell viability was assessed by MTT reduction assay as previously 
reported [19,20]. The effect of ferruginol on cell growth was assessed as the 
percentage of inhibition in cell growth where non-treated cells were taken as 
100% of viability. IC50 values were determined from three independent 
experiments. 
2.4. Western blotting analysis 
Following treatment of cells with ferruginol, the medium was 
aspirated and the cells were washed with cold physiological solution. The cells 
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were then incubated in 200 ml of lysis buffer (50 mM TriseHCl (pH 7 .4), 1 50 
mM NaCl, 1 mM EGTA, 20 mmol/L NaF, 1 mM Na�NO4., 0.25% sodium 
deoxycholate and protease inhibitors ( 1  mg/ml aprotinin, 10 mg/ml leupeptin, 
and 1 mM 4-(2-aminoethyl) benzenesulfonylfluoride hydrochloride)) over ice 
for SO min. Protein extracts were cleared by centrifugation and protein 
concentrations were determined using the Lowry method [2 1 ] .  An equal 
volume of 2x sodium dodecyl sulfate (SDS) gel loading buffer ( 1 00 mM 
TriseHCl (pH 6.8), 200 mM DTT, 4% SDS, 0. 1 % bromophenol blue and 20% 
glycerol) was added to samples which were subsequently boiled for 1 0  min. 
Cell extracts, corresponding to 50 µg of protein, were resolved by SDS 
polyacrylamide gel ( 1 2%) electrophoresis (PAGE) and transferred to PVDF 
membranes. Membranes were blocked in 1 % fat-free dried milk or bovine 
serum albumin ( 1 % ) in Tris-buffered saline (TBS )-Tween 20 ( 0.05%) and 
incubated overnight at 4°C with appropriate primary antibody at 1 :  1 000 
dilution. After washing in TBS-Tween 20 (0.05%), membranes were incubated 
with anti-rabbit, anti-mouse or anti-goat horseradish peroxidase-conjugated 
secondary antibodies, at 1 :2000 dilutions (in all Western blotting assays), in 
blocking buffer for 1 h .  The detection was made using enhanced 
chemiluminescence ECL. 
2.5. Immunoprecipitation of LMWPTP 
After treatment of the cells with ferruginol for 24 h, whole-cell lysates 
were prepared with lysis buffer (20 mM HEPES pH 7.7 ,  2.5 mM MgCL2, 0. 1 
mM EDTA, 1 % Nonidet-P40 (NP40), 1 mM 4-(2-amino-ethyl)­
benzenesulfonyl-fluoride hydrochloride), 1 mM DTT, 1 0  mg/ml aprotinin, 
and 10 mg/ml leupeptin) and chilled on ice for 2 h. After centrifugation, 
lysates were rotated with anti-LMWPTP and Protein A-Sepharose at 4°C for 
2 h. The beads were washed three times with lysing buffer and twice with 0.5 
M Mes, pH 6.0. Next, the phosphatase activity was determined using pNPP as 
a substrate. 
2.6. Caspases S, 8 and 9 activity assays 
Caspase activities were determined by the measurement at 405 nm of 
p-nitroaniline (pNA) released from the cleavage of Ac-DEVD-pNA, IETD­
pNA and LEHD-pNA as substrates of caspases s, 8 and 9, respectively. The 
enzyme activities were expressed in pmol/min and the extinction coefficient of 
pNA was 1 0,000 M- 1 cm- 1 • 
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2. 7. NFKB p65 and AIF nuclear translocation 
Briefly, 2 x 107 cells were harvested and washed twice with ice-cold 
phosphate-buffered saline (PBS) and resuspended in 0.2 ml ice-cold cell extract 
buffer ( IO  mM HEPES (N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic 
acid) e KOH pH 7.9, 1 .5 mM MgCl2, IO  mM KCI , o.5 mM DTT, and 0.2 mM 
phenylmethysulfonyl fluoride (PMSF)). The cells were kept on ice for 10 min 
to allow them to swell, mixed by vortex for I O  s, and microfuged at 4°C at 
14,000 x g for 30 s. The supernatant was discarded, and the pellet was 
resuspended in 30 µl nuclear extraction buffer (20 mM HEPESeKOH pH 7.9, 
25% glycerol, 420 mM NaCl, 1 .5 mM MgCl2, 0.2 mM EDTA 
( ethylenediaminetetraacetic acid), 0.5 mM DTT, and 0.2 mM PMSF), placed 
on ice for 20 min, and centrifuged at 4°C at 1 4,000 x g for 2 min. The 
supernatant was saved as the nuclear extract and used in Western blotting 
assay. 
2.8. Quantification of reduced and oxidized glutathione 
Cells were washed twice with PBS, detached with 5 mM EDTA in 
PBS and washed twice again with cold PBS. Cell number was counted using a 
hemocytometer; afterwards the cells were centrifuged and equal volumes of 
cold PBS and 6% 5-sulfosalicylic acid (SSA) were added to cell pellets. The 
samples were sonicated, centrifuged at 10,000 rpm for 5 min and the 
supernatants used for the assays. Total glutathione (GSH + GSSG) and 
glutathione disulfide (GSSG) were determined by using recycling assays 
involving the reaction of 5,5'-dithio-bis(2nitrobenzoic acid) and glutathione 
reductase. The total amount of glutathione was calculated from a reduced 
glutathione standard curve prepared in SSA. For GSSG assay, 100 µl of 
supernatant was incubated with 2 µl of 2-vinylpiridine for 60 min on ice. The 
amount of GSSG was calculated from the GSSG standard curve. The amount 
of reduced GSH per cell was calculated by subtracting the amount of GSSG 
per cell from the amount of total glutathione per cell [22]. 
2.9. Annexin V and 7-amino-actinomycin D assays 
Control and ferruginol-treated cells were collected and resuspended in 
I x  binding buffer (0.01 M HEPES-NaOH (pH 7.4), 0. 1 4  mM NaCl and 2.5 
mM CaCl2) at a concentration of 2 x 107 cells/ml. Subsequently, 1 00 ml of cell 
suspension was transferred to a 5 ml tube and 5 µl each of Annexin V-APC 
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and 7-amino-actinomycin D (7-AAD) was added. Cells were incubated at room 
temperature for 15 min, after which 400 µl of 1 x binding buffer was added and 
apoptosis detected by flow cytometry (Becton Dickinson FACSCalibur, 
Rockville, MD), the data obtained were analyzed using the software Cell Quest 
Pro BD Biosciences Pharmingen (Erembodegem, Belgium). 
2. 1 o. Flow cytometry 
After treatment of PCs cells with ferruginol for 24 h, cells were 
harvested by the addition of 5 mM EDTA and gently washed off the plate. 
Cells were pelleted along with the previously collected media. Cell pellets were 
fixed with 70% ethanol for 30 min on ice and than rinsed three times with 1 ml 
of 0.1% glucose in PBS (20 mM NaH2PO4, 150 mM NaCl), repelleted and 
resuspended in propidium iodide (PI) staining solution (10 µl of 10 mg/ml 
RNase A, 5 µl of 10 mg/ml PI per 1 ml of PBS with o. 1 % glucose). After so 
min the cells were analyzed using a flow cytometer. 
2. 1 I .  Statistical analysis 
All experiments were performed in triplicate and the results shown in 
the graphs represent the means and standard errors. Cell viability data were 
expressed as the mean ± standard error of three independent experiments 
carried out in triplicate. Data from each assay were analyzed statistically by 
ANOVA. Differences were considered significant when the P value was less 
than 0.05. Western blots represent three independent experiments. 
Quantitative analysis of the proteins was performed by volume densitometry 





3. 1 .  Inhibition of PC3 growth by ferruginol 
PCs cells were treated with ferruginol in concentrations up to 1 00 µM 
and the effect of ferruginol on cell viability was determined employing the 
MTT method. As shown in Fig. I B, ferruginol caused a dose-dependent 
reduction in the cell number displaying an IC5o value of 55 µM. Importantly, 
pre-treatment of the cells with 1 0  mM GSH prevented the toxic action of 
ferruginol (inset plot). In agreement, the microscopy analysis also 
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Figue I .  Ferruginol induces toxic effects in PCs cells. Cells were treated with 
specified concentrations of ferruginol (A) for 24 h. (B) Mitochondria function was 
evaluated through the MTT reduction.  The results are expressed as the mean % of 
absorbance (ratio of absorbance in ferruginol treated and control cells); cell viability 
was also evaluated when the cells were pre-treated for 1 h with 1 0  mM GSH (inset 
plot). (C) Morphological analysis of PCs cells treated with 25 µM and 50 µM 
ferruginol for 24 h ( 1 00 x magnification).  Ferruginol was dissolved in DMSO and the 
final concentration of this solvent was remained at 0. 1 %. 
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3.2. Ferruginol induces apoptosis of PCs cells via caspases and AIF 
activation 
In the next series of experiments, it was determined whether 
treatment of PCs cells to ferruginol led to apoptosis. Ferruginol caused around 
1 5% and so% (in the presence of 25 and 50 µM ferruginol, respectively) of cell 
death via apoptosis as detected through phosphatidylserine exposure (Fig. 2A). 
In agreement, we also observed activation of caspases 8, 9 and s (Fig. 2B). 
Additionally, at the lowest concentration, ferruginol led to an overexpression 
of TNFR I ;  however, F ADD expression was not affected. We also examined 
the possible participation of mitochondria in response to ferruginol. Bcl2:Bax 
ratio was not significantly affected; however the expression of AIF was 
dramatically increased at 50 µM ferruginol. Accordingly, AIF nuclear 
translocation was detected (Fig. 2C). These findings suggest that PCs cell 
response toward ferruginol involves activation of caspases and release of AIF 
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Figure. 2. Apoptosis induction of PCs cells by ferruginol. (A) Cell samples were 
prepared as described in Section 2 and Annexin V-positive, 7-AAD-positive and 
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Annexin V /7-AAD-positive populations were analyzed by flow cytometry. (B) 
Caspases 3, 8 and 9 activities were determined by using colorimetric assay. (C) The 
expression of pro- and anti-apoptotic proteins was determined by Western blot 
analysis. Soluble lysates were matched for protein content and analyzed on Western 
blot and immunoblots were probed with actin antibody to ensure equal loading. 
Nuclear translocation of AIF was also determined. 
3.3. Ferruginol treatment impairs prostate cancer cell survival 
To obtain more insight into the molecular mechanisms mediating 
ferruginol effects on PCs cells, the phosphorylation/ expression state of a 
panel of signal transduction mediators in response to ferruginol was examined. 
As shown in Fig. 3, PCs cell treatment with 50 µM ferruginol provoked 
downregulation of p85 subunit of PI.SK and inhibition of AKT. The results 
presented above indicate that ferruginol should produce a decrease of the 
survival and anti-apoptotic relevant kinase activities. Accordingly, cells treated 
with 50 µM ferruginol displayed activation of MAPK p.38, an important 
apoptosis inductor, and a slight inhibition of ERK2. However, the upstream 
activator of ERK, MEK, was not affected. Apparently, ferruginol impairs 
prostate cancer proliferation by modulating survival and proliferation 
signaling cascades. 
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Figure 3. Effect of ferruginol treatment on the function of key mediators 
involved in the PCs cells proliferation/ survival. Cells were treated with specified 
concentrations of ferruginol for 24 h and the expression or phosphorylation of the 
proteins determined by Western blot. Equal loading was confirmed by reprobing them 
for f3-actin.  
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3.4. Inhibition of cell cycle progression by Ferruginol 
By plotting the ratio of the cells in Go plus GI  against cells in G2/M 
plus S-phase it is  apparent that PCs cells undergo Go/ G I -phase cell cycle 
arrest after ferruginol treatment (Fig. 4A). Approximately 2.5-fold of the PCs 
population was at phase Go/GI after exposure to ferruginol for 24 h. We 
therefore turned to characterize the effect of ferruginol treatment on direct 
regulators of cell cycle progression. As shown by immunoblot analysis (Fig. 
4B), the expression of p2 I was increased even at the lowest concentration of 
ferruginol. On the other hand, the phosphorylated Rb protein and the 
expression of PCN A were not affected. The level of phosphor-cdc2, the key 
protein of the cell cycle progression from G2 to M phase, remained unchanged. 
Ferruginol decreased the level of CDK4, CDK6, cyclin D I  and cyclin Ds . This 
response directly mirrored the ability of ferruginol to induce cell cycle arrest 
in PCs cells. We conclude that the combination of reduced mitotic activity and 
induction of apoptosis accounts for the observed cytotoxic effect of ferruginol 
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Figure 4. Ferruginol impedes prostate cancer cell proliferation by targeting key 
cell cycle mediators. After treating PCs cells with ferruginol for 24• h, cells were 
harvested, stained with PI and analyzed by flow cytometry (A) or lysed for Western 
blotting analysis (B). The number of cells in each phase of the profile and ratios of cells 
in resting phase (Go/G I )  versus those undergoing mitosis (S, G2/M) was determined. 
The expression or phosphorylation of the proteins was determined by Western blot. 
Equal loading was confirmed by reprobing them for �-actin. 
3.5. Ferruginol causes downregulation of IKKa and hypophosphorylation 
of STATs 
The immunoblot analysis data showed that the expression of IKKa 
was significantly decreased after treatment with ferruginol; however, the total 
level of NFKB remained unchanged (Fig. 5). In addition, ferruginol caused a 
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decrease of this transcription factor into the nucleus. The phosphorylation 
status of ST AT S and 5, key signaling molecules for many cytokines and 
growth-factor receptor response, was also evaluated by Western blot. The 
treatment of PCs with 50 µM ferruginol was able to decrease the 
phosphorylation levels of STATS (Tyr705) and STATS (Tyr694). 
Interestingly, 50 µM ferruginol caused a strong decline in Hsp27 expression, 
which can be associated with the increase in the number of apoptotic cells. 
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Figure. 5. Ferruginol modulates molecules that play a crucial role in the prostate 
cancer aggressiveness. Cells were treated with specified concentrations of Ferruginol 
for 24 h, harvested and total cell lysates were prepared. The expression of IKB kinase, 
cytosolic and nuclear NFKB, and phosphorylation status of Hsp27 and ST AT s and 5 
were determined by Western blot analysis. Equal loading was probed with actin 
antibody to ensure equal loading. 
3.6. Redox status on PCs cells treated with ferruginol 
Based on the diterpene chemical properties, which can lead to 
antioxidant and/ or oxidant action depending on its concentration, and the 
importance of reducing equivalents for PCs cells survival [2S], we 
investigated the effect of ferruginol on PCs cell GSH metabolism. PCs cells 
treated with ferruginol displayed a more oxidizing environment as defined by 
a decrease of GSH and an increase of GSSG levels (Fig. 6). Both effects were 
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dose dependent and the highest concentration of ferruginol employed caused a 
2-fold change. It is important to note that even at the highest concentration of 
ferruginol, GSH:GSSG ratio remained almost in equilibrium (GSH:GSSG = 
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Figure 6. Influence of ferruginol on the level of intracellular GSH and GSSG. 
Cells were treated with ferruginol for �H h and the concentration of GSH and GSSG 
determined as described in Section 2. 
3. 7. Low molecular weight protein tyrosine phosphatase is modulated by 
ferruginol 
Besides the fact that protein tyrosine phosphatases are highly sensitive 
to cell redox status, there is some evidence that this class of phosphatases can 
contribute to tumor cell progression and aggressiveness. Especially 
LMWPTP has been recognized as a positive regulator of tumor growth [24]. 
Therefore, to address the possible modulation of LMWPTP by ferruginol, we 
examined the LMWPTP activity as well as expression. LMWPTP 
immunoprecipitated from PCs cells was inhibited around so% by 50 mM 
ferruginol (Fig. 7). On the other hand, when the LMWPTP activity was 
checked after treating the cells for 24 h, this enzyme displayed only 20% of 
residual activity. Reduced LMWPTP activity is consistent with the change in 
redox status in response to ferruginol. In addition, treated cells demonstrated 
downregulation of LMWPTP expression. 
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Figure 7. Ferruginol affects low molecular weight protein phosphatase activity 
and expression. (A) The effect of ferruginol was examined directly in the LMWPTP 
immunoprecipitated from non-treated PCs cells and also after PCs treatment with 
ferruginol (inset plot). The LMWPTP specific activity was used to determine the 
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Figure 8. Schematic representation of the molecular mechanism of ferruginol­
induced PCs cell death. Data presented in this report revealed that ferruginol 
exhibits multi-activities, which culminate with apoptosis induction of prostate cancer. 
Ferruginol caused inhibition of two important signaling cascade pathways involved in 
the cell survival/proliferation (Ras/PisK and Jak/STAT). Additionally treated 
prostate cancer cells displayed a decrease in  the phosphorylated form of Hsp27 .  
Ferruginol- induced apoptosis was accompanied by activation of caspase S, an increase 
of AIF expression and maintenance of Bax and Bcl-2 levels .  A IF  is released from 
mitochondria and translocated to the nucleus, and participates in peripheral chromatin 
condensation . In  accordance with cell survival diminishing, Ferruginol caused cell 
cycle arrest. Ferruginol caused an overexpression of protein p2 l (a member of the 
cyclin-dependent kinase inhibitors), and downward express ion of cyclin D 1 ,  cyclin Ds, 
CDK4 and CDK6, which indicates cell cycle arrest at Go/G I .  Importantly, LMW PTP 
was directly and indirectly modulated by ferruginol, which indicates that this enzyme 
can be a target for this natural compound. 
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4. DISCUSSION 
Prostate cancer is commonly malignant and it is the second leading 
cause of cancer-related deaths (after lung cancer) of males in Brazil, with a 
similar trend in many Western countries (data from Instituto Nacional do 
Cancer-INCA). Since prostate cancer usually occurs in men aged 50 years and 
older and because of the increasing life expectancy, its incidence is expected to 
further rise in the years to come [25]. Chemoprevention and intervention 
strategies using anticancer agents are considered as promising therapeutic 
options. The search for new chemopreventive and/ or chemotherapeutic agents 
that are more effective without toxic side-effects has generated great interest 
in phytochemicals with potential activity in this respect [26]. Suppression of 
tumorigenesis often involves modulation of signal transduction pathways, 
leading to alterations in gene expression, cell cycle progression or apoptosis. 
Apoptosis is considered as an ideal way for destroying damaged cells and also 
a potential target for chemopreventive elimination of cancer cells [27] and as 
a consequence targeting signaling elements controlling apoptosis may open 
novel therapeutic avenues [28,29]. Several plant-derived bioactive agents may 
have such action, at least as judged from model systems [ 4,9,S0-SSJ ; the 
present study may add ferruginol to this growing list. 
Our results suggest that ferruginol is a negative regulator of cancer 
cell proliferation. Androgen-independent human prostate cancer cells (PCs 
cells) a model that exhibits extreme therapy resistance exhibited, upon 
treatment with this phytocompound, remarkable induction of apoptosis via 
extrinsic and intrinsic pathways, as demonstrated by the observation of 
overexpression of TNFR I and activation of caspases 8, 9 and s. The extrinsic 
pathway for cell death involves plasma membrane death receptors [S4J . These 
receptors trimerize and recruit the adaptor molecule F ADD which, in turn, 
activates caspase 8 and also leads to the activation of downstream execution 
caspases [S5-S8J. In both pathways, activation of effector caspases leads to a 
series of morphological changes that are characteristic for apoptosis [28]. 
Ferruginol-induced apoptosis and cell growth inhibition were also 
accompanied by an increase of apoptosis-inducing factor (AIF) expression and 
maintenance of Bax and Bcl2 levels. AIF was identified as a mitochondrial 
intermembrane space protein, which is released from mitochondria and 
translocated to the nucleus, in response to apoptotic stimuli, and participates in 
peripheral chromatin condensation and the exposure of phosphatidylserine in 
the outer leaf of the plasma membrane. Increasing evidence supports the 
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notion that AIF plays an important role in caspase-independent apoptosis 
[39,40]. 
Ferruginol, even at lower concentration, caused inhibition of 
Ras/PISK cascade and suppression of downstream mitogenic targets such as 
cyclin D 1 .  Additionally, this diterpene also induced activation of MAPK p.38. 
The phosphatase and tensin homologue (PTEN) gene is deleted in PCs cells. 
This phosphatase is defined as a tumor suppressor, since it is the major 
negative modulator of AKT protein, an important mediator of cell survival. It 
is therefore important to identify agents that can overcome the therapeutic 
resistant properties of PTEN deficient tumor cells. Importantly, in accordance 
with cell survival diminishing, ferruginol caused cell cycle arrest. Eukaryotic 
cell cycle progression is regulated by sequential activation and subsequent 
inactivation of a series of CD Ks at different phases [ 41]. Ferruginol caused an 
overexpression of protein p21 a member of the cyclin-dependent kinase 
inhibitors, and downward expression of cyclin D I ,  cyclin Ds, CDK4 and 
CDK6. These data showed the involvement of p21 in ferruginol- induced G 1 
phase arrest, through binding to and subsequently inhibiting the cyclin-CDK 
activity. The active complex of cyclin D/CDKt, targets the Rb protein for 
phosphorylation, allowing the release of E2F transcription factors that activate 
G 1 IS-phase gene expression. Importantly cdc-2, a key protein responsible for 
the entry of the cell from G2 to M phase, remained unchanged. Cell cycle 
regulation and its modulation by various plant-derived agents are gaining 
widespread attention in recent years. A large number of phytochemicals has 
been shown to inhibit cell cycle progression of various cancer cells [ 42]. 
Ferruginol decreased the phosphorylation level of ST A Ts, ST AT 5 
and Hsp27. ST A Ts are latent cytoplasmic transcription factors consisting of 
seven mammalian members. They become phosphorylated on Tyr residues 
upon activation, a post-translational modification that is critical for 
dimerization, nuclear import, DNA binding, and transcriptional activation 
[ 43]. The activation of ST A Ts is mediated by the action of an upstream Janus 
kinase (JAK), usually JAK 1 or JAK2, showing that the JAK cascade might 
itself be a target for therapy in prostate cancer. Ahohen and coworkers [44] 
demonstrated that STATS is activated in a significant number of human 
prostate cancer specimens. Additionally, these authors also reported induction 
of apoptosis via caspases 9 and 3 activation dependent on inhibition of ST AT 5 
phosphorylation. Activated ST A Ts was reported in many types of 
malignancies, such as myeloma, head and neck cancer, breast cancer, and 
prostate cancer [ 45]. Recently, it has been demonstrated that inhibition of 
ST A Ts in tumors impeded vascular endothelial growth factor production 
1 50 
Ferruginol suppress survival pathways in human prototc cancer cel ls 
[ 46] . Data from the literature have identified Hsp27 as a modulator of 
STATS-regulated apoptosis after androgen ablation. Hsp27 is a 27 kDa 
protein of which expression is seen to be correlated with an increase of 
survival in response to a wide variety of physiological and environmental 
insults including heat, reactive oxygen species and anticancer drugs. I ndeed 
analysis by co-immunoprecipitation and immunofluorescence confirmed that 
Hsp27 is able to interact with ST A Ts and that ST A Ts levels correlate 
directly with Hsp27 levels. There are some reports in the literature 
demonstrating that the prostate cancer Hsp27 level increases after androgen 
ablation and that this protein is highly expressed in androgen-independent 
tumors, and inhibition of Hsp27 in prostate cancer cells can increase the 
number of apoptotic cells (Go/G 1 ), an event that seems to be associated with 
the decrease in the ST A Ts levels [ 47] . These findings indicate that the anti­
apoptotic effects of Hsp27 are associated with its ability to interact and 
stabilize the ST A Ts molecule, leading to more resistant prostate cancer cells. 
In accordance with this notion, our results show a decrease in the 
phosphorylated forms of Hsp27 and STATS, when PCs cells were treated with 
ferruginol at the concentration of 50 mM, suggesting that the pro-apoptotic 
and anti-proliferative actions of ferruginol might be associated with diminished 
function of STATS through the decrease of Hsp27 levels. 
Another important finding is that ferruginol did not induce the NFKB 
translocation to the nucleus; this result is in agreement with the findings of 
Rodriguez and coworkers [ 1 7] related to the anti-inflammatory effect of 
ferruginol. 
Recently, Chaiswing and collaborators [23] reported in a very well 
designed paper the effect of cellular redox state on prostate cancer cell growth 
in vitro. These authors demonstrated that during PCs cells growth, these cells 
require higher ratio of reduced glutathione (GSH)/ glutathione disulfide 
(GSSG). Based on this observation, we evaluated the redox status toward PCs 
cell treatment with ferruginol. This diterpene caused a decrease of GSH and 
increase of GSSG, indicating a dominant effect in favor of oxidizing equivalent. 
Several signaling mediators can be modulated by redox modifiers, including 
protein tyrosine phosphatases [ 48, 9] . To investigate the effect of ferruginol 
on PTPs we chose LMWPTP. The rational reason for this was based on the 
following aspects: ( a) we have observed a high level of this phosphatase in PCs 
cells and (b) Chiarugi and collaborators [24] have reported the importance of 
this enzyme for cancer cell growth. Interestingly, we observed a direct effect of 
ferruginol on LMWPTP but also there was a correlation between cellular 
oxidizing equivalents and inhibition of this enzyme. The oxidation of catalytic 
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site cysteine of PTPs, such as LMWPTP, leads to the transformation of the 
sulfhydrylic residue in sulfenic acid and the consequent inactivation of the 
enzyme due to its inability to form cysteinyl-phosphate intermediate during 
the first step of the catalysis [ 48]. Altogether, our results demonstrate that 
ferruginol can act as a chemical and genetic modulator of LMWPTP. These 
data indicate that at least in part, the anti-proliferative ction of ferruginol is 
dependent on changing cellular redox, which is in agreement with the 
protective effect of GSH. This observation also confirms the importance of 
reducing equivalents for PCs cell survival, as recently reported [23]. Further 
experiments to clarify the role of LMWPTP on prostate cancer progression 
are currently in progress in our laboratory. 
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5. CONCLUSION 
One of the challenges of cancer therapy is to combine efficacy with few 
side effects and consequently improve the quality of life of the patient. Prostate 
cancer represents a spectrum of diseases in which the cost of cure may be 
substantial, with short- and long-term side effects. Therefore, new agents are 
needed to extend survival, improve cure rates, and avoid undesired treatment­
related toxicities. In this scenario, there are at least two aims: (a) to provide 
therapeutic agents with a very specific target and (b) to discover agents which 
present differential action mechanisms in comparison with the traditional 
chemotherapy. In  this context, ferruginol appears as an interesting bioactive 
compound, since it exhibits multi-activities m the signal 
transduction/biochemical aspects in prostate cancer cells. In summary, 
ferruginol negatively modulates signaling cascades, which are known to be 
defective in some types of prostate cancers, namely Ras/PlsK and Jak/STA T, 
as well as cell cycle regulators (Fig. 8). Importantly, we demonstrated for the 
first time that LMWPTP is directly and indirectly modulated by ferruginol, 
which indicates that this enzyme can be a target for this natural compound. 
Besides affecting signal transduction triggered by TNFR 1, ferruginol also 
affected mitochondria permeability as demonstrated by the presence of nuclear 
AIF (protein involved with chromatin condensation and DNA fragmentation); 
however, the Bax:Bcl2 ratio remained unchanged. In general, this study 
provides an overview of biochemical aspects which were affected by ferruginol 
and in turn confirms its anti-tumor activity. This type of investigation can 
contribute to the development of "smart" drugs. 
ACKNOWLEDGMENTS 
Financial support by FONDECYT (Grant No. 1 06084 1 )  and the 
Programa de Productos Bioactivos, University of Talca is gratefully 
acknowledged. C.A. thanks the Universidad de Talca for a doctoral grant. The 
authors acknowledge financial support by the Brazilian Agencies: Fundai;ao de 
Amparo a Pesquisa do Estado de Sao Paulo, Conselho Nacional de 
Desenvolvimento Cientffico e Tecnol6gico and Fundo de Apoio ao Ensino, a 




1. J. Moul, Report from Durham, Prostate Cancer Prostatic Dis. 8 (2005) 1. 
2. N. Dawson, New molecular targets in advanced prostate cancer, Expert Rev. Anticancer 
Ther. 6 (2006) 993e1002. 
3. M.A. Miranda, A.K. Okamoto, C.V. Ferreira, T.L. Silva, J.M. Granjeiro, H. Aoyama, 
Differential effects of jlavonoids on bovine kidney low molecular mass protein tyrosine 
phosphatase, J. Enzyme Inhib. Med. Chem.21 (2006) 419e4•25. 
4•. A.G. Freire, P.S. Melo, M. Haun, N. Duran, H. Aoyama, C.V. Ferreira, Cytotoxic effect of 
the diterpene lactone delrydrocrotonin f rom Croton cajucara on human promyelocytic leukaemia 
cells, Planta Med. 69 (2003) 67e69. 
5. C.V. Ferreira, C.L. Bos, H.H. Versteeg, G.Z. Justo, N. Duran, M.P. Peppelenbosch, 
Molecular mechanism of violacein-mediated human leukemia cell death, Blood 104 (2004) 
l 4•59e 1464. 
6. A.D. Martins Cavagis, C.V. Ferreira, H.H. Versteeg, C.F. Assis, C.L. Bos, S.A. 
Bleuming, S.H. Diks, H. Aoyama, M.P. Peppelenbosch, Tetralrydroxyquinone induces 
apoptosis of leukemia cells through diminished survival signaling, Exp. Hematol. 34 (2006) 
l 88e l 96. 
7. L.L. Kodach, C.L. Bos, N. Dura'n, M.P. Peppelenbosch, C.V. Ferreira, J.C. Hardwick, 
Violacein synergistically increases 5-:fluorouracil cytotoxicity, induces apoptosis and inhibits 
Akt-mediated signal transduction in human colorectal cancer cells, Carcinogenesis 27 (2006) 
508e516. 
8. A.C.S. de Souza, L. Kodach, F.R. Gadelha, C.L. Bos, A.D. Cavagis, H. Aoyama, M.P. 
Peppelenbosch, C.V. Ferreira, A promising action of ribeflavin as a mediator of leukaemia 
cell death, Apoptosis 11 (2006) 176 l e l  771. 
9. R.R.R. Sousa, A.C.S. Souza, K.C. Queiroz, M.P. Peppelenbosch, C.V. Ferreira, H. 
Aoyama, Plwsphoprotein levels, MAPK activities and NFKB expression are affected byfisetin, 
J. Enzyme Inhib. Med. Chem. 22 (2007) 4•39eH4•. 
I O. K.C. de Souza Queiroz, W.F. Zambuzzi, A.C. Santos de Souza, R.A. da Silva, D. 
Machado, G.Z. Justo, H.F. Carvalho, M.P. Peppelenbosch, C.V. Ferreira, A possible 
anti-proliferative and anti-metastatic effect of irradiated ribciflavin in solid tumours, Cancer 
Lett. 258 (2007) 126e l S4. 
11. M. Iwamoto, T. Minami, H. Tokuda, H. Ohtsu, R. Tanaka, Potential antitumor 
promoting diterpenoids from the stem bark of Thuja standishiz: Planta Med. 69 (2003) 
69e72. 
12. J. Becerra, C. Flores, J. Mena, P. Aqueveque, J. Alarcon, M. Bittner, V. Hernandez, M. 
Hoeneisen, E. Ruiz, M. Silva, Antifungal and antibacterial activity of diterpenes isolated 
from wood extractables of Chilean Podocarpaceae, Boletf n de la Sociedad Chilena de 
Qufmica 47 (2002) 15 l e l 57. 
13. S. Chang, P. Chen, S. Wang, H. Wu, Antimite activity of essential oils and their constituents 
from Taiwania cryptomerioides, J. Med. Entomol. S8 (2001) 455e4•57. 
14. A. Ulubelen, H. Birman, S. Oksuz, G. Topcu, U. Kolak, A. Barla, W. Voelter, 
Cardioactive diterpenesfi·om the roots of Salvia eriophora, Plan ta Med. 68 (2002) 8 l 8e82 l .  
15. M .  Ono, M. Yamamoto, C. Masuoka, Y. Ito, M. Yamashita, T. Nohara, Diterpenesfrom 
thefruits ofVitex rotundifolia, J. Nat. Prod. 62 (1999) 1532e l 537. 
16. C. Clarkson, W.E. Campbell, P. Smith, In vitro antiplasmodial activity of abietane and 
totarane diterpenes isolatedfi·om Harpagophytum procumbens (devil 's claw), Planta Med. 69 
(2003) 720e724. 
17. J.A. Rodriguez, C. Theoduloz, T. Yanez, J. Becerra, G. Schmeda-Hirschmann, 
Gastroprotective and ulcer healing effect of ferruginol in mice and rats: assessment of its 
mechanism of action using in vitro models, Life Sci. 78 (2006) 250Se2509. 
1 54 
Ferruginol suppress survival pathways in human protote cancer cel ls 
18. C. Areche, J .A. Rodrf guez, I. Razmilic, T. Y afiez, C. Theoduloz, G. Schmeda­
Hirschmann, Gastroprotective and cytotoxic effect of semisynthetic ferrugi.nol derivatives, J. 
Pharm. Phamacol. 59 (2007) 289eS00. 
19. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assay, J. lmmunol. Methods 65 (1983) 55e63. 
20. F. Denizot, R. Lang, Rapid colorimetric assay for cell growth and survival· modifications to 
the tetrazolium dye procedure giving improved sensitivity and reliability, J. Immunol. 
Methods 89 ( 1986) 71 e77. 
21. E.F.Hartree, Determination of proteins: a modification of Lowrymethod that give a linear 
photometric response, Anal. Biochem. 48 (1972) 422e4•27. 
22. N. Li, T.D. Oberley, Modulation of antioxidant enzymes, reactive oxygen species, and 
glutathione levels in manganese superoxide dismutase-overexpressing NJH/3T3 fibroblasts 
during the cell cycle, J. Cell Physiol. 177 ( 1998) 148e l 60. 
23. L. Chaiswing, J.M. Bourdeau-Heller, W. Zhong, T.D.Oberley, Characterization of redox 
state of two human prostate carcinoma cell lines with dffferent degrees of aggressiveness, Free 
Radie. Biol. Med. 43 (2007) 202e215. 
24. P. Chiarugi, M.L. Taddei, N. Schiavone, L. Papucci, E. Giannoni, T. Fiaschi, S. 
Capaccioli, G. Raugei, G. Ramponi, LMfV-PTP is a positive regulator of tumor onset and 
growth, Oncogene 23 (2004·) .'3905e3914. 
25. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E.J. Feuer, M.J. 
Thun, American Cancer Society Cancer statistics, Cancer J. Clin. 54 (2004) 8e29. 
26. A.S. Tsao, E.S. Kim, W.K. Hong, Chemoprevention of cancer, CA Cancer J, Clin 54 (2004) 
150e180. 
27. R.P. Singh, S. Dhanakakshmi, R. Agarwal, Plzytoclzemicals as cell cycle modulators: a less 
toxic approach in halting human cancer, Cell Cycle 1 (2002) 1 56e 1 6 1 .  
28. W. Hu, J.J. Kavanagh, Anticancer therapy targeting the apoptotic pathway, Lancet Oncol. 4 
(2003) 72 I e729. 
29. S. Fulda, K.M. Debatin, Extrinsic versus intrinsic apoptosis pathways in anticancer 
chemotherapy, Oncogene 25 (2006) 4798e48 I I .  
SO. M. D-Huang, J.-H. Guh, Y.-T. Huang, S.-C. Chueh, P.-C. Chian, C.-M. Teng, Induction 
of mitotic arrest and apoptosis in human prostate cancer pc-3 cells by evodiamine, J. U rol. I 7.'3 
(2005) 256e261. 
31. G.Z. Justo, C.V. Ferreira, Coagulation and cancer therapy: the potential of natural 
compounds, Curr. Genomics. 6 (2005) 46 I e469 . 
.'32. J.C. Hsu, A. Dev, A. Wing, C.T. Brew, L.F. Bjeldanes, G.L. Firestone, Indole-3-carbinol 
mediated cell cycle arrest of LnCap human prostate cancer cells requires the induced production 
of activated pss tumor suppressor protein, Biochem. Pharmacol. 72 (2006) I 714el72S. 
33. L. Gapter, Z. Wang, J. Glinski, K. -Y. Ng, Induction of apoptosis in prostate cancer cells by 
paclzyniic acid from Poria cocos, Biochem. Biophys. Res. Commun. 332 ( 2005) I I 5Se 1161. 
34. E. Solary, N. Droin, 0. Sordet, Cell death pathways as targets for anticancer drugs, in: B.C. 
Baguley, D.J. Kerr (Eds.), Anticancer Drug Development, Academic Press, San Diego 
2002, pp. 55e76 . 
.'35.  N. Thornberry, Y. Lazebnik, Caspases: enemies within, Science 28 I ( I 998) 1 S I  2e I 316 . 
.'36. A. Ashkenazi, V.M. Dixit, Death receptors: signaling and modulation, Science 281 
(1998) 1305e1S08 . 
.'37. A.M. Chinnaiyan, K. O'Rourke, M. Tewari, V.M. Dixit, FADD, a novel death domain­
containing protein, interacts with the death domain of Fas and initiates apoptosis, Cell 81 
( 1 995) 505e5 1 2. 
38. M.E. Peter, P.H. Krammer, Mechanisms of CD95 (APO- I /  Fas)-mediated apoptosis, 
Curr. Opin. lmmunol. I O  ( I 998) 545e55 1 .  
1 55 
Chapter 6 
39. C. Pepper, T. Hoy, D.P. Bently, Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their 
correlation with in vitro apoptosis and clinical resistance, Br. J. Cancer 76 (1997) 935e938.  
4•0. C. Cande, I .  Cohen, E. Daugas, L. Ravagnan, N. Larochette, N. Zamzami, G. Kroemer, 
Apoptosis-inducing factor (AIF): a novel caspase- independent death effector released 
from mitochondria, Biochimie. 84 (2002) 215e222. 
4•1. C.J. Sherr, GI phase progression: Cycling on cue, Cell 79 (1994) 55 I e  555.  
4•2. J.-M. Yun, M.-H. Kweon, H. Kwon, J.-K. Hwang, H.  Mukhtar, Induction ef apoptosis and 
cell cycle arrest by a clzalcone panduratin A isolated from Kaempferia pandurata in androgen­
independent human prostate cancer cells PC3 and DU145, Carcinogenesis 27 (2006) 
I 4•54e 1464. 
4•3. C.P. Lim, X. Cao, Structure, function, and regulation ef STAT proteins, Mol. Biosyst. 2 
( 2006) 536e550. 
44. T.J. Ahonen, J. Xie, M.J. LeBaron, J. Zhu, M. Nurmi, K. Alanen, H. Rui, M.T. 
Nevalainen, Inhibition ef transcriptionfactor Stats induces cell death ef human prostate cancer 
cells, J. Biol. Chem. 278 (2003) 27287e27292. 
4•5. B.E. Barton, J.G. Karras, T.F. Murphy, A. Barton, H.F. Huang, Signal transducer and 
activator ef transcription 3 (ST AT3) activation in prostate cancer: Direct ST AT3 inhibition 
induces apoptosis in prostate cancer lines, Mol. Cancer Ther. 3 (2004) 1 l e20. 
4•6. G. Niu, K.L. Wright, M. Huang, L. Song, E. Haura, J. Turkson, S. Zhang, T. Wang, D. 
Sinibaldi, D. Coppola, R. Heller, L.M. Ellis, J. Ifarras, J. Bromberg, D. Pardall, R. Jove, 
H. Yu, Constitutive Stat3 activity upregulates VEGF e.xpression and tumor angiogenesis, 
Oncogene 21 (2002) 2000e2008. 
4•7. P. Rocchi, E. Beraldi, S. Ettinger, L. Fazli, R.L. Vessella, C. Nelson, M. Gleave, 
Increased Hsp27 after androgen ablation facilitates androgen- independent progression in 
prostate cancer via signal transducers and activators <if transcription 3-mediated suppression ef 
apoptosis, Cancer Res. 65 (2005) I 1083e l 1093. 
4•8. J. den Hertog, A. Groen, T. van der Wijk, Redox regulation ef proteintyrosine 
plwsphatases, Arch. Biochem. Biophys. 4•34• (2005) I l e  1 5 . 
4•9. C.V. Ferreira, G.Z. Justo, A.C.S. Souza, K.C. Queiroz, W.F. Zambuzzi, H. Aoyama, 
M.P. Peppelenbosch, Natural compounds as a source ef protein tyrosine phosphatase 
inhibitors: application to the rational design ef small-molecule derivatives, Biochimie 88 








1 .  SUMMARIZING DISCUSSION 
Although cancer chemotherapy has been one of the major medical 
advances in the last few decades, cancer remains a very serious health problem 
worldwide. Considering the different causes, the different tissues affected, the 
different symptoms and the different response to treatment, cancer is a very 
complex and still incurable disease. Much effort has been directed at 
comprehending carcinogenesis and a lot of progress has been achieved. 
However, there is still no effective treatment for most cancers, and a new 
challenge arises when some patients, for no apparent reason, develop 
resistance to the treatment. In this status quo, studies about molecular 
mechanisms of carcinogenesis, chemoresistance acquisition and apoptosis 
induction of cancer cells can contribute enormously to overcome the cancer 
challenges. With the studies described in this thesis we strive to contribute to 
the ongoing battle against cancer. In this last section of the thesis, we 
summarize the work done and discuss the implication of the studies. 
In Chapter I, we invite the reader to understand the structure of this 
thesis, showing the importance of studying the molecular mechanism and 
effects of natural compounds as chemotherapeutics and giving some successful 
examples of these kinds of studies in cancer treatment. 
In Chapter 2 we summarize the potential role of phosphatases in the 
treatment of hematological malignancies. This article describes extensively the 
protein phosphatases implicated in three major kinases pathways deregulated 
in hematological malignancies, the JAK-STAT signaling, Ras-Raf-MEK­
ERK signaling and PisK-PKB signaling. Many papers have discussed the role 
of kinases in cancer progression but relatively few have given attention to 
phosphatases. It is important to remember that the regulation of 
phosphorylation levels which control activation and deactivation of proteins is 
very delicate and controlled by both kinases and phosphatases. Therefore, we 
feel it would be a gross negligence to ignore the role of phosphatases in 
carcinogenesis. Our literature studies suggest that there may be a potential 
relevance for phosphatases in cancer treatment, and we hope to prompt an 
increase in the interest for these enzymes in cancer studies. 
In the Chapter 3, the role of Hedgehog (Hh) signaling m 
chemoresistance acquisition is studied in myeloid leukemia cells. Multidrug 
Resistance (MDR) against chemotherapy remains one of the major challenges 
in overcoming leukemic diseases. Thus the characterization of signaling 
pathways sustaining MDR is fundamental for success in therapies for MDR 
leukemias. In this study, we show that chemoresistant myeloid leukemia cells 
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display activation of Hh signaling. Inhibition of this pathway reverses 
chemoresistance in Lucena- I cells. The effect of Hh inhibitors is probably 
dependent on their ability to decrease P-gp expression. This explains why Hh 
inhibitors can sensitize Lucena- I cells but not K562 cells, which do not express 
P-gp, or GlC4-doxo cells which express MRP-I ,  but not P-gp. Interestingly, 
overexpression of constitutively active Smoothened, a downstream target of 
Hh, protects K562 leukemia cells from vincristine-induced cell death. These 
data provide evidence that the Hh pathway is not only sufficient but also 
essential for resistance to classical chemotherapy in myeloid leukemia. 
Furthermore, this study can be relevant for early detection of resistance, for 
example the expression of Ptch- I may be a marker in patients developing 
chemoresistance. 
In Chapter 4 we studied the cytotoxic effect of the flavonoid fisetin in 
myeloid leukemia cells. Fisetin can induce cell death in HL60 leukemia cells 
but not in peripheral human lymphocytes. After publication of our paper, 
numerous other studies regarding the effect of fisetin in cancer cells have come 
out. Confirming our result that fisetin displays antiproliferative effects only in 
tumor cells, Khan and co-workers showed a cytotoxic effect in prostate cancer 
cell lines but not in epithelial prostate cells [ I ] .  The molecular mechanism of 
the cytotoxic effect induced by fisetin in tumor cells has received vast attention 
[2-5] . The antiproliferative activity of fisetin was shown to be dependent on 
the activation of death receptor- and mitochondrial-dependent pathways and 
subsequent activation of caspase cascades [SJ . Nevertheless, not only the 
classical apoptosis pathway as shown in LNCap prostate can be activated by 
fisetin, [ 1 ] ,  but also autophagic-programmed cell death may occur, as was the 
case in PCs prostate cancer cells [ 5] . 
Fisetin anticarninogenic effect, antioxidant and anti-inflamatory 
activity are clearly defined via inhibition of cell proliferation and free radical 
scavenging respectively [6] . However, fisetin can also be a pro-oxidative 
agent in cancer cells, thereby inducing cell death. In Chapter 4 we observed 
this pro-oxidative effect of fisetin. We showed inactivation of aconitase, a 
sensitive mitochondrial marker for oxidative stress, as a result of fisetin 
treatment. Reactive oxygen species (ROS) can induce cell death through 
activation of TNF receptor and induction of JNK and pS8 signaling [7] , which 
was exactly what we observed in HL60 cells treated with fisetin. In addition, 
fisetin decreases levels of ERK phosphorylation, which is essential for its 
kinase activity. Other studies have also described fisetin-induced inhibition of 
kinase activity involved in proliferation signaling pathways [2-5] . For 
instance, treatment of prostate cancer cells with fisetin inhibits mTOR and 
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AKT act1v1t1es [5], and in human lung cancer cells, fisetin can induce 
inhibition of ERK, leading to inhibition of cell adhesion, migration and 
invasion in addition to cell death [2], showing an anti-metastatic effect of 
flavonoid. 
Another interesting observation we made in Chapter 4 was that NFKB 
levels were reduced in HL60 cells upon treatment with fisetin. NFKB is a 
transcription factor involved in the production of cytokines acting as a pro­
inflammatory modulator. This finding indicates the anti-inflammatory 
property of fisetin. Recent studies have shown a similar effect of fisetin in 
human prostate cancer cells and human colon cancer cells, where fisetin 
significantly decreased the nuclear levels of NF-KB in a concentration­
dependent manner [ 2] [ 4]. This effect could be correlated to the anti­
inflammatory effect of fisetin observed through inhibition of COX-2, but not 
COX-I , or prostaglandin E production [4]. In conclusion, we and others have 
shown that fisetin may hold promise as a chemotherapeutic agent in diverse 
tumor types. 
In Chapter 5, the effect of apigenin, a flavonoid common in human 
diet, was investigated in leukemia cell lines. Studies into the apigenin effects on 
cancer cells may contribute to the understanding of its possible 
chemopreventive and chemotherapeutic properties. In this chapter we show 
that apigenin induces cell-cycle arrest in G2-M in HL60 cells whereas TF-I 
cells were arrested in Go/GI phase. Some research groups have shown that 
apigenin can induce cell cycle arrest in different phases, depending on the cell 
type [8] [9]. Numerous studies have correlated G2/M arrest with apoptosis 
induction, as was the case in our study. On the other hand, Go/GI arrest is 
observed on reduction of mTOR activity [10] and has been associated to 
autophagy [I I ], evocative of TF-I cells in his study. Interestingly, apigenin 
down regulates mTOR in TFI cells without affecting PTEN, showing that its 
effect is either independent or downstream of this lipid phosphatase which 
normally plays a regulatory role in mTOR pathway activation. Hence apigenin 
might be a very attractive therapeutic agent for treating tumors carrying 
inactivated PTEN. Apigenin-induced autophagy in TF-I cells occurs via 
inactivation of p70S6K, an inhibitor of autophagy. Unlike TNF-a-induced 
autophagy, apigenin does not increase the level of sentinel autophagy proteins. 
Although the final consequence of apigenin treatment is different in 
HL60 and TF- 1 ,  they share one common target: the Src/JAK/STAT pathway, 
a major mediator of cytokine activity. Our results suggest that JAK/STAT 
signaling pathway is a principal target of apigenin. As the JAK/STAT 
pathway is one of the most deregulated pathways in not only hematological 
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malignancies (as reviewed in Chapter 2), but other tumors as well [12], a 
broader application of apigenin treatment of cancer may be envisioned. 
An interesting note to be made is that whereas apigenin affects PKB 
activity in HL60 cells, it does not influence this molecule in TF I cells. This 
correlates with the finding that PTEN activity is increased in the former cell 
line, but not in the latter. Conversely, a more pronounced decrease of 
JAK/STATs/ 5 pathway activity was observed in TF I cells as compared to 
HL60, which correlated with the finding that apigenin causes LMWPTP 
activation in TF I but not HL60 cells. These data show that the 
antiproliferative effect of apigenin on leukemic cells is as much attributable to 
its effects on phosphatases as its effects on kinases, thus strengthening the 
notion that the study of phosphatases in oncogenetic processes and treatment 
are very important, and deserve more attention. 
One of the most important findings in this study was that apigenin 
impairs the cytotoxic effect of a chemotherapeutic agent that acts on M phase 
progression. Causing a cell cycle arrest in Go/GI phase in TF I cells, apigenin 
hampers the cell death induced by vincristine, a clinical chemotherapeutic 
which binds to tubulin dimers, inhibits microtubule formation and arrests 
mitosis in metaphase. Interestingly, apigenin did not impair the effect of 
chemotherapeutics with targets other than the M phase, such as mitoxantrone 
(which inhibits S-phase) and Imatinib (which inhibits mainly ABL kinase and 
c-KIT), implying that its action might be specific for M-phase-affecting 
chemotherapeutics. 
This study concludes that apigenin is a potential chemopreventive and 
chemotherapeutic agent in leukemia, but the consumption of apigenin must be 
carefully studied in patients treated with anti-mitotic chemotherapy. 
In Chapter 6, ferruginol, a natural compound found in Chilean trees 
(Podocarpaceae) was studied in prostate cancer cells. This diterpene negatively 
modulates cancer cell proliferation and positively regulates apoptosis in PCs 
cells, a model of very aggressive prostate cancer. Both intrinsic and extrinsic 
apoptosis pathways were induced by ferruginol in prostate cancer cells. A high 
ratio of Bax:Bcl2, high nuclear AIF levels and caspase 9 activity are the 
modifications observed in the intrinsic apoptosis pathways. High expression of 
TNFR 1 and high activity of caspase 8 were also observed in ferruginol­
treated cells, indicating the activation of the extrinsic apoptosis pathway. 
Consequently, ferruginol increases caspase S activity, where these two 
pathways converge. In addition to its effect on apoptosis induction, ferruginol 
is able to inhibit proliferation and survival signaling pathways such as the 
Pisk/ AKT and MEK/ERK pathways. Cell-cycle arrest in Go/GI  phase was 
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observed, corroborating with high expression of p21 protein and low levels of 
CDK6, CDK4, cyclin DI and cyclin Ds. One of the most interesting 
observations in this study was the inhibition of Hsp27 by ferruginol. 
Inhibition of Hsp27 destabilizes and inhibits STATS, and can thereby reduce 
cell survival. 
As shown by others, diterpenes possess anti-inflammatory properties 
and in our model, we observed less translocation of NFKB into the nucleus in 
ferruginol treated cells. Furthermore, the oxidative state of the prostate cancer 
cells was altered upon ferruginol treatment, and obtaining higher GSH/GSSH 
ratios may be the initial cause of cell death induction in PCs cells. 
Although the natural compounds studied in this thesis display different 
mechanisms leading to the same final effect, i.e. cell death and cell cycle arrest, 
they also share similarities in their modes of action. Ferruginol and apigenin 
can induce apoptosis via caspase-dependent mechanisms, as was observed for 
prostate cancer cells treated with ferruginol and HL60 cells with apigenin. In 
both these studies, PisK/ AKT and JAK/STAT signaling were inhibited and 
MAPK p.38 activated by the natural compounds. 
Fisetin also induces caspase-dependent apoptosis [3] and activates 
MAPK p.38. Both ferruginol and fisetin were able to induce oxidative stress, 
and although not studied by us, apigenin has been shown to induce apoptosis 
through ROS production [13]. ROS can act as a cell death inducer by causing 
damage in DNA, lipid peroxidation and protein oxidation, in addition to 
playing a role in cell signaling. ROS activates signaling cascades that trigger 
gene expression, through directly oxidizing components of signaling 
pathways and interfering in their activity, ultimately changing gene expression 
by modifying the activity of transcription factors [14]. MAP kinase signaling 
has also been show to be target of ROS [ 15]. 
One class of enzymes that can be inactivated by ROS is that of the 
protein tyrosine phosphatases. Protein tyrosine phosphatases (PTPs) share a 
common CX2R active site motif and an identical catalytic mechanism based on 
the participation of a crucial cysteine residue [16]. When this cysteine is 
oxidized, PTP activity is inhibited. One of possible mechanisms through 
which fisetin could increase protein phosphorylation levels is through the 
inhibition of phosphatases by ROS. Indeed, we observed a drastically reduced 
activity of the LMWPTP by ferruginol treatment of PCs cells and apigenin 
treatment of HL60 cells. In the case of TFI cells, the ROS production might 
be not related to the apigenin effect, since LMWPTP was activated by 
apigenin treatment. LMWPTP has been shown to be up-regulated in different 
human cancers and it can be correlated with bad prognosis [16]. 
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TF 1 cells displayed a completely different cell death mechanism in 
response to apigenin treatment. These studies can be considered as a model for 
apoptosis resistance. In this case, apigenin was not able to induce apoptosis, but 
instead autophagy was observed. A very interesting finding was the increased 
LMWPTP activity upon treatment of TFI cells with apigenin. As described 
in Chapter 2, the role of LMWPTP in hematological malignancies is not well 
known, and nothing was yet described about the role of LMWPTP in cancer 
resistance. We now suggest a link between resistance and LMWPTP because 
apigenin treatment increases LMWPTP activity in a dose-dependent fashion. 
As apigenin increases LMWPTP activity, and impairs vincristine induced cell 
death, LMWPTP might be the responsible for the failure of apigenin to 
induce cell death in TF I cells. Hence we emphasize the importance of 
studying phosphatases for understanding the success or failure of a treatment. 
The mechanism by which the natural compounds are taken up by the 
cells may contribute to their biological effect. For example, the antioxidant and 
antibacterial properties of flavonoids are related to their interaction with 
biological membranes [ I  7, 18]. Moreover, the organization of the lipids in the 
membranes is essential for signal transduction, especially for tyrosine kinases 
signaling, which requires adaptors, scaffolds and enzymes. It is established that 
activation of some tyrosine kinase receptors involves lipid rafts, the 
cholesterol and sphingolipids enriched microdomains in the plasma membrane 
[ I  9]. Some examples of these include T-cell [20] , B cell [2 I], Ephrin BI  
[22], Hedgehog receptors [23]. As all flavonoids intercalate into 
phosphatidylcholine bilayers [24]. phosphatidylcholine is present in a non­
lipid raft area, suggesting that flavonoids might interfere in rafts formation 
and thus, block tyrosine kinases receptor activation. However, their effect on 
membrane proteins is not restricted to their effect on membranes per se. 
Flavonoids can also interact directly with proteins in the membrane, affecting 
their activity. Flavones apigenin and acacetin and flavonols morin and 
myrecetin are effective inhibitors of MRP 1. Apigenin was demonstrated to 
stimulate ATPase activity in drug-resistant small cell lung cancer [25] and 
binds to P-gp [26] and MRP I [27]. Intriguingly, depending on the substrate, 
apigenin can inhibit or stimulate MRP I activity: apigenin decreases 
accumulation of daunomycin while increasing the accumulation of vinblastin 
in Pane- I cells [28]. Fisetin decreases the effiux of both substrates, indicating 
the stimulation of MRP 1 activity [28]. Additionally to the effects on 
membrane lipids and proteins, flavonoids can pass through the plasma 
membrane and reach the cytosol, where other interactions can take place. 
Although flavonoids can be detected within the cells minutes after treatments, 
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they diffuse very slowly across lipid membranes or not at all .. Therefore, a 
transport system is required to achieve the rapid flavonoid uptake [29] . 
Schramm and coauthors showed that the uptake of the flavonoid morin by 
epithelial cells is increased by the presence of ATP in culture medium and 
using MRP I inhibitors the uptake is reduced [29] . Krotta and coauthor, using 
an oocyte model, showed that Na+/ glucose transporter is not responsible for 
apigenin uptake. Despite some studies h ave shown how morin enters in the 
cells, other flavonoids do not necessary h as the same pattern. Changes in 
number and position of the hydroxyls groups can change the way how 
flavonoids are taken up by the cells. Thus, the uptake of apigenin and fisetin 
remains to be solved. 
Together this thesis investigates the molecular mechanisms mediated 
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2. FUTURE PERSPECTIVES 
As mentioned above, our literature and experimental studies suggest 
that there might be a bigger role for phosphatases in hematological 
malignancies and other cancers then so far assumed. Although we found in all 
our studies that natural compounds affect kinases, our results in Chapter 5 
suggest that phosphatase activities are also modulated. We have already 
established a role for PTEN and LMWPTP in apigenin-induced cell death in 
leukemic cells and modulation of LMWPTP activity by ferruginol. It is 
conceivable that other phosphatases are also regulated by ferruginol, apigenin 
and fisetin. As our studies suggest a significant impact of natural compounds 
on cell cycle regulation, it would be of interest to study their effect on cell 
cycle division phosphatases such as CDC25. Indeed, it has recently been shown 
that the natural compound indole S-carbinol initiates breast cancer G I  arrest 
by modulation of CDC25 expression [so]. In addition, protein phosphatase 2C 
mediates caspase dependent apoptosis in HL60 cells induced by the diterpene 
pisiferdiol [s I], further demonstrating the importance of studying 
phosphatases in natural compound mediated cell killing. 
Studies into the mechanism of how ferruginol, apigenin and fisetin 
are taken up by the cells are relevant to find to specific targets. Furthermore, 
natural compounds can be a platform for synthesis of new drugs. Modification 
of the molecular structure can improve the desired biological effects and 
produce fewer side effects. In addition, although many natural compounds have 
already been shown to be tolerated in humans, clinical implementation of these 
compounds may be hampered by their differential interaction with, and effect 
on, signaling and cellular function of other agents, as was shown by our 
finding of the negative effect of apigenin on chemotherapy. Careful further 
studies with hedgehog inhibitors, fisetin, apigenin and ferruginol are obviously 
necessary, and validation of the effects of new drugs in animal models is 
essential for a safe future use in humans. 
Nevertheless, the idea of going back to nature for treatment of diseases 
is an appealing one, and, according to our data, one that shows great promise. 
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3. NEDERLANDSE SAMENV ATTING 
Kanker is een van de meest voorkomende ziektebeelden in Nederland. In 
2008 werden in totaal 89200 nieuwe gevallen geconstateerd, waarbij borst (1 4%), 
long (1 2%) ,  prostaat (1 1 %), colon (9%) en hematologische aandoeningen (8%) bet 
meest prevalent waren (V ereniging integrale kankercentra, http:/ /www.ikcnet.nl) . 
Ondanks voortschrijdend medisch inzicht betreffende de behandeling van 
verschillende vormen van kanker er sterven momenteel in Nederland evenveel 
mensen aan kanker als aan hart en vaatziekten. (Nationaal Kompas 
Volksgezondheid, RIVM) . Naast bet feit dat voor sommige vormen van kanker 
geen adequate bestrijdings mogelijkheden beschikbaar zijn, gebeurt bet regelmatig 
dat tumor cellen resistent warden tegen de gegeven chemotherapieen. Ook komt 
bet in sommige gevallen voor dat na volledige verdwijning van de tumor een 
recidief optreedt, die vaak moeilijker te bestrijden is clan de originele ziekte. Er is 
derhalve een dringende behoefte aan ontwikkeling van nieuwe therapeutische 
kankerbestrijding mogelijkheden. 
Alie celfuncties warden in grate mate bepaald door signaal transductie 
routes, bestaande uit intracellulaire enzymen die warden aangezet door 
extracellulaire stimuli, waaronder groeifactoren. Wanneer er in deze signalering 
cascades fouten optreden is bet mogelijk dat de eel te heftig reageert op 
omgevingsfactoren, of afwijkend gedrag vertoont. In veel kankervormen zijn 
verstoringen in signaaltransductie routes aangetoond, die leiden tot de voor kanker 
karakteristieke ongeremde celdeling en celoverleving. Het is clan ook niet 
verwonderlijk dat veel onderzoek is gericht op bet ontwikkelen van medicijnen die 
aangrijpen op deze verstoorde signalering. Recentelijk is gebleken dat sommige 
stoffen uit natuurlijke producten zoals groente, fruit, bomen en planten, in staat 
zijn cellen te be:invloeden door te interfereren in deze signaaltransductie routes, en 
de mogelijke toepasbaarheid van deze in de natuur voorkomende stoffen in de 
bestrijding van verschillende ziektebeelden krijgt clan ook steeds meer aandacht. 
Met bet werk beschreven in dit proefschrift proberen wij een bijdrage te 
leveren in de strijd tegen kanker. Hierbij hebben wij ons voornamelijk gericht op 
bet effect van enkele natuurlijke stoffen op de groei van bloed en prostaat kanker, 
en de signalerings eiwitten die daarbij betrokken zijn. 
In Hoofdstuk 1 wordt de opzet van dit proefschrift uitgelegd. Het belang 
van de studie naar bet effect van natuurlijke stoffen als kankerremmende middelen 
en de moleculaire mechanismen daarvan wordt besproken. Enkele studies uit de 
literatuur, die een succesvolle remming van kanker celgroei door natuurlijke stoffen 
beschrijven, warden aangehaald om bet belang van natuurlijke kankerremmende 
stoffen als mogelijke nieuwe chemotherapeutica te illustreren. 
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In Hoofdstuk 2 onderzochten wij aan de hand van literatuurstudie de 
mogelijke rol van phosphatases in de behandeling van hematologische 
aandoeningen. Een belangrijke manier van het doorgeven van intracellulaire 
signalen is de fosforylering van eiwitten en lipiden. Enzymen die in staat zijn om 
een fosfaatgroep aan een eiwit/lipide te bevestigen, de zogenaamde kinases, zijn 
veelvuldig bestudeerd. Met name hun rol in de ontwikkeling van kanker heeft veel 
aandacht gekregen. Drie belangrijke kinasengereguleerde signalering cascades, 
waarvan een verstoring is aangetoond bij bloed kankers, warden in Hoofdstuk 2 
beschreven; de JAK/STAT, Ras-Raf-MEK-ERK en de PI3K-PKB routes. 
Naast het aanzetten van signalerings routes, veelal door kinasen, moeten 
deze cascades ook weer warden uit gezet. Fosfatasen zijn in staat fosfaatgroepen 
van eiwitten en lipiden te verwijderen, en warden daarmee veelal gezien als negatief 
regulerende factoren in signaal transductie. Hun rol in kankercel biologie wordt 
daarmee echter onderschat, een verhoogde activiteit van signalen zou theoretisch 
immers kunnen warden verklaard door zowel een verhoogde activiteit van kinases, 
als een verlaagde activiteit van fosfatasen. Bovendien blijkt uit literatuur studie dat 
sommige fosfatasen, waaronder CD45, SHP-2 en SHIP, naast een inactiverende 
functie ook een activerende rol kunnen uitoefenen. In Hoofdstuk 2 beschrijven wij 
hoe deze en andere fosfatasen betrokken lijken te zijn bij de pathogenese van 
hematologische kankers, en mogelijk een aangrijpingspunt zouden kunnen vormen 
voor de behandeling van deze ziektebeelden. 
In Hoofdstuk 3 gaan we dieper in op de ontwikkeling van resistentie 
tegen chemotherapeutica door tumor cellen. Het overkomen van deze 
zogenoemde multidrug resistentie (JVll)R) blijft een van de grootste uitdagingen in 
de bestrijding van kanker. Een van de mechanismen waarmee tumor cellen 
resistentie verkrijgen is door de expressie van membraaneiwitten waarmee 
antikankermiddelen uit de eel warden gepompt. Wij beschrijven hier de rol van 
Hedgehog (Hh) signaaltransductie in de expressie van een van deze pompen, P-gp. 
Lucena-1 leukemische cellen hebben een hogere mate van activatie van de Hh 
signalerings route clan hun zuster cellijn K652, wat gepaard gaat met een 
verhoogde resistentie tegen chemotherapeutica. Geforceerde expressie in K562 
cellen van constitutief actief Smoothened, een van de eiwitten in de Hh 
signaleringsroute, maakt ook deze cellen resistentie tegen antikankermiddelen. 
Inhibitoren van de Hh signaaltransductie maken Lucena-1 cellen weer gevoelig 
voor chemotherapeutica, wat waarschijnlijk veroorzaakt wordt doordat inhibitie 
van Hh activiteit de expressie van P-gp verlaagd. Dit verklaart ook waarom K562 
en GLC4-doxo, die geen P-gp maar andere multidrug pompen tot expressie 
brengen, geen invloed ondervinden van Hh inhibitoren. 
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De studies beschreven in dit hoofdstuk lichten geven een mogelijk 
mechanisme waarop tumoren ontsnappen aan de celdodende eigenschappen van 
chemotherapeutica, namelijk het opreguleren van Hh signalering en P-gp expressie. 
Het onderzoeken van Hh activiteit bij leukemie patienten zou mogelijk een 
voorspellende waarde kunnen hebben voor het al clan niet van nut zijn van Hh 
inhibitoren in de behandeling van resistente tumoren. 
In Hoofdstuk 4 bestuderen we het celdodende effect van de natuurlijke 
stof fisetin in myeloide leukemie. De flavonoide Fisetin, een stof die van nature 
voorkomt in groente en fruit, kan celdood induceren in de leukemische eel lijn 
HL60, maar niet in normale witte bloedcellen uit het perifere bloed. We tonen aan 
dat fisetin leidt tot activatie van de moleculair stress signalen p38 MAPK en JNK, 
terwijl activatie van het celoverleving signaal ERK.1 /2 juist verminderd wordt. Ook 
de expressie van de transcriptie factor NFKB, waarvan eerder een rol in celdood 
werd aangetoond, wordt verhoogd door fisetin behandeling van HL60 cellen. In 
totaliteit werd er in fisetin-behandelde cellen een verhoogde mate van eiwit 
fosforylering gevonden, wat hoogstwaarschijnlijk een gevolg was van een 
verminderde fosfatase activiteit in deze cellen. Tevens toonden we aan dat fisetin 
in HL60 cellen een verminderde activiteit van aconitase, catalase en superoxide 
dismutase bewerkstelligde. Deze enzymen zijn allen betrokken bij de afbraak van 
zuurstofradicalen; een verlaging van deze enzymactiviteit resulteert derhalve in een 
verhoogde hoeveelheid zuurstofradicalen in de eel. Zuurstofradicalen zijn toxisch 
voor cellen en kunnen via activatie van p38 en JNK leiden tot celdood. De studies 
beschreven in dit hoofdstuk laten zien dat de natuurlijke stof fisetin in staat is 
leukemische celfgroei te remmen door de afbraak van zuurstofradicalen te remmen 
en daarmee signaaltransductie routes aan te zetten die leiden tot celdood. 
Een andere flavonoide met antitumor activiteit, apigenin, werd bestudeerd 
in Hoofdstuk 5. Allereerst toonden we aan dat deze stof, die veel voorkomt in 
onder andere appels en thee, de groei van leukemische eel lijnen HL60 en TF-1 
remt. HL60 cellen waren echter gevoeliger voor behandeling met deze flavonoide. 
Analyse van de moleculaire mechanismen betrokken bij de apigenin-geinduceerde 
remming van celgroei toonden aan dat de twee leukemische eel lijnen op 
verschillende manieren reageerden op deze stof. HL60 cellen werden in hun 
celdeling geblokkeerd in de G2/M fase, wat resulteerde in een geprogrammeerde 
celdood (apoptosis) . Dit was waarschijnlijk het gevolg van een remming van de 
eiwitten PK.13, STAT3, STATS en Src, allen nodig voor de overleving van cellen. In 
TF-1 cellen werd ook remming van ST AT3, STATS en Src, maar geen remming 
van PKB. In deze eel lijn werd echter wel inactivatie van de enzymen mTOR en S6 
gevonden, die geassocieerd zijn met een andere vorm van celdood; autofagie. 
Autofagie is een proces waarbij een eel in tijden van stress zichzelf 'opeet' om 
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energie te sparen en zodoende langer in leven te kunnen blijven, en wordt 
gekenmerkt door de aanwezigheid van intracellulaire dubbel membraan vacuoles 
die cytoplasmatisch materiaal bevatten. Als de stress lang genoeg aanhoud zal de 
eel uiteindelijk doodgaan, bij verdwijnen van de stress kan de eel zich herstellen. 
Met behulp van electronen microscopie werd de inductie van dubbel membraan 
vacuoles door apigenin in TF-1 cellen inderdaad aangetoond, wat gepaard ging met 
een blokkade van de eel cyclus in GO/ G 1 fase. Een belangrijke bevinding hierbij 
was tevens dat apigenin de werking van sommige chemotherapeutica op TF-1 
cellen remde, wat uit het oogpunt van kankerbestrijding uiteraard onwenselijk is. 
Men zal clan ook uiterst voorzichtig te werk dienen te gaan indien natuurlijke 
stoffen als apigenin in de kliniek een gebruik zullen vinden. Een interessante 
bevinding in deze studie is dat de verlaagde fosforylering van PKB in HL6O cellen 
gepaard gaat met een verhoogde activiteit van de fosfatase PTEN, terwijl in TF-1 
cellen de verlaagde fosforylering van STAT3 / 5 gepaard gaat met een verhoogde 
activiteit van de fosfatase LMWPTP. Deze data tonen aan dat fosfatasen een 
belangrijke rol kunnen spelen in de moleculaire mechanismes betrokken bij de 
behandeling van kanker. 
In Hoofdstuk 6 bestudeerden we een andere natuurlijke stof, ferruginol, 
die wordt gevonden in bomen van de familie Podocarpaceae. We toonden een 
kankerremmende werking aan van deze stof in de prostaat kanker eel lijn PC3. 
Analyse van de moleculaire mechanismen die hiervoor verantwoordelijk zijn liet 
zien dat ferruginol de activatie van PKB en ERK remt, en een blokkade in de 
GO/ G 1 fase van de celcyclus induceert. Behandeling van PC3 cellen met ferruginol 
leidt uiteindelijk tot apoptosis via 2 verschillende routes; intrinsiek ( een verhoging 
van de ratio pro-apoptotische versus anti-apoptische eiwitten, nucleaire 
aanwezigheid van bet eiwit AIF en activatie van caspase 9) en extrinsiek (verhoging 
van TNF-receptor expressie en caspase 8 activatie) . De oxidatie status van de eel 
werd door forruginol verhoogd, wat zijn weerslag vond op de phosphatase 
LMWPTP; zowel de expressie als de activiteit van deze werd door ferruginol 
negatief be:invloed. 
In zijn totaliteit laten de studies in dit proefschrift zien dat verschillende 
natuurlijke stoffen, voorkomend in groente, fruit, thee en bomen een 
kankerremmende werking kunnen hebben op verschillende types tumoren. Al naar 
gelang het type kanker en de natuurlijke stof die getest werden verschillende 
verantwoordelijke mechanismen hiervoor aangemerkt. In zijn algemeenheid kan 
gezegd warden dat remming van de activiteit van signaal transductie routes die 
belangrijk zijn in de overleving van cellen (PKB, ERK.) warden een van de 
belangrijkste werkwijzen is van deze stoffen. De exacte manier waarop deze 
stoffen bun effect uitoefenen en de mogelijke rol die deze stoffen kunnen spelen in 
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de bestrijding van tumoren behoeven uiteraard nog veel onderzoek. 
Desalniettemin is het een aantrekkelijk idee om voor de behandeling van kanker 
terug te grijpen op de natuur, en gebruik te maken van stoffen die vrij voorhanden 
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